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ABSTRACT 
 
Although differentiated cells normally retain cell-type-specific gene expression 
patterns throughout their lifetime, cell identity can sometimes be modified or reversed 
in vivo by transdifferentiation, or experimentally through cell fusion or by nuclear 
transfer. Several studies have illustrated the importance of chromatin remodelling, DNA 
demethylation and dominant transcriptional factor expression for changes in lineage 
identity. Here the epigenetic mechanisms required to “reset” genome function were 
investigated using experimental heterokaryons. 
To examine the epigenetic changes that are required for the dominant 
conversion of lymphocytes to muscle, I generated stable heterokaryons between 
human B-lymphocytes and mouse C2C12 myotubes. I show that lymphocyte nuclei 
adopt an architecture resembling that of muscle and initiate the expression of muscle-
specific genes in the same temporal order as developing muscle. The establishment of 
this novel gene expression program is coordinated with the shutdown of several 
lymphocyte-associated genes. Interestingly, inhibition of histone deacetylase (HDAC) 
activity during reprogramming selectively blocks the silencing of lymphocyte-specific 
genes but does not prevent the establishment of muscle-specific gene expression. 
In order to reprogram somatic cells to pluripotency, I fused human B-
lymphocytes and mouse embryonic stem (ES) cells. The conversion of human cells is 
initiated rapidly, occurring in heterokaryons before nuclear fusion. Reprogramming of 
human lymphocytes by mouse ES cells elicits the expression of a human ES-specific 
gene expression profile in which endogenous hSSEA4, hFgf receptors and ligands are 
expressed while factors that are characteristic of mouse ES cells, such as Bmp4 and 
Lif receptor are not. Using genetically engineered mouse ES cells I demonstrate that 
successful reprogramming requires the expression of Oct4, but importantly, does not 
require Sox2, a factor implicated as critical for the induction of pluripotency. Following 
reprogramming, mOct4 becomes dispensable for maintaining the multi-potent state of 
hybrid cells. Finally, I have examined the reprogramming potential of embryonic germ 
(EG), embryonic carcinoma (EC) and ES cells deficient for the Polycomb repressive 
complex 2 (PRC2) proteins Eed, Suz12 and Ezh2. While EC and EG cells share the 
ability to reprogram human lymphocytes with ES cells, the lack of Polycomb proteins 
abolishes reprogramming. Thus, the repressive chromatin mark (H3K27 methylation) 
catalysed by PRC2 play a crucial role in keeping ES cells with full reprogramming 
capacity. Collectively my results underscore the importance of chromatin events during 
cell fate reprogramming. 
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CHAPTER 1. INTRODUCTION 
 
 
In higher eukaryotic organisms development is a remarkably orderly process. 
Starting from the totipotent zygotic cell an impressive array of differentiated cell types is 
generated in the adult. In humans at least 200 different cell types can be histologically 
defined with distinctive functions, such as the defence of the organism, muscle 
contraction or the establishment of neural networks. A central question in 
developmental biology asks how cells acquire different cell identities during 
development and how those are stably maintained. 
In 1892 Weismann (Weismann, 1892) proposed that heritable elements (genes) 
are lost as cells became specialised. So according to this argument, a liver cell would 
lose genetic information except what was needed for liver cell function. Spemann 
(Spemann, 1938) made an early attempt to test this idea. However, it was following 
studies of Briggs & King (Briggs and King, 1952) that Gurdon and colleagues showed 
that, in Xenopus laevis, nuclear transfer from differentiated somatic cells to enucleated 
oocytes supported embryonic development (Gurdon, 1962). They reasoned that if the 
genetic material were lost, the differentiated state would be irreversible following 
nuclear transfer. Instead, they showed that the specialised intestinal cell nucleus 
retained the capacity to direct development of the resulting embryos into tadpoles and 
adult fertile frogs. The first mammal to be cloned from an adult cell, Dolly (Wilmut et al., 
1997), and the cloning of mice from terminally differentiated lymphocytes (Hochedlinger 
and Jaenisch, 2002), demonstrate the theory of nuclear equivalence; that specialised 
cells of metazoans possess a gene pool identical to that of the zygote nucleus. 
Importantly, this established the principle that mechanisms underlying lineage 
restriction and cell identity are ultimately reversible. 
We now know that differences in terminally differentiated cells arise from the 
selective expression of only a fraction of genes encoded by the genome. But how are 
differential transcriptional programs established and maintained during the process of 
cell specialisation? It has been long held, in contrast to lower vertebrate and 
invertebrate embryos, that early mammalian development is highly regulative and 
flexible. Experimental manipulation of the early pre-implantation embryo revealed that 
early blastomeres are remarkably plastic in their lineage potency (Rossant and Tam, 
2004; Stern, 2006). The current view, however, is that the mammalian embryo has 
some order or bias from the very beginning (fertilisation), with inflexibility and cell 
determination increasing over time (Plusa et al., 2005; Zernicka-Goetz, 2005). Lineage 
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specification is often associated with signalling events, which in the presence of the 
appropriate gene regulatory network determine the specialised cell fate. These 
networks are modulated by the availability of lineage-specific transcriptional factors that 
leads to the activation and silencing of specific and distinct sets of genes. An example 
of such regulation can be observed very early in the mouse embryonic development, 
where the first differentiation event segregates embryonic and extra-embryonic 
lineages (Rossant, 2001). In the early blastocyst, cells form the inner cell mass (ICM) 
and trophectoderm (TE) can be distinguished by their requirements for extrinsic and 
intrinsic regulators. Among these are the transcription factors Oct4 and Cdx2 which are 
essential for development of the ICM and TE, respectively (Niwa et al., 2005). In 
addition, extrinsic factors such as the leukaemia inhibitory factor (LIF) and BMP4 
maintain ES cell self-renewal (derived from ICM) and FGF4 is required for the 
maintenance of trophoblast stem (TS) cells (Chambers and Smith, 2004; Rossant, 
2001). Later in ontogeny, key signalling ligands with well-know roles in embryo 
patterning are fundamental during myogenesis in muscle progenitor specification. 
These signals include Shh, Wnts, BMPs, Notch and FGFs, which are known to control 
the transcription factors Myf5 and MyoD in muscle progenitors (Pownall et al., 2002). 
MyoD has been implicated as a dominant factor for myogenesis as its forced 
expression is sufficient to convert fibroblasts in skeletal muscle cells (Davis et al., 
1987). The importance of single transcription factors for dictating lineage fate is also 
clear from studies of the transcriptional regulator Pax5 in B-lymphocytes (Nutt et al., 
1999). In this case, Pax5 functions not only by the activation of the B-cell program, but 
also by repression of other lineage fates, since its removal favours the development of 
alternative haematopoietic cell fates from haematopoietic precursors (Busslinger et al., 
2000). 
There are formally only about 7 distinct signalling pathways through which cells 
modulate gene expression and the number of examples where a single transcription 
factor dictate a specific cell fate are limited. How is it then possible to generate such a 
huge diversity of cell types? Cells seem to accumulate a "history" of what signals they 
have received over time, and therefore the same signal will have different outcomes 
depending on the cellular context. For example, LIF signalling contributes to the self-
renewal of ES cells but later on in development induces macrophage maturation and 
enhances the survival of sensory and motor neurons (Metcalf, 2003). The same 
rationale also applies to intrinsic regulators: when overexpressed in mature B-
lymphocytes, the transcription factors C/EBPα and C/EBPβ were shown to promote 
cell fate conversion to macrophages (Xie et al., 2004). However, the same transcription 
factors when overexpressed in pancreatic cells promote their conversion to 
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hepatocytes (Shen et al., 2000). Similarly, while MyoD was shown to be sufficient to 
generate muscle cells from a range of cell types (Choi et al., 1990; Davis et al., 1987), 
ectopic expression of MyoD in more distant related cell lineages to muscle, like 
ectoderm (Faerman et al., 1993), endoderm (Schafer et al., 1990) or ES cells (Dekel et 
al., 1992) does not result in complete conversion, indicating that developmental history 
do indeed impose constraints in tissue-specific transcription factor function. Allelic 
differences in gene expression (imprinting and allelic exclusion) and mammalian X-
chromosome inactivation provided direct evidence that gene expression is not solely 
regulated in trans by diffusible signalling molecules and transcriptional regulators but 
also regulated in cis along the chromosome. Collectively these experiments provided 
evidence for cellular memory and epigenetic regulation of gene expression. 
 
1.1. Epigenetic levels of gene regulation 
 
The modern usage of the term “epigenetic”, originally coined by Conrad 
Waddington (Waddington, 1942), refer to heritable traits (over rounds of cell division 
and sometimes transgenerationally) that do not involve changes to the underlying DNA 
sequence. The ability to acquire and inherit gene expression programs efficiently is 
crucial for the process of cell differentiation. The molecular mechanisms that allow 
differentiated cells to perpetuate the “memory” and the developmental decisions that 
created it are now beginning to be revealed. These mechanisms involve heritable but 
potentially reversible modifications in chromatin structure, methylation of DNA, 
regulation by small interfering RNAs and higher-order genome organisation (Figure 
1.1). DNA methyltransferases, histone-modifying enzymes, chromatin-binding proteins, 
non-coding RNAs and many other regulators may act together with sequence-specific 
transcriptional factors to establish and convey gene expression patterns during 
development, ensuring the stability of the “committed” state. 
 
1.1.1. Chromatin structure and epigenetic inheritance 
 
In eukaryotic cells, DNA is complexed with core histones and other 
chromosomal proteins in the form of chromatin (Figure 1.1). The basic repeating unit of 
chromatin, the nucleosome, includes the compact octameric histone complex 
consisting of two copies of each of the four core histones H2A, H2B, H3 and H4 
wrapped by 146 basepairs (bp) of DNA (Luger et al., 1997). While the length of DNA 
engaged in nucleosomes is always the same, the length of the spacer between 
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nucleosomes varies from several to about 80 bp. The positioning of nucleosomes with 
respect to the DNA template plays an important role in transcription regulation 
(Henikoff, 2008; Li et al., 2007a; Schones et al., 2008).  
 
 
 
Figure 1.1. Epigenetic levels of gene regulation. Schematic representation of different levels of genome 
organisation that have an impact on gene activity. (a) The DNA double helix carries the genetic information 
used for development and functioning of all known living organisms. Beyond the sequence, DNA 
methylation (Me) at the carbon 5 of cytosines (C) provides the most direct epigenetic mechanism of gene 
regulation (see section 1.1.2). (b) DNA is wrapped around histones to form a “beads on a string” structure 
that is folded into higher order chromatin domains. Specific amino acids within histone tails (black wavy 
lines) are targets for a number of covalent modifications, including acetylation (Ac), methylation (Me), 
phosphorylation (P) and ubiquitylation (Ub). Dynamic changes in chromatin structure are influenced by 
post-transcriptional modifications of the N-terminal tails of histones, chromatin remodelling complexes, 
histone variants and small interfering RNAs (see sections 1.1.3 and 1.1.4). The nucleosome particles that 
comprise chromatin are represented as yellow cylinders and DNA as black lines. (c) Nucleosomal arrays 
are packed into several levels of condensed, higher-order chromatin domains and organised in functional 
nuclear compartments. These three-dimensional structures along with temporal constraints provide 
additional levels of regulation (see sections 1.1.5 and 1.1.6). Together these mechanisms provide some 
molecular clues on how a single genome can produce such a diversity of cell types. Adapted from (Lanctot 
et al., 2007; Sparmann and van Lohuizen, 2006). 
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Specific chromatin remodelling proteins that dynamically regulate nucleosome 
positioning and/or nucleosome structure were identified. Many of these proteins are 
ATPases that often function as subunits of large complexes, including the SWI/SNF, 
ISWI and CDH complexes (Saha et al., 2006; Tsukiyama, 2002). With the aid of 
additional proteins, including histone H1, nucleosomal arrays are packed into several 
levels of condensed, higher-order chromatin domains, which are organised in specific 
nuclear compartments (Figure 1.1) (Maresca and Heald, 2006; Tremethick, 2007). 
Together, this folding can compact DNA by a factor of 30-40 fold (Widom, 1989), but 
the topology of higher-order chromatin structure, especially that of the most condensed 
interphase chromosomes, remain controversial (Goetze et al., 2007; van Holde and 
Zlatanova, 2007). 
Early cytological studies observed that interphase chromatin is present in two 
distinguishable states: a less condensed form, euchromatin, and a more condensed 
form, heterochromatin, which stained intensely with specific dyes (Craig, 2005; Heitz, 
1928). Euchromatin is a form of chromatin that is decondensed during interphase, 
highly accessible to nucleases (suggesting that it may also be more accessible to 
transcription factors) and contains actively transcribed genes (Kornberg and Lorch, 
1999). In contrast, the higher-order structures of heterochromatin are thought to favour 
gene silencing, as it was initially demonstrated by the phenomenon of position effect 
variegation (PEV). The positioning of genes in close proximity to heterochromatin, often 
results in gene silencing, giving rise to a mosaic pattern of expression within a given 
tissue. This heritable silencing phenomenon was first identified in Drosophila (Muller 
and Altenburg, 1930), and has been reported in other organisms from yeast to humans 
(Dillon and Festenstein, 2002). At least two types of heterochromatin have been 
distinguished: constitutive heterochromatin that is generally silenced in all cell types 
and includes major and minor satellite DNA repeats clustered around mouse 
centromeres, other repetitive DNA elements and transposons and facultative 
heterochromatin which is developmentally regulated and can be formed at loci that in 
other cell-types are found in euchromatic form. One obvious example of facultative 
heterochromatin formation is the inactivation of one of the two X-chromosomes in early 
embryonic development (Arney and Fisher, 2004; Heard, 2005). 
In the course of cell division the genome is faithfully duplicated and divided 
between two daughter cells. For this purpose the cell must replicate its DNA sequence 
but also the underlying information in chromatin structure as well as its higher-order 
packaging in the nucleus. Given that each of the levels of chromatin organisation can 
be propagated throughout cell generations, this could represent the molecular basis of 
heritable traits (Holliday, 1994; Patterton and Wolffe, 1996). Such maintenance of 
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clonal gene expression patterns achieved by chromatin modifications is referred to as 
epigenetic inheritance, which potentially provides means to explain how a single 
genome can produce such a diversity of cell types. However, chromosome structure 
must also be dynamic and capable of regulated unfolding–folding transitions to allow 
the accessibility of proteins involved in various cellular processes such as transcription, 
replication and DNA repair. Indeed, recent studies have revealed the highly dynamic 
nature of chromatin and chromosome structure at all levels (Misteli, 2007). Uncoupling 
the chromatin changes that are “locked” and stably propagated throughout cell division 
from those that are transiently regulated constitutes a big challenge to define the 
“epigenetic” value of chromatin. 
 
1.1.2. DNA methylation 
 
There is a wide interest in understanding how chromatin structure impacts on 
gene regulation, and the mechanistic relationships between epigenetic phenomena 
(Lande-Diner and Cedar, 2005). DNA methylation provides an example of a direct 
epigenetic mechanism for the maintenance of the repressed state (Figure 1.1). 
Methylation of DNA within the mammalian genome is catalysed by a family of DNA 
(cytosine-5)-methyltransferases (Bestor, 2000) and occurs primarily at CpG 
dinucleotides. CpG methylation, especially within the promoter region of genes, is 
associated with stable transcriptional repression and plays important roles for X-
chromosome inactivation, genomic imprinting and cell differentiation (Bird, 2002; Reik 
and Dean, 2001). Aberrant DNA methylation contributes to tumorigenesis and other 
diseases (Jones and Baylin, 2002). 
Methylation patterns are propagated in mitotic cells by maintenance methylation 
activity that takes place in concert with DNA replication. The methyltransferase Dnmt1 
performs this maintenance function (Bestor et al., 1988; Li et al., 1992). Consistent with 
its role, Dnmt1 has a substrate preference for hemimethylated DNA in vitro and is 
usually associated with replication foci in the S-phase of dividing cells (Chuang et al., 
1997; Leonhardt et al., 1992). As DNA methylation patterns are stably maintained in 
differentiated mitotic cells, new patterns arise during embryonic cell differentiation and 
germ line specification in development. Dnmt3a and Dnmt3b, the two closely related de 
novo methyltransferases, are required for this process (Bestor, 2000). Inactivation of 
both genes cause a complete failure to establish genome-wide methylation (Okano et 
al., 1999). Consistent with this, the expression of Dnmt3a and Dnmt3b is 
developmentally regulated. Both genes are expressed at a high levels in 
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undifferentiated cells, including embryonic stem cells, and undergo down-regulation 
upon cell differentiation (Chen et al., 2002; Watanabe et al., 2002). Accordingly, the 
overall patterns of DNA methylation change dramatically during development. In early 
embryonic development parental methylation is lost, but methylation levels are restored 
at the blastocyst stage. Methylation patterns that are established at imprinted loci at 
this stage, such as the Igf2/H19 locus, are preserved in all cells of the adult organism, 
except for germ lineage cells (Edwards et al., 2007). A well characterised example of a 
locus regulated by DNA methylation is the ES-specific factor Oct4, which undergoes 
stable repression with cell differentiation. In differentiating human and mouse EC or ES 
cells and mouse post-implantation embryos, the inactivation of Oct4 involves 
recruitment of transcriptional repressors, alterations in chromatin structure and DNA 
methylation at the promoter region (Deb-Rinker et al., 2005; Feldman et al., 2006; Gu 
et al., 2006; Hattori et al., 2004). Dnmt3a and Dnmt3b were shown to function 
synergistically to methylate the promoter region of the Oct4 gene (Li et al., 2007b), 
which along with further recruitment of the methyl-CpG binding proteins MBD2 and 
MBD3 (Gu et al., 2006) may play an important role in the stable inactivation of Oct4 in 
differentiated tissues (Tsuji-Takayama et al., 2004). Functionally, DNA methylation is 
thought to interfere with gene transcription by at least two independent mechanisms 
(Bird and Wolffe, 1999). Firstly, methyl-CpGs can directly prevent transcription factors 
from binding to their recognition sites on the DNA. For example, the parental allele-
specific binding of CCCTC-binding factor (CTCF) at the Igf2/H19 imprinting control 
region (ICR). The binding of CTCF to the Igf2/H19 ICR is prevented by CpG 
methylation (Holmgren et al., 2001). Secondly, methyl-CpGs can recruit a protein 
family sharing the methyl CpG-binding domain (MBD) which indirectly was shown to 
induce silencing by recruiting co-repressor complexes to methylated DNA (Boyes and 
Bird, 1991), including HDACs or histone methyltransferases (HMTs) (Bird, 2002). 
Likewise, DNA methylation is impaired across pericentric major satellite repeats in ES 
cells deficient for the HMT Suv39h, due to abrogation of pericentric Dnmt3b localisation 
(Lehnertz et al., 2003). The links between DNA and histone methylation are thought to 
be important for propagating (hetero-) chromatin states through mitosis. 
It was suggested that DNA methylation is not a primary silencing mechanism, 
but rather one that makes silencing more stable and potentially irreversible (Jones and 
Takai, 2001; Li, 2002; Pannell et al., 2000). For example, DNA methylation was shown 
to follow the establishment of gene silencing and onset of histone 3 lysine 27 
methylation during X-chromosome inactivation (Heard, 2005). Likewise, in absence of 
Dnmt1 X inactivation is unstable, as suggested by random reactivation of an X-linked 
transgene in mouse embryonic cells and in cultured somatic cells when Dnmt1 was 
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absent or inhibited (Sado et al., 2000). Upon ES cell differentiation, Oct4 promoter is 
methylated after transcriptional repression (Feldman et al., 2006). This view has been 
recently challenged with evidence that DNA methylation can be dynamically regulated. 
Cyclical methylation and demethylation of CpG dinucleotides, with a periodicity of 1-2 
hours, was shown to be a characteristic of the oestrogen (E2)-responsive pS2 gene, in 
human cells (Kangaspeska et al., 2008). These results, together with the exceptional 
occasions when DNA methylation is broadly erasured (after fertilisation, during germ 
cell development and somatic cell reprogramming), implies a mechanism for CpG 
demethylation. DNA demethylation can be passive, presumably brought about during 
DNA replication by exclusion of Dnmt1, or active. Despite the intensive research, the 
mechanism for active erasure of the methylation mark remains largely unknown. 
Current evidence suggests that methyl groups attach through a carbon–carbon bond to 
the cytosine base and therefore might not be able to be directly removed (Morgan et 
al., 2005), so demethylation may proceed by pathways that involve base-excision or 
mismatch repair (Barreto et al., 2007; Morales-Ruiz et al., 2006; Morgan et al., 2004; 
Reik, 2007). The DNA deaminases Aid and Apobec1 have been shown in vitro to 
deaminate 5-methylcytosine in DNA to thymine (Morgan et al., 2004); this results in T-
G mismatches, which can be repaired by the base-excision repair pathway. Indeed, Aid 
and Apobec1 are highly expressed by oocytes, stem cells and germ cells (Morgan et 
al., 2004). Another DNA-damage-responsive gene, Gadd45 (growth arrest and DNA-
damage-inducible 45), might also have a role in demethylation but it remains 
controversial (Barreto et al., 2007; Jin et al., 2008).  
 
1.1.3. Covalent histone modifications and chromatin 
dynamics 
 
Chromatin modification also occurs at the core protein components of 
nucleosomes, the histones (Figure 1.1), which are among the most highly conserved 
eukaryotic proteins. These are small basic proteins consisting of a globular domain and 
a more flexible, charged NH2-terminus (histone tail) that protrudes from the 
nucleosome. Indeed, a number of enzymes modify histone tails amino acids at specific 
positions. These post-translational modifications include acetylation (of lysine 
residues), methylation (lysine and arginine), phosphorylation (serine and threonine), 
ubiquitylation (lysine), sumoylation (lysine) and ADP-ribosylation, which are thought to 
modulate the biological role of underlying DNA (Figure 1.2) (Bhaumik et al., 2007; 
Peterson and Laniel, 2004; Santos-Rosa and Caldas, 2005). Although histone 
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modifications were identified decades ago, only very recently their functional 
significance has been elucidated and the enzymes responsible for adding and 
removing each of these marks, characterised (Kouzarides, 2007). Distinct histone 
amino-terminal modifications can recruit additional chromatin-associated proteins, 
which may be important for regulating transition between transcriptionally active and 
silent chromatin states (Jenuwein and Allis, 2001). These covalent histone 
modifications provide an attractive “annotation” system for mitotically inheritable 
information that can be “read” by various effector proteins. By regulating access to 
underlying DNA, histone modifications and effector proteins can potentially dictate 
correct cell type-specific gene expression patterns (Jenuwein and Allis, 2001). The total 
number of possible different combinations of tail modifications is in excess of a 
thousand. Notably, several studies have indicated that specific combinations of histone 
modifications correlate well with a particular biological function. For instance, the 
combination of H4K8 acetylation, H3K14 acetylation, and H3S10 phosphorylation is 
often associated with transcription. Conversely, tri-methylation of H3K9 and the lack of 
H3 and H4 acetylation correlates with transcriptional repression in higher eukaryotes 
(Peterson and Laniel, 2004). The histone H3 tail appears to exist in two distinct states 
that are likely to be regulated by a “switch” between modifications of neighbouring 
residues. H3S10 phosphorylation inhibits H3K9 methylation but is synergistically 
coupled with H3K9 or H3K14 acetylation (Rea et al., 2000). This lead to the hypothesis 
that distinct histone modifications act sequentially or in combination to form an “histone 
code” that is read by other proteins to bring about distinct downstream biological events 
(Jenuwein and Allis, 2001; Spotswood and Turner, 2002). 
 
1.1.3.1. Histone acetylation 
 
One of the most consistent associations between histone modifications and 
chromatin structure is the underacetylation of all four histones, present at 
heterochromatin (Jeppesen and Turner, 1993; Maison et al., 2002). Conversely, 
histone hyperacetylation correlates with chromatin accessibility (Bode et al., 1980; Lee 
et al., 1993) and transcriptional activity (Allfrey et al., 1964; Pogo et al., 1966). These 
associations have been recently confirmed by several large-scale studies mapping 
histone modifications across the genome (Birney et al., 2007; Koch et al., 2007). 
Moreover, the role of histone acetylation on chromatin dynamics was functionally 
addressed in vivo by the incorporation of H4 homogeneously acetylated at lysine 16 
into nucleosome arrays. This led to chromatin compaction defects equivalent to 
deletion of the entire H4 tail (Shogren-Knaak et al., 2006). Hypoacetylation also seems 
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to be important for centromere function and constitutive heterochromatin organisation, 
as treatment with the histone deacetylase inhibitors (HDACi) causes increased 
acetylation of centromeric chromatin, defects in chromosome segregation and inhibition 
of centromeric clustering during muscle differentiation (Ekwall et al., 1997; Terranova et 
al., 2005). 
 
 
Figure 1.2. Human histone tail regions with some of the post-translational modifications that are 
known to regulate gene activity. Acetylation is represented by (ac), phosphorylation by (ph), 
ubiquitylation (ub1) and methylation is represented by (me). Modifications are shown above the amino acid 
sequence of NH2-terminus of histones. Globular domains of each core histones are represented as ovals. 
Acetylation of lysines 9 or 14 of histone H3 (H3K9ac or H3K14ac) or dimethylation of lysine 4 (H3K4me2) 
are generally associated with open genomic regions and transcription, whereas others, such as H3K9me3 
or H3K27me3, are indicative of a repressed chromatin state. Covalent histone modifications, alone or in 
combination, can influence nucleosome mobility and function as a platform for the recruitment of effector 
proteins (adapted from Bhaumik et al, 2007). 
 
All core histones are rich in lysines and those can be acetylated in vivo. 
Modifications of histone H3 and H4 are, however, more extensively characterised. 
Important positions for acetylation are K9 and K14 on histone 3 and K5, K8, K12, K16 
on histone 4 (Figure 1.2). Lysine positive charges neutralise the negatively charged 
phosphate groups on the DNA backbone resulting in a tight association of histones with 
DNA. Biochemical studies have shown that histone lysine acetylation “loosens” DNA-
histone interactions through the neutralisation of lysine positive charge (Hansen, 2002; 
Marmorstein, 2001) facilitating transcription machinery accessibility. However, the 
outcome of histone acetylation in chromatin structure is more complex as this 
modification can also form binding sites for various chromatin-associated proteins 
 25
containing bromodomains, which include members of the SWI/SNF class of ATP-
dependent chromatin remodellers (Agalioti et al., 2002; Loyola and Almouzni, 2004). 
Histone acetylation equilibrium is maintained by the balance of histone 
acetyltransferase (HAT) and HDAC activities (Wade et al., 1997). Turnover cycles of 
histone acetyl-groups have been shown to be very fast, with half-lives ranging from 
only a few minutes to several hours. This suggests that histone acetylation is highly 
dynamic and can rapidly change in response to external cues (Spotswood and Turner, 
2002). The identification of histone modifying enzymes themselves remained elusive 
until the first nuclear HAT, a Tetrahymena homolog of yeast Gcn5 (Skvirsky et al., 
1986), was identified in 1996 (Brownell et al., 1996). In vivo studies in yeast had 
previously characterised Gcn5 as a transcriptional co-activator protein, and thus its 
identification as a HAT solidified the view that histone modifications directly regulate 
transcription. Subsequently, a variety of other transcriptional co-activators, such as 
CBP/p300, TAF130/250 and P/CAF (a mammalian factor similar to Gcn5) were found 
to have intrinsic HAT activity (Lee and Workman, 2007; Peterson and Laniel, 2004), 
and many co-repressors, such as Rpd3, were found to have HDAC activity (Taunton et 
al., 1996). It is clear that targeting of histone acetylation is achieved by direct 
interactions between histone modifying enzymes and sequence-specific transcriptional 
regulators. For instance, the yeast HAT complex SAGA interacts with the 
transcriptional activation domains of a variety of gene-specific activator proteins, and 
these interactions target histone acetylation to specific promoter regions in vivo (Grant 
et al., 1998). Likewise, HDACs associate with several co-repressor complexes: HDAC 
1 and 2 are found in the ubiquitously expressed mSin3A, NuRD/Mi2/NRD and CoREST 
co-repressor complexes. HDAC3 associates to and is activated by SMRT and NCoR 
co-repressors that play an important role in the regulation of gene expression by 
nuclear hormone receptors (Pazin and Kadonaga, 1997; Yang and Seto, 2003). 
Moreover, in cycling myoblasts, interactions between HDAC1 and MyoD (Mal et al., 
2001), and HDAC4 and 5 and Mef2 (Lu et al., 2000) have been implicated in 
suppressing differentiation until specific cues (such as serum deprivation) initiate 
terminal differentiation. Under these conditions, pRb becomes dephosphorylated, 
sequesters HDAC1 from the MyoD-HDAC1 complex and releases MyoD to promote 
terminal muscle differentiation (Puri et al., 2001). 
HDACs are not redundant in function (Bolden et al., 2006; Marks and 
Dokmanovic, 2005). Eighteen HDACs have been identified in humans, and they are 
subdivided into four classes based on their homology to yeast HDACs, their subcellular 
localisation and their enzymatic activities (Figure 1.3) (Bolden et al., 2006; 
Thiagalingam et al., 2003). The class I HDACs (1, 2, 3 and 8) are related to the yeast 
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Rpd3 deacetylase and can generally be detected in the nucleus and show ubiquitous 
expression in various human cell lines and tissues. Class II HDACs (4, 5, 6, 7, 9 and 
10) are related to the yeast Hda1 protein and can shuttle between the nucleus and the 
cytoplasm and their expression is tissue-restricted. HDAC6 and 10 form a subclass 
(class IIb) that contain two deacetylase domains and are found predominantly in the 
cytoplasm. Members of a third class, sirtuins, require NAD+ for their enzymatic activity 
(Blander and Guarente, 2004). The enzymatic activity of class III HDACs is not 
inhibited by compounds such as trichostatin A (TSA) that broadly inhibit the other 
HDAC classes, which are zinc-dependent enzymes. HDAC11 is the sole member of 
class IV, it shares sequence similarity with the catalytic core regions of both class I and 
II enzymes but does not have strong enough identity to be placed in either class (Gao 
et al., 2002). 
HDACi such as TSA or valproic acid (VPA), disrupt the acetylation equilibrium, 
leading to a general increase in bulk histone acetylation. HDACi therefore provide good 
tools to analyse the cellular effects of histone acetylation. Importantly, HDACi 
selectively alter gene transcription. Studies using cDNA arrays showed only 7–10% of 
genes were altered in their expression in several different cell lines upon HDAC 
inhibition (Chambers et al., 2003a; Glaser et al., 2003; Iezzi et al., 2004; Mitsiades et 
al., 2004), suggesting that the effect of hyper-acetylation in gene expression is cell-type 
dependent. The structural details of the HDAC–HDACi interaction have been 
elucidated in studies of a histone deacetylase-like protein from an anaerobic bacterium 
with TSA and suberoylanilide hydroxamic acid (SAHA) (Finnin et al., 1999). More 
recently, the crystal structure of HDAC8–hydroxamic inhibitors interaction has been 
solved (Somoza et al., 2004; Vannini et al., 2004). These studies provided insight into 
the deacetylation mechanism of acetylated substrates. The hydroxamic acid moiety of 
the inhibitor directly interacts with the zinc ion at the base of the catalytic pocket. 
However, the diverse structural characteristics of HDACi translates in differential 
specificity for HDAC classes or proteins (Xu et al., 2007). While some HDACi such as 
TSA and SAHA broadly inhibit deacetylase activity, others selectively inhibit different 
HDACs (Figure 1.3). For example, depsipeptide reportedly possesses stronger activity 
against HDAC1 and HDAC2 than against the HDAC4 and HDAC6 (Furumai et al., 
2002). MS-275 preferentially inhibits HDAC1 with IC50, at 0.3 mM, compared to 
HDAC3 with an IC50 of about 8 mM, and has no inhibitory effect against HDAC6 and 
HDAC8 (Hu et al., 2003). Finally, two novel synthetic compounds, SK7041 and 
SK7068, preferentially target HDAC1 and 2 (Kim et al., 2003). 
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Figure 1.3. The histone deacetylase family and inhibitors. The figure shows the class I (HDAC1, 2, 3 
and 8), class IIa (HDAC4, 5, 7 and 9), class IIb (HDAC6 and 10) and class IV (HDAC11) HDACs with the 
various structural/functional domains listed (lower panel). The capacity of structurally diverse HDACi to 
inhibit the activity of different HDAC classes or specific HDACs is also shown. SAHA, suberoylanilide 
hydroxamic acid; TSA, trichostatin A; VPA, valproic acid (adapted from Bolden et al, 2006). 
 
1.1.3.2. Histone methylation 
 
Histone methylation targets selected arginine and lysine residues in the N-
terminal tails of histones H3 and H4 (Figure 1.2). The enzymes that catalyse these 
modifications are known as histone methyltransferases and are either lysine or arginine 
specific. In contrast to acetylation (which broadly correlates with transcriptional 
activation), histone methylation is associated with different outcomes depending on the 
site and also the extent of methylation (one, two or three methyl groups attached to the 
lysine ε–amino group, while arginine can be either mono- or dimethylated) (Kouzarides, 
2007). Although several characterised arginine methyltransferases and their identified 
role in transcriptional activation suggest that this modification is relatively abundant 
(Boisvert et al., 2005), it has been challenging to detect in vivo by mass-spectrometry 
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(Bannister and Kouzarides, 2005; Strahl et al., 2001). Recently, arginine methylation by 
the methyltransferase CARM1 has been implicated in the choice between embryonic 
and extraembryonic commitment of blastomeres in early mouse development (Torres-
Padilla et al., 2007). Methylation of lysine residues is known to occur on histone H3 at 
lysines 4, 9, 27, 36 and 79 and on histone H4 at lysine 20 (Figure 1.2). Histone H3 
lysine 4, 36 and 79 methylation has been correlated with transcriptional activity being 
mostly found in euchromatic regions, whereas methylation of H3K9 and H4K20 are 
found predominantly but not exclusively at constitutive heterochromatin (Martin and 
Zhang, 2005; Peters et al., 2003). H3K27, in turn, is enriched at facultative 
heterochromatin, including the inactive X-chromosome (Peters et al., 2003; Rougeulle 
et al., 2004). It is unlikely that histone methylation by itself has a pronounced effect on 
nucleosome structure, as the methyl group is neutrally charged. Instead, histone 
methyl marks create binding sites for a variety of regulatory proteins that induce 
changes in chromatin compaction and transcription (Daniel et al., 2005). Several 
proteins have been shown to specifically recognise and interact with methylated lysines 
(including chromo domain-, tudor domain- and WD40-repeat domain proteins) (Martin 
and Zhang, 2005). Those that associate with methylated H3K4 are involved in 
transcriptional activity (Pray-Grant et al., 2005; Wysocka et al., 2005), whereas those 
that bind methylated H3K9 or H3K27 have been implicated in transcriptional repression 
(Fischle et al., 2003; Thiagalingam et al., 2003). 
Histone lysine methylation is catalysed by enzymes containing a conserved 
130-aminoacid SET-domain (Jenuwein and Allis, 2001). The first identified histone 
methyltransferases were Suv39h1 and Suv39h2 in mammals and its fission yeast 
homolog Clr4 (Ivanova et al., 1998; Rea et al., 2000). These HMT specifically catalyse 
the trimethylation of H3K9 at constitutive heterochromatin. More than 70 other SET-
domain proteins have been found since in mammals, including G9a that catalyses the 
dimethylation of H3K9 at euchromatic areas, the Polycomb group protein Ezh2 that 
catalyses the trimethylation of H3K27 and Trithorax/MLL that catalyses the 
trimethylation of H3K4 (Lachner and Jenuwein, 2002). H3K9 methylation creates a 
high-affinity binding site for the chromodomain of heterochromatin protein 1 (HP1) 
(Lachner et al., 2001) that recruits additional proteins involved in heterochromatin 
maintenance. These include Suv39h itself, suggesting a possible mechanism of 
heterochromatin spreading, whereby HP1 binding to H3K9m3 recruits Suv39h, which 
methylate adjacent histones (Hiragami and Festenstein, 2005). In addition, this 
modification was shown to create binding sites for the RITS (RNA induced 
transcriptional gene silencing) complex, a component of RNAi machinery. It is 
suggested that RITS and small double-stranded RNAs transcribed from repetitive DNA 
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elements are able to mediate the targeted recruitment of the fission yeast (S. pombe) 
HMT Clr4 to heterochromatic regions. Deletion of crucial components of the RNAi 
pathway results in the aberrant accumulation of complementary transcripts from 
centromeric heterochromatic repeats. This is accompanied by transcriptional de-
repression of transgenes integrated at the centromere, loss of histone H3K9 
methylation, and impairment of centromere function (Verdel and Moazed, 2005; Volpe 
et al., 2002). There is also evidence that RNAi is involved in the maintenance of 
constitutive heterochromatin in higher organisms, including Drosophila and humans 
(Kim et al., 2006; Pal-Bhadra et al., 2004). 
Histone methylation was initially thought to be a relatively stable and irreversible 
modification, as initial studies presented evidence that the turnover rates of histone 
methyl groups were slower than those of histones themselves (Spotswood and Turner, 
2002). However, several families of histone demethylases have been recently 
identified. The first histone demethylase to be identified was the lysine-specific 
demethylase 1 (LSD1), a protein previously found to be part of several HDAC 
complexes, being shown to catalyse mono- or dimethylated (but not trimethylated) 
H3K4 demethylation by an oxidative demethylation reaction (Shi et al., 2004). LSD1 
has been implicated in transcriptional regulation and chromatin boundary formation 
(Lan et al., 2007b; Metzger et al., 2005). Unlike LSD1, a structurally unrelated family of 
enzymes has been found capable of removing both mono-, di- and trimethyl marks 
(Tsukada et al., 2006). These proteins share a JmjC motif that is conserved from S. 
cerevisiae to human and are thought to demethylate histones through an oxidative 
reaction that requires iron and α-ketoglutarate as co-factors. The methylation marks 
removed by these family of demethylases include H3K9, H3K27 and H3K36 (Klose and 
Zhang, 2007). Of particular interest is that the reported H3K27 demethylases JMJD3 
and UTX were found to be recruited with the H3K4 methylation machinery (Trithorax 
complex), resulting in the concerted demethylation of H3K27 (repression mark) and 
methylation of H3K4 (activation mark) at homeotic (Hox) loci during developmental 
activation (Agger et al., 2007; Lan et al., 2007a). Conversely, the functional interplay 
between the complex containing the Polycomb methyltransferase Ezh2 (that 
methylates H3K27) and the H3K4 demethylase Rbp2 was recently shown in mouse ES 
cells (Pasini et al., 2008). 
 
1.1.3.3. Histone variants 
 
 As well as specific modifications at histone tails, certain histone variants that 
share different degrees of homology to conventional histones are also implicated in 
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chromatin dynamics. In particular, regions of active transcription have been shown to 
incorporate the histone variant H3.3, which differs in only four amino acids from H3, but 
has different biological properties. While the “canonical” H3 is synthesised exclusively 
in dividing cells and integrated into chromatin during DNA replication, H3.3 is 
constitutively expressed and deposited into chromatin throughout the cell cycle (Ahmad 
and Henikoff, 2002a, b). H3.3-specific assembly complex lacks a p150 subunit that is 
present in the CAF-1 complex (involved in the replication-coupled nucleosome 
assembly), but instead contains a distinct chaperone termed histone regulator A (HirA) 
(Ray-Gallet et al., 2002; Tagami et al., 2004). It has been proposed that the replication-
independent histone replacement can be involved in the propagation of active 
chromatin states. Using a model where transcription was induced in a heterochromatic 
multicopy transgenic array, it was shown that loss of heterochromatic markers upon 
transgene activation is tightly linked with H3.3 deposition on chromatin (Janicki et al., 
2004). In this context, the “memory” of active transcription is retained at some loci 
when endoderm cell nuclei is transplanted into enucleated amphibian eggs. This 
epigenetic memory was shown to correlate with the association of histone H3.3 at loci 
that display memory but not in those where memory has been lost (Ng and Gurdon, 
2008). 
 Several variants have also been described for histone H2A. For example, 
H2A.Z in yeast  is a euchromatic variant associated with suppression of silencing, but it 
is localised to heterochromatin and interacts with HP1 in mammals (Fan et al., 2004). 
Mammalian H2A.Z was shown to be associated with Polycomb-mediated repression 
(Sarcinella et al., 2007), but was also found at actively transcribed genes (Bruce et al., 
2005; Farris et al., 2005). H2A.Z incorporation requires specific nucleosome assembly 
machinery that in budding yeast includes a member of SWI2/SNF2 chromatin 
remodelling family, Swr1, that is thought to destabilise the nucleosome and facilitate 
the exchange of H2A–H2B for H2A.Z–H2B (Mizuguchi et al., 2004). This process was 
also shown to depend on the transcription-coupled complex FACT, supporting the idea 
that H2A–H2B exchange occurs during transcription (Belotserkovskaya et al., 2003).  
 
1.1.4. Transcriptional silencing by Polycomb group 
proteins 
 
During embryogenesis and organogenesis, subsets of genes are activated in a 
temporally and spatially restricted manner. Shaping an embryo depends critically on 
the precise temporal and spatial expression of Hox genes. Trithorax (TrxG) and 
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Polycomb (PcG) group proteins were originally identified in Drosophila as products of 
genes that when mutated would affect the spatially restricted expression pattern of Hox 
genes and developmental patterning (Lewis, 1978). Transcription of Hox genes is 
initially achieved by transcription factors and subsequently maintained by PcG or TrxG 
proteins (Francis and Kingston, 2001). These proteins are part of a widely conserved 
“cell memory” system that stabilises cell identity by restricting or maintaining 
transcription patterns set in the first stage of embryonic life, throughout development 
and in adulthood (Ringrose and Paro, 2004). It is now recognised that PcG proteins 
regulate many genes in addition to the Hox genes and these include cell cycle and 
developmental-regulated genes such as transcription factors and signalling proteins 
(Boyer et al., 2006; Schwartz et al., 2006). Consistent with this, several mammalian 
PcG and TrxG members have been implicated in cell cycle regulation and 
tumorigenisis (Sparmann and van Lohuizen, 2006). PcG proteins are involved in gene 
repression and silencing, whereas TrxG proteins counteract repressive PcG functions 
and maintain gene activity (Orlando and Paro, 1995; Pirrotta, 1998). Notably, both 
groups encode components of multiprotein complexes that regulate chromatin structure 
in opposite ways (Mahmoudi and Verrijzer, 2001). 
TrxG protein complexes were found to methylate histone H3 lysine 4 (Milne et 
al., 2002), a modification characteristically associated with active chromatin 
(Ruthenburg et al., 2007). H3K4 trimethylation has been found at the 5’ regions of 
virtually all actively transcribed genes from budding yeast to humans, whereas H3K4 
monomethylation was shown to selectively localise to putative enhancer regions in 
human cells, but not in yeast (Heintzman et al., 2007). In Drosophila, TrxG (and PcG) 
bind to specialised DNA elements known as Polycomb/Trithorax response elements 
(PRE/TRE), which include many conserved short motifs, some of which are also 
recognised by other DNA-binding proteins. These sequences are necessary and 
sufficient for TrxG/PcG function and often reside within the promoters of target genes 
(Schwartz and Pirrotta, 2007). In mammals, however, PRE/TRE sequences were not 
identified suggesting that targeting of these complexes might be more complex. The 
recruitment of the mammalian TrxG protein MLL is facilitated by basal transcriptional 
machinery as well as sequence-specific transcription factors (Ruthenburg et al., 2007). 
The activity of another H3K4 methyltransferase, Ash1, was shown to be mediated by 
non-coding RNAs (Sanchez-Elsner et al., 2006). H3K4 methylation is known to recruit 
transcriptional activators and nucleosome remodelling factors, such as the HAT-
containing complexes SAGA and the ISWI-containing complex NURF (Pray-Grant et 
al., 2005; Wysocka et al., 2006). 
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Methylation of histone H3 lysine 27 is associated with PcG proteins, a family of 
structurally unrelated proteins involved in the epigenetic maintenance of the 
transcriptionally silent state (Figure 1.4). PcG proteins were found to be involved in the 
regulation of other cellular processes including proliferation, X-inactivation and the 
maintenance of pluripotency (the latter will be further discussed in Section 1.2.2.1) 
(Heard, 2005; Martinez and Cavalli, 2006; Spivakov and Fisher, 2007). Several 
Polycomb repressor complexes (PRCs) have been identified. The mammalian PRC2 
complex contains the histone methyltransferase Ezh2 and also two other proteins, Eed 
(embryonic ectoderm development) and Suz12 (suppressor of zeste-12) that are 
essential for the catalytic activity of the complex (Cao and Zhang, 2004). This complex 
catalyses the trimethylation of H3K27 (Figure 1.4), creating a binding site for another 
Polycomb repressor complex, PRC1, that comprises Ring1A/Ring1B, Bmi-1, Polycomb 
and Polyhomeotic proteins (Wang et al., 2004a). In addition, Ring1A/B in cooperation 
with Bmi-1 were recently shown to act as ubiquitin ligases catalysing the ubiquitylation 
of lysine 119 of H2A (Figure 1.4) (de Napoles et al., 2004), an event that was 
implicated in preventing active transcription of a number of developmental genes in ES 
cells (Jorgensen et al., 2006; Stock et al., 2007). This suggests that PRC1 and PRC2 
collaborate in maintaining silent chromatin. It is possible that PcG proteins can repress 
transcription by other means. In Drosophila, PcG proteins were also shown to interfere 
with transcriptional initiation and nucleosome remodelling (Dellino et al., 2004; Wang et 
al., 2004b). PRC1 is thought to maintain locus silencing by preventing chromatin 
remodelling at sites already rendered inactive by conventional DNA-binding factors 
(Francis and Kingston, 2001; Shao et al., 1999). Binding of PcG proteins might also 
alter the topology of the DNA itself, leading to the formation of negative superhelical 
turns (Mohd-Sarip et al., 2006). In addition, there is also evidence that link PcG 
proteins with RNAi-mediated transcriptional repression: PcG proteins co-localise in 
human cells with a core component of the RNAi machinery, Argonaute 1 (Kim et al., 
2006), and transcription of non-coding RNAs was found from a well-studied PRE-
containing transgene, Fab-7. Deletion of components of the RNAi pathway such as 
PIWI, Dicer-2 and Argonaute severely disrupted Polycomb-induced long distance 
interactions between different Fab-7 transgenic copies and between known Hox target 
loci (Grimaud et al., 2006). 
Notably, PcG and TrxG proteins maintain the status of their target genes 
through mitosis in a manner that is stable but not static. Thus, the interaction of PcG 
and TrxG proteins is proposed to ensure not only transcriptional memory, but also the 
capacity to switch if a new transcriptional stimulus is received (Ringrose et al., 2003). 
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Figure 1.4. Polycomb repressive complexes. Ezh2 methyltransferase, a component of Polycomb 
Repressor Complex 2 (PRC2) that also contains the Eed and Suz12 proteins, methylates lysine 27 of 
histone H3 (H3K27me). This modification recruits the Polycomb repressive complex 1 (PRC1) complex 
containing Polycomb (PC1), Polyhomeotic (PH1) and Bmi1 proteins as well as RING1A and RING1B that 
function as ubiquitin (Ub) ligases for lysine 119 of histone H2A (H2AK119). It is thought that Polycomb 
complexes or the histone modifications that they induce can interfere with nucleosome dynamics and 
prevent RNA polymerase from active transcription. The H3K27me mark and PRC2 binding at promoters 
can be lost (dotted line) by poorly understood mechanisms (adapted from Spivakov and Fisher, 2007). 
 
1.1.5. Spatial constraints – nuclear organisation 
 
Beyond histone and DNA modifications there is evidence that suggests that 
active and inactive chromatin domains occupy different nuclear compartments in some 
cell types (Brown et al., 1997; Mahy et al., 2002), and that this organisation may be 
important for maintaining the heritable state of some genes (Brown et al., 1999; Kosak 
et al., 2002; Su et al., 2004).  
A striking feature of nuclear architecture is the existence of distinct structural 
and functional compartments. Also, components of the machinery that is required for 
gene transcription or repression are known to have a non-homogeneous distribution in 
the nucleoplasm (Iborra et al., 1996; Jackson, 1995; Negre et al., 2006). At the level of 
the genome itself, it is known that individual chromosomes occupy distinct positions in 
the nucleus, referred to as chromosome territories (Figure 1.1) (Cremer et al., 2006). 
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As a result of different compaction levels, different chromosome segments adopt a 
complex organisation and topography within their chromosome territory (Croft et al., 
1999; Edelmann et al., 2001). A polarised intranuclear distribution of gene-rich and 
gene-poor chromosomal segments has been shown to be an evolutionarily conserved 
principle of nuclear organisation (Cremer et al., 2003; Tanabe et al., 2002) . Gene-rich 
regions tend to be oriented towards the nuclear interior, whereas gene-poor regions 
tend to be oriented towards the periphery (Foster and Bridger, 2005). Although 
chromosomes are organised as distinct territories in the interphase nucleus, 
chromosomes are dynamic structures and can be repositioned during development and 
cell differentiation, implying that nuclear organisation vary between cell types (Parada 
et al., 2004). One global example of such is the clustering of heterochromatin in distinct 
foci in the nucleus of mammalian cells, which can undergo morphological changes 
during differentiation. For example, when ES cells differentiate towards neural 
progenitor cells, the number of heterochromatic foci per nucleus decreased while the 
average cluster size increased, suggesting a global reorganisation of chromatin 
associated with differentiation (Williams et al., 2006). The same phenomenon is 
observed during terminal muscle differentiation. The spatial clustering of constitutive 
heterochromatin is accompanied by enhanced H3K9 and H4K20 tri-methylation across 
major satellite regions and increased non-coding transcription (Terranova et al., 2005). 
This clustering was shown to be dependent on histone deacetylation (Terranova et al., 
2005) and on the methyl-CpG binding proteins MeCP2 and MBD2 (Brero et al., 2005) 
that modulate the association of HP1 with heterochromatin (Agarwal et al., 2007). 
There is increasing evidence that gene repositioning to specific nuclear 
compartments is important for regulating expression (Gasser, 2002). Positioning of 
genes at the nuclear periphery is often correlated with silencing and repositioning 
towards the nuclear interior allows efficient transcription. Examples of this phenomenon 
include the IgH locus (immunoglobulin heavy chain) in committed B lymphocytes 
(Kosak et al., 2002), c-maf in T cells (Hewitt et al., 2004) and Mash1 in neuronal cells 
(Williams et al., 2006) that are repositioned to the nuclear interior upon activation. In 
addition, the inactive X-chromosome is often observed at the nuclear periphery of 
female cells (Burke and Stewart, 2002). However, there is not always a strict 
correlation between movement away from the periphery and gene activation. The 
interferon-γ locus, for instance, is detected at the nuclear periphery irrespective of its 
transcriptional activity (Hewitt et al., 2004). Furthermore, analysis of a 2-Mb segment 
encompassing the Mash1 gene showed that the entire region relocalised to the nuclear 
interior in Mash1-expressing neuronal cells, even though some of the genes in this 
region are not expressed in this cell type (Williams et al., 2006). Findings in yeast have 
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further complicated our understanding of the relationship between transcriptional 
activation and gene positioning relative to the nuclear periphery. In S. cerevisiae, this 
region contains silencing compartments (Andrulis et al., 1998), but also activating ones. 
Indeed, the nuclear pores are important sites of transcription in this species and 
genome-wide analysis has shown that nuclear pore-associated proteins bind 
preferentially to active genes (Casolari et al., 2004). Transcriptional activation is 
frequently accompanied by an apparent movement of genes in the opposite direction to 
that observed in mammalian cells — that is, from the nuclear interior to the periphery 
(Brickner and Walter, 2004).  
The presence of large amounts of heterochromatin is also thought to constitute 
another form of structural constraint that influences gene expression in mammalian 
cells. Several studies have reported a correlation between gene silencing and 
intranuclear positioning close to constitutive heterochromatin in mammalian cells. It has 
been suggested that this type of transcriptional repression could be explained by 
competition between heterochromatic proteins and transcriptional activators at the 
target locus (Brown et al., 1997), or by chromatin compaction that is mediated by 
heterochromatin-associated remodelling complexes (Grigoryev et al., 2006). Analysis 
of differentiating cells of the haematopoietic lineage have shown that gene activation is 
often associated with movement of the locus away from the heterochromatin 
compartment (Delaire et al., 2004; Hewitt et al., 2004) and, conversely, that gene 
silencing is correlated with repositioning of the locus close to heterochromatin (Brown 
et al., 1999), histone deacetylation and increased H3K9 methylation (Su et al., 2004). 
Chromosomal context seems to be an important determinant of association between 
specific loci and heterochromatin. This was demonstrated in a study of the human α-
globin and β-globin genes (Brown et al., 2001). In lymphocytes, in which both loci are 
silenced, the β-globin but not the α-globin locus localises close to centromeric 
heterochromatin. A possible explanation for this observation is that the two loci reside 
in regions of the genome that differ in several aspects: the α-globin locus lies in an 
early-replicating subtelomeric region that contain genes that are highly and widely 
expressed, whereas the β-globin cluster is embedded within a late-replicating AT-rich 
region that contains genes that show tissue-specific expression patterns. It is plausible 
that the lack of association between the inactive α-globin locus and heterochromatin 
reflects the need for neighbouring genes to be expressed; these might exert a 
dominant effect on the positioning of the entire genomic region away from 
heterochromatin. 
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Genomic interactions between distal regulatory elements and target genes that 
are located on the same chromosome can also occur. The β-globin locus control region 
(LCR) and the active β-globin itself have been shown to physically interact in erythroid 
cells, causing the intervening 50 kb of DNA sequence to loop (Carter et al., 2002; 
Tolhuis et al., 2002). This suggests that bending of chromatin facilitates tissue-specific 
functional interactions between these sites and this spatial proximity might be required 
for high transcriptional activity. The formation of loops is not simply a consequence of 
transcriptional activity since its formation precedes gene activation in mouse erythroid 
progenitors that are committed to this lineage but do not yet express β-globin (Palstra 
et al., 2003). Conversely, chromatin loops can spatially separate genomic regions and 
contribute to gene silencing (Horike et al., 2005). Physical interactions in trans between 
different chromosomes can also contribute to gene silencing. Of interest is the reported 
long-distance pairing of genomic regions that contain PREs (such as Fab-7 and Mcp) 
in a tissue-specific manner in D. melanogaster nuclei. These interactions enhance 
transcriptional repression that is mediated by PcG proteins (Bantignies et al., 2003; 
Vazquez et al., 2006) and are not detected in Polycomb-null background. Because 
PcG proteins are known to be compartmentalised in the nucleus (Buchenau et al., 
1998; Saurin et al., 1998), these data led to the suggestion that endogenous PcG 
target genes may undergo physical associations at nuclear PcG bodies dedicated to 
their regulation.  
 
1.1.6. Temporal correlates – replication timing 
 
In contrast to bacteria, which replicate their genome using a single origin, DNA 
replication in eukaryotes initiates bi-directionally at multiple chromosomal positions 
named origins of replication. Activation of all replication origins does not occur 
synchronously but progresses in a defined temporal order during S-phase of the cell 
cycle - some origins fire early and some fire late in S-phase (Camargo and Cervenka, 
1982). This pattern is clonally inherited through subsequent cell divisions, but can 
change at genes undergoing developmental activation or silencing (Cimbora and 
Groudine, 2001; Perry et al., 2004). The temporal order of gene replication during S-
phase has been proposed to be important for maintaining gene expression patterns 
(Gilbert, 2002). Early replication is generally associated with accessible chromatin 
carrying acetylated histones (Lin et al., 2003; Perry et al., 2004; Vogelauer et al., 
2002), whereas late replication is a characteristic of constitutive heterochromatin and 
some facultative heterochromatin, formed through gene repression (Gilbert, 2002). In 
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addition to its association with the epigenetic status, replication timing correlates with 
the genomic context of the loci. Genome-wide analyses in Drosophila and human cells 
have shown that GC-rich, gene-dense regions tend to replicate early in S-phase, while 
AT-rich, gene-poor regions with high LINE (linear interspersed nuclear element) 
content tend to replicate later (Schubeler et al., 2002; Woodfine et al., 2004). 
Consistent with this, a study of 54 developmental genes in a model of neural 
differentiation in vitro demonstrated that only genes that map to AT-rich, LINE-poor 
regions changed replication timing upon transcriptional activation or repression during 
differentiation, while those mapping to GC-rich backgrounds remained early-replicating 
irrespective of transcriptional state (Hiratani et al., 2004). 
The nature of the correlation between replication timing and genomic and 
epigenetic features remains unclear. It was hypothesised that histone acetylation 
renders replication origins more efficient or specifically orchestrates earlier firing 
leading to earlier completion of locus replication (Aparicio et al., 2004; Vogelauer et al., 
2002). Histone acetylation is, however, almost completely restricted to early-replicating 
areas (Azuara et al., 2006; Jorgensen et al., 2007) and therefore other factors are likely 
to determine whether a locus replicates in the middle or end of the S-phase. The 
cause-and-effect relationship between replication timing and the chromatin status is 
also not fully established. Single-cell injection experiments in mammalian cells suggest 
that the timing of replication plays a role in the maintenance of heritable epigenetic 
states through mitosis. Reporter plasmids injected in early S-phase cells were more 
transcriptionally active and packaged into chromatin enriched in acetylated histones 
compared to when injected in late S-phase cells (Zhang et al., 2002). Consistent with 
this, replication forks are thought to include different subsets of chromatin modifiers in 
early and late S-phase (Chakalova et al., 2005; Gilbert, 2002). However, recent 
unpublished findings from our laboratory showing that only a fraction of early-
replicating sequences in ES cells is enriched for active histone modifications argue 
against this as a generalised rule. 
During other phases of the cell cycle, other temporal constraints might influence 
chromatin regulation, such as the length of G1-phase. It is during G1 that interactions 
between gene loci and heterochromatin become established. Therefore the length of 
G1 (which varies among cell types) might influence gene expression patterns. In 
Drosophila the occurrence of association of the bw(D) allele with a heterochromatic 
compartment was proportional to the time spent in G1/G0 of the cell cycle. According to 
this model, the longer the time that a locus spend in G1 exploring nuclear space, the 
bigger the probability that it will encounter an heterochromatic compartment and make 
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stable contacts that leads to stable silencing (Harmon and Sedat, 2005; Thakar and 
Csink, 2005). 
 
In summary, maintenance of a stable epigenetic memory is a complex task that 
involves multiple layers of regulation, acting at all levels from DNA and histone 
modifications to the folding of chromosomal domains in the cell nucleus. The sum of all 
these epigenetic modifications is thought to confer identity to a cell dependent on their 
developmental history. Despite apparent stability over multiple cell cycles or long 
phases of quiescence, these epigenetic modifications are ultimately reversible and their 
functional significance can be addressed experimentally during somatic cell 
reprogramming, for example in nuclear transfer or heterokaryon assays. 
 
1.2. Somatic cell reprogramming 
 
Once committed, the differentiated state of a cell is normally stable and can be 
inherited through cell division. Under certain conditions cell fate can, however, be 
modified or reversed (DiBerardino, 1988; Simonsson and Gurdon, 2005; Surani, 2001). 
This exceptional change in cellular identity leading to the establishment of a novel gene 
expression program is here referred to as reprogramming. Such reprogramming can be 
demonstrated in vivo by trans-differentiation and regeneration or experimentally 
through nuclear transfer and cell fusion (Baron and Maniatis, 1986; Gurdon, 1962; 
Gurdon and Byrne, 2003; Hochedlinger and Jaenisch, 2002; Wilmut et al., 1997). 
 
1.2.1. Conversion between differentiated cell types 
 
Under exceptional circumstances cells can change their developmental 
program and give rise to cell-types that differ from their normal fate. 
Transdifferentiation, the conversion of cells from one differentiated cell type to another 
can occur particularly during the process of regeneration (Tanaka, 2003; Tsonis and 
Del Rio-Tsonis, 2004). One well known example is the regeneration of the lens of 
various species of urodele amphibia (newts and salamanders). Here, after removal of 
the lens of the eye, a new lens regenerates from the dorsal iris (Eguchi and Kodama, 
1993; Tsonis et al., 2004). Iris cells are pigmented epithelial cells which upon 
regeneration give rise to modified keratinocytes containing high concentrations of 
crystallin proteins characteristic of the lens. Changes in cell fate between 
undifferentiated cells committed to form specific tissue types, to another cell lineage 
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were also observed in vivo. This phenomenon, known as transdetermination, has been 
extensively characterised in Drosophila melanogaster. At the end of Drosophila larval 
development, the cells required to produce the adult cuticular structures are found in 
determined structures called imaginal discs. If these discs are manually fragmented 
and kept in culture, cells at the wound site undergo proliferation and regenerate the 
missing part. In rare cases, however, during the regeneration of Drosophila imaginal 
discs, cellular identities can switch fate (McClure and Schubiger, 2007). For example, 
tissue from a leg disc may produce wing structures (Hadorn, 1968). At the molecular 
level it was shown that ectopic expression of the transcription factor gene vestigial can 
drive transdetermination of other discs to wing phenotype (Klebes et al., 2005; Maves 
and Schubiger, 1995). Recent studies indicate that the plasticity of disc cells during 
regeneration is associated with cell cycle changes (extended S-phase), and the re-
organisation of chromatin structure (Sustar and Schubiger, 2005). Downregulation of 
PcG proteins by JNK signalling in some leg cells may reactivate vestigial expression 
leading to transdetermination (Lee et al., 2005). The fact that regeneration is a 
widespread phenomenon in metazoans (Brockes and Kumar, 2008) suggests that, 
despite being determined or differentiated, cells remain remarkably plastic. 
In mammals however, conversion of cell fate is more controversial. Work done 
between the years of 1997 and 2002 in mice suggested that lineage committed 
progenitors may also undergo transdetermination in vivo when cells are placed in 
environments appropriate for a different developmental program. Differentiated somatic 
tissues could be populated by cells from bone marrow grafts (Raff, 2003; Tosh and 
Slack, 2002; Wagers and Weissman, 2004). For example, injection of haematopoietic 
progenitors into the cardiomyocite pool could facilitate its regeneration following 
myocardial infarction (Orlic et al., 2001) as well as give rise to glial cells in the brain 
(Eglitis and Mezey, 1997; Mezey et al., 2000). Recent research however, has directly 
challenged the possibility of conversion of genetically unmodified cells in vivo, 
suggesting that earlier studies were simply inaccurate in defining the transdetermined 
phenotype. In some cases the donor cells were simply lodged in the host tissues but 
the cells had not actually changed cell fate. In addition, it was shown that the donor 
cells can spontaneously fuse in vitro (Terada et al., 2002; Ying et al., 2002) and in vivo 
(Palermo et al., 2005; Weimann et al., 2003) with host cells, providing an alternative 
explanation of cell plasticity. Given all these problems it is now generally accepted that 
haemotopoietic progenitors remain committed to their fate even within 
microenvironments appropriate for other lineages (Balsam et al., 2004; Massengale et 
al., 2005; Murry et al., 2004). 
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In humans, it is not infrequent to find foci of a particular tissue in the wrong 
place (metaplasia), but it is difficult to rule out the possibility that the ectopic tissue has 
arisen by cell migration rather than by transdifferentiation (Slack and Tosh, 2001). 
Examples include the occurrence of bone in the soft connective tissue, or squamous 
patches in an epithelium that is normally glandular in histology (Slack, 1985; Slack and 
Tosh, 2001). Metaplasias usually arise in tissues subject to chronic trauma or infection, 
hence undergoing continuous regeneration. Some examples of metaplasia are now 
understood in molecular terms, for example patches of intestinal epithelium in the 
stomach can be produced by ectopic expression of the transcription factor Cdx2 
(Silberg et al., 2002). Some metaplasias have clinical significance because they 
predispose to development of cancer, for example squamous metaplasia of the 
bronchus or intestinal metaplasia of the stomach. However, all these in vivo examples 
of cell identity changes occur in the course of regeneration, which somehow may 
destabilise the differentiated or committed cell. Whether transdifferentiation and 
transdetermination represent a rare event in normal development or if it does occur at 
all in mammals remain controversial. 
Experimentally, the constitutive expression of specific transcription factors by 
certain cell types can sometimes modify or override lineage outcome. For example, 
expression of individual muscle regulatory factors (MRF) of the MyoD family has been 
shown to convert a range of non-muscle cell types into muscle. However, ectopic 
expression of MyoD in ectoderm lineages in vivo (Faerman et al., 1993) or in 
hepatocytes in vitro (Schafer et al., 1990) does not initiate a complete conversion of 
these lineages into differentiated muscle. Similarly, MyoD expression in mouse ES 
cells and in transgenic embryos promotes activation of endogenous MyoD and 
expression of a few muscle-specific protein genes but does not activate a complete 
skeletal muscle differentiation program (Dekel et al., 1992). Herein, MyoD over-
expression can convert ES cells to differentiated muscle only if differentiation is 
induced by embryoid body formation, indicating that MyoD myogenic regulatory 
functions require changes in cell context in order to initiate a complete differentiation 
program. Similarly, mis-expression of the erythroid factor Gata1 in myeloid 
haematopoietic progenitors resulted in their conversion to erythroid lineages (Heyworth 
et al., 2002) and the transcription factors C/EBPα and C/EBPβ can reprogram 
committed mature B-lymphocytes to become macrophages (Xie et al., 2004) or in a 
different cell context promote the conversion of pancreatic cells to hepatocytes (Shen 
et al., 2000). More recently, using a strategy of re-expressing key developmental 
regulators in vivo, Zhou et al identified a specific combination of three transcription 
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factors (Ngn3, Pdx1 and Mafa) that reprograms differentiated pancreatic exocrine cells 
in adult mice into cells that closely resemble beta-cells (Zhou et al., 2008). 
In most cases reported here the original and final tissue type are 
developmentally related in some way, for example being formed as adjacent regions 
from one sheet of cells in the embryo. Reprogramming between different germ layers 
has been more challenging, probably due to the developmental history of the cells. To 
directly analyse more extensive changes in cell fate, another approach has been used: 
fusion of two distinct somatic cells to form a single cell that contains different nuclei 
sharing the same cytoplasm. 
 
1.2.1.1. Cell fate conversion in heterokaryons and hybrid cells 
 
Somatic cell fusion, pioneered by H. Harris and N. Ringertz, has been used to 
illuminate many interesting cellular processes involving cytoplasmatic-nuclear 
interactions (Harris, 1965; Ringertz and Savage, 1976). Cell fusion creates cells 
harbouring two or more nuclei sharing the same cytoplasm, termed heterokaryon if the 
fused cells originate from different tissues or species, or homokaryons if the parental 
cells belong to the same cell-type. If heterokaryons are maintained in culture for 
several days, hybrids will form, resulting from fusion between nuclei and subsequent 
cell division. For example, studies with hybrids provided early evidence that the 
malignant state is, in some cases, recessive to the differentiated state (Harris et al., 
1969; Peehl and Stanbridge, 1982), a prediction now confirmed at the molecular level 
for many cancers. In addition, the combination of two cell types through cell fusion to 
form somatic cell hybrids yielded early evidence that mammalian gene expression can 
be altered by diffusible trans-acting factors. Following fusion with another cell type, the 
expression of differentiated functions frequently ceased (Mevel-Ninio and Weiss, 
1981). For example, in hybrids between hepatocytes or lymphocytes and less 
specialised cells such as fibroblasts, the expression of cell-type-specific genes derived 
from the more differentiated parental cell are selectively turned off (Massa et al., 2000). 
The reason why more undifferentiated cell-types usually dominate over more 
differentiated fusion partners remains unknown. Somatic-cell hybrids often lose 
chromosomes in culture which led to the attribution of individual repressive effects to 
particular chromosomes (Ephrussi, 1972; Massa et al., 2000). Interestingly, the 
principle of phenotypic exclusion seen during normal development also applies to 
hybrid cells. When two differentiated cell types are fused, hybrid cells have the 
potential to express either one or the other phenotype, but not both (Fougere and 
Weiss, 1978). The molecular mechanisms that make gene expression programs 
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mutually exclusive remain elusive. In some cases, trans-activation of genes was also 
reported (Peterson and Weiss, 1972; Rankin and Darlington, 1979). However, it is 
difficult to draw conclusions about mechanisms of gene activation in stable hybrid cell 
lines because their genetic composition is variable and difficult to control (Ephrussi, 
1972). Tetraploid hybrid cells, in particular formed between cells of different species 
lose chromosomes with cell division. It has been suggested that this happens due to 
non-synchronous control of DNA replication (Lin and Davidson, 1975). To circumvent 
this problem, Blau and colleagues performed experiments in heterokaryons which have 
clearly shown that fusion of one differentiated cell (a muscle cell) with a cell in which 
muscle genes are not normally expressed (a human amniocyte) leads to the activation 
of muscle genes in the amniocyte (Blau et al., 1983). Remarkably, cells derived from 
mesoderm, endoderm and ectoderm could also be dominantly reprogrammed in mouse 
myotubes to express muscle specific genes (Blau et al., 1985). Cells that were more 
closely related to muscle – mesodermal derivatives – consistently expressed muscle 
genes sooner and at a greater extent than the cells of ectodermal or endodermal origin 
(Blau et al., 1985). These studies have established that differentiated cells do retain 
flexible lineage potential and that lineage conversion and gene activation can occur in 
absence of DNA replication (Chiu and Blau, 1984). Gene activation in muscle 
heterokaryons is rapid (usually within two days), and is dependent on gene dosage, i.e. 
activation levels are dependent of a threshold concentration of positive regulators 
(Pavlath and Blau, 1986). These results suggest that factors capable of activating 
genes can either exchange freely between nuclei or exist in excess within the 
cytoplasm. Some experiments have shown this to be true for regulatory transcription 
factors such as the glucocorticoid receptor (Hache et al., 1999). The maintenance of 
specialised cellular phenotypes through dynamic interplay between positive and 
negative regulatory molecules could involve either direct interaction by complementing 
a particular deficiency in one of the cell types in a heterokaryon (Baron, 1993; Blau, 
1992), or it could involve indirect effects. Such indirect effects might occur when a 
positive regulatory factor induces other cell type-specific transcription factors that in 
turn might activate a diverse group of downstream genes (Hardeman et al., 1986). This 
latter mechanism appears to operate when erythroid cells are fused with non-erythroid 
cells (Baron and Farrington, 1994; Baron and Maniatis, 1986).  
Experiments on heterokaryons have been interpreted as evidence for 
continuous regulation of a plastic differentiated state (Blau and Baltimore, 1991), and 
providing an argument for the continuous need to impose (actively) or maintain the 
differentiated state (DiBerardino, 1988). Implicit in this model is the idea that all genes 
are continuously and actively regulated by trans-acting factor networks that either 
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activate or repress genes (Blau and Baltimore, 1991; Blau et al., 1985; Chiu and Blau, 
1984). Accordingly, considerable remodelling of chromosomal structure occurs in 
heterokaryons. For example, the nuclei of chicken erythrocytes consist predominantly 
of heterochromatin containing the specialised linker histone H5. In heterokaryons 
formed by fusion of chicken erythrocytes with proliferating mammalian cells, the 
chicken erythrocyte nuclei once again become transcriptionally active. This process is 
accompanied by decondensation of chromatin, enlargement of the nucleus and the 
appearance of nucleoli. The enlargement of the chicken erythrocyte nucleus is due to a 
massive, but selective, uptake of mammalian nuclear proteins, including RNA 
polymerases. Conversely histone H5 is partially lost from the chicken erythrocyte 
nucleus (Ringertz et al., 1985). Histones H2A and H2B also exchange under these 
circumstances, but histones H3 and H4 do not. These results are predicted based upon 
the relative affinity of the histones for DNA and their organisation in the nucleosome 
(Pruss et al., 1995). The stability of DNA methylation states has also been recently 
explored in stable heterokaryons. Upon cell fusion of human keratinocytes with mouse 
myotubes, unknown factors alter regulatory regions of genes in keratinocyte nuclei, 
demethylating and activating a muscle-specific gene (MyoD) and methylating and 
silencing a keratinocyte-specific gene (Keratin14) (Zhang et al., 2007). Because these 
changes occur in the absence of chromosome replication or cell division, they should 
be mediated by an active mechanism (Zhang et al., 2007). DNA methylation has also 
been shown to restrict the reprogramming potential of some cell-types (Hela cells) in 
heterokaryons. When treated with the DNA demethylating agent 5-aza-cytidine prior to 
cell fusion, the previously non-inducible Hela cell nuclei were capable to activate early 
and late myogenic proteins (Chiu and Blau, 1985). 
 
1.2.2. Reprogramming somatic cells to pluripotency 
 
By “reversing” development, the reprogramming of somatic cells to embryonic 
state provides an exciting approach to address the functional significance of epigenetic 
mechanisms implicated in cellular differentiation and establishment of pluripotency. In 
addition, reprogramming somatic cells to become pluripotent is an important goal in cell 
replacement therapy since it affords the opportunity to generate and use patient-
specific ES-derived cells as grafts. Using this strategy it would be possible to 
circumvent the problems of immune rejection that are likely to occur, unless the 
recipient and donor stem cells are very closely matched. Much of our knowledge of the 
biology of the uncommitted state came from the derivation of self-renewing cell lines 
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from human and animal stem cell populations. In particular, the study of the in vitro 
counterparts of undifferentiated cells in the embryo shed light on some of the 
mechanisms that control the pluripotent state. 
 
1.2.2.1. Genetic and epigenetic regulators of pluripotency 
 
Stem cells are characterised by the ability to self-renew and generate 
differentiated progeny and are often functionally classified according to their 
developmental potential. In mammals only the zygote and early blastomeres are 
totipotent and can generate the entire organism. Pluripotent stem cells – i.e., those that 
have the potential to generate all cell types of the adult organism excluding the extra-
embryonic tissue (Rossant, 2007) – can be obtained from pre- and early post-
implantation stages of embryonic development. In particular, ES cells are derived from 
the ICM of blastocysts (Evans and Kaufman, 1981; Thomson et al., 1998) (Figure 1.5a) 
that later gives rise to the three germ layers. In contrast, EC cells isolated from 
naturally occurring or experimentally induced teratocarcinomas have a more restricted 
lineage potential that varies between different EC cell lines (Andrews et al., 2005; 
Chambers and Smith, 2004). Later in development, pluripotency is retained only within 
cells of the primordial germ layer that can give rise to EG cells in vitro (Lovell-Badge, 
2001). The main difference between EG and ES cells observed so far is that in EG 
cells, a number of genes have lost allele-specific parental imprints. This reflects the 
genome-wide reprogramming that occurs during primordial germ cell (PGC) 
development (Reik et al., 2001) with the purpose to modulate egg and sperm 
chromatin to a state that allows successful formation of a zygote, which then has the 
capacity to form an entire organism. PGCs begin to migrate at embryonic day 8.5 to the 
genital ridge where they arrive at day 11.5 dpc. EG cells are derived from PGC cells 
from the genital ridges at 11.5 to 13.5 embryonic days, which coincide with the period 
of genome-wide reprogramming (Morgan et al., 2005). Nonetheless, germline 
contribution has been demonstrated for at least some EG (Stewart et al., 1994; Tada et 
al., 1998) and EC (Stewart and Mintz, 1982) cells, thus demonstrating their 
pluripotency. 
Pluripotent ES cells undergo symmetrical self-renewal and can be propagated 
clonally, producing two identical cells upon cell division. For these cells, self-renewal 
entails the suppression of differentiation (Ying et al., 2008). When introduced into a 
blastocyst, ES cells can contribute to formation of all tissues in the organism (including 
the germ line), whereas their transplantation to adult immunologically compromised 
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animals gives rise to teratomas – tumours containing a highly diverse array of cell 
types originated from all three embryonic layers. 
 
Human and mouse embryonic stem cells and their regulation 
 
ES cell pluripotency is thought to be maintained by several key transcription 
factors. These include the POU-family transcription factor Oct4, the SOX-family 
transcription factor Sox2 and a homeodomain DNA-binding protein called Nanog 
(Chambers and Smith, 2004). Embryos lacking Oct4 do not form ICM, consisting 
exclusively of trophectoderm tissue (Nichols et al., 1998). In vitro, deletion of Oct4 
leads to the conversion of ES cells to trophectoderm (Niwa et al., 2000). Mouse ES 
cells deficient for Nanog are still able to self-renew, but show an increased propensity 
to differentiate (towards extra-embryonic endoderm) and cannot give rise to mature 
germ cells (Chambers et al., 2003b; Chambers et al., 2007). The role of Sox2 in early 
embryonic development is more difficult to study due to the presence of maternally-
derived mRNA. It is however known that following implantation, as the maternal 
component is largely lost, Sox2-null embryos generate exclusively trophoblast and 
extraembryonic ectoderm (Avilion et al., 2003). Similarly to Oct4, Sox2 deletion in ES 
cells also leads to their conversion in trophectoderm (Masui et al., 2007). Sox2 was 
shown to heterodimerise with Oct4, acting synergistically to activate Oct-Sox 
enhancers, and thereby regulating the expression of stem cell-associated genes (Chew 
et al., 2005; Okumura-Nakanishi et al., 2005; Tomioka et al., 2002). Recent data from 
H. Niwa’s laboratory implicated Sox2 in the regulation of multiple transcription factors 
that affect Oct4 expression (Masui et al., 2007). Forced expression of Oct4 rescues the 
self-renewal and pluripotency defect of Sox2-null ES cells. These results indicate that 
the essential function of Sox2 is to stabilise ES cells in a pluripotent state by 
maintaining the requisite level of Oct4 expression, rather than in the establishment of 
pluripotency (Masui et al., 2007). In addition to its expression in early embryonic cells, 
Sox2 is also expressed in neural stem cells and is essential for primitive ectoderm 
development (Miyagi et al., 2008). 
To gain more insight into the transcriptional regulatory network operating in ES 
cells, different studies have mapped genome-wide Oct4, Nanog and Sox2 binding sites 
in human and mouse ES cells (Boyer et al., 2005; Loh et al., 2006; Mathur et al., 2008). 
Despite the low overlap between human and mouse datasets, these authors found that 
Oct4 and Nanog (and in human ES cells, also Sox2) co-occupy a large number of 
developmental genes, including both transcriptionally active and inactive genes in ES 
cells (Figure 1.5b). Among the active genes, targets included Oct4, Nanog and Sox2 
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themselves as well as other transcription factors, chromatin remodelling and modifying 
factors and components of signalling pathways known to be important for ES cell 
biology. In contrast, a large portion of the inactive targets identified encode 
developmentally important transcription factors, such as genes involved in the 
specification of ectoderm, endoderm, mesoderm and extra-embryonic lineages. These 
findings have been collectively taken to suggest that Oct4, Sox2 and Nanog serve as 
so-called “master regulators” of the pluripotent stem cell identity (Spivakov and Fisher, 
2007). However, the network that control pluripotency is more complex and many other 
players are now being involved (Dejosez et al., 2008; Kim et al., 2008a). 
Although human and mouse ES cells seem to share intrinsic regulators, the 
extrinsic signals required for pluripotency have undergone significant species-specific 
modification (Figure 1.5a) (Pera and Trounson, 2004). The undifferentiated state of 
mouse ES cells can be maintained in culture by foetal calf serum in combination with 
LIF, a cytokine known to act mainly via the JAK-STAT3 signalling pathway (Niwa et al., 
1998). The activation of the STAT3 pathway involves heterodimerisation of LIF 
receptor with the gp130 membrane protein that leads to the activation of JAK tyrosine 
kinase. Withdrawal of LIF triggers differentiation to a mixture of lineages (Nichols et al., 
2001) and the provision of activated STAT3 renders mouse ES cells independent of 
LIF (Matsuda et al., 1999). In addition, signalling through bone morphogenic proteins 
(BMPs) maintain ES cell self-renewal. Usually these factors are supplemented by the 
serum, however, the addition of BMP and LIF to the media allows culturing 
undifferentiated ES cells in serum-free conditions (Ying et al., 2003). Recently 
however, it was shown that mouse ES cells can be efficiently derived and maintained 
in minimal conditions without extrinsic requirements for growth factors or cytokines 
(Ying et al., 2008). This work showed that ES cells can be maintained in their self-
renewing state by blocking differentiation-inducing signalling using a cocktail of 
inhibitors (for FGF receptor tyrosine kinases, ERK and GSK3 pathway). In contrast to 
mouse ES cells, LIF signalling is not active in undifferentiated human ES (hES) cells 
(Daheron et al., 2004; Humphrey et al., 2004) and BMPs induce trophectoderm 
differentiation, either in the presence (Gerami-Naini et al., 2004; Pera and Trounson, 
2004) or absence (Xu et al., 2002) of serum. Conversely, the MEK kinase pathway 
promotes differentiation in mouse ES cells (Nichols et al., 2001), but in hES cells, 
fibroblast growth factor 2 (FGF2) (Amit et al., 2000), activates this pathway through 
FGF receptors, and is required to maintain the undifferentiated state. Several studies 
suggest that FGF and TGFβ signalling interactions are important for maintenance of 
hES cell pluripotency (Amit et al., 2004; Noggle et al., 2005; Wang et al., 2005; Xu et 
al., 2005). Thus, long-term maintenance of hES cells can be achieved with a 
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combination of Activin or Nodal (signalling branch TGFβ/Activin/Nodal through 
Smad2/3 activation) plus FGF2 in the absence of feeder-cell layers, conditioned 
medium or serum replacer (Beattie et al., 2005; Vallier et al., 2005). 
Several phenotypic differences between mouse and hES cells have been 
reported (Giadrossi et al., 2007; Pera et al., 2000). Mouse cells grow in rounded 
colonies, and have indistinct borders, whereas hES cell colonies are flatter and often 
display more distinct borders. The embryonic markers defined by the antibodies SSEA-
1, -3 and -4 against cell surface glycolipids are expressed differently in mouse 
(SSEA1+) and hES (SSEA3/4+) cells. Also the cell-surface proteoglycan recognised by 
several monoclonal antibodies reactive with hES cells, including TRA-1-60 and TRA-1-
81, are not detected in mouse ES cells (Thomson et al., 1998). The question of 
whether differences between mouse and hES cells are related to species differences or 
relate to differences in the stages of embryonic development when they were derived 
remains open (Lovell-Badge, 2007). Some data suggest that the same pattern of 
antigen expression is seen in the ICM of the human blastocyst and in hES cells. 
SSEA3, SSEA4 and TRA-1-60 were all found to be expressed in the ICM in a limited 
series of human pre-implantation blastocysts cultured in vitro (Dimos et al., 2008). As 
these markers are not expressed in the mouse ICM, this finding suggests that there are 
intrinsic species-specific differences in the expression of these markers in pluripotent 
cells. Moreover, a general argument in favour of the existence of species-specific 
differences in pluripotent stem cell phenotype is that pluripotent cells in mice and 
humans show differences irrespective of whether they originate directly from embryos 
or from primordial germ cells or through process of teratocarcinogenesis (Pera et al., 
2000). Thus, human EC cells resemble hES cells, mouse EC stem cells resemble 
mouse ES cells, and the two cell-types show the same inter-species differences. 
However, the recent derivation of pluripotent stem cells from post-implantation mouse 
embryos, the so-called epiblast stem cells, challenged this view. These novel 
pluripotent cell lines are distinct from mouse ES cells in their epigenetic state as well as 
the signals driving their differentiation. Furthermore, they share some features with 
human ES cells such as patterns of gene expression and signalling responses, 
suggesting that the differences between human and mouse ES could be potentially 
explained by their temporal derivation in the embryo (Brons et al., 2007; Tesar et al., 
2007). 
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Epigenetic signatures of pluripotency 
 
It has been suggested that chromatin features of pluripotent ES cells reflect a 
generalised “open” and transcriptionally “permissive” state (Meshorer and Misteli, 
2006). For example, Meshorer and colleagues have demonstrated that chromatin 
proteins such as H2B, H3 and HP1 are more dynamic in ES and EC cells than in 
differentiated cells (Meshorer et al., 2006). ES cell differentiation resulted in an 
increase in global levels of the heterochromatic mark H3K9me3 and a decrease of 
acetylated H3 and H4 (Lee et al., 2004; Meshorer et al., 2006). Also in Drosophila 
melanogaster, living cell measurements showed that, despite similar diffusion 
coefficients, chromatin mobility is more constrained in the nuclei of differentiated than 
in the nuclei of undifferentiated counterparts (Thakar and Csink, 2005). ES cells have 
also been shown to have a characteristic replication timing profile in which many non-
expressed tissue-specific regulator genes replicate early in S-phase (Azuara et al., 
2006; Hiratani et al., 2004). Consistent with this, several ATP-dependent remodelling 
factors are highly expressed in ES cells (Kurisaki et al., 2005) and mutations in 
components of the SWI/SNF chromatin-remodelling complex such as Brg1, results in 
developmental arrest at the 2-cell stage (Bultman et al., 2006). 
A series of studies have shown that tissue-specific genes that were thought to 
be in a repressed state in pluripotent cells might in fact be poised for transcription in ES 
cells. Szutorisz and co-workers showed that in ES cells, the B-cell specific λ5-VpreB1 
locus is already marked by H3K4me2 and H3 acetylation (active chromatin 
modifications) prior to activation during B-cell commitment, and that these marks 
disappear from the locus upon ES cell differentiation into a non-lymphoid lineage 
(Szutorisz et al., 2005). In addition, PcG proteins were identified to have a crucial role 
in the regulation of ES cell identity. Chromatin immunoprecipitation studies in mouse 
and human ES cells revealed that the members of the PRC2 complex Suz12 and Eed 
bind to the promoters of many developmental genes that are not actively transcribed in 
ES cells, but are important for the regulation of lineage specification of extra-embryonic 
lineages or in later stages of development (Boyer et al., 2006; Jorgensen et al., 2006; 
Lee et al., 2006). Remarkably, Suz12 occupied the majority of non-expressed genes 
co-bound by transcription factors Oct4, Sox2 and Nanog, suggesting that these 
regulators may specifically recruit PcG proteins to their repressed targets (Figure 1.5b) 
(Lee et al., 2006). Supporting this role for PcG proteins, many developmental PcG 
target genes become derepressed upon genetic disruption of the PRC2 components 
Eed (Figure 1.5c) or Suz12 (Azuara et al., 2006; Boyer et al., 2006; Lee et al., 2006) or 
the PRC1 component Ring1B (Jorgensen et al., 2006; Stock et al., 2007).  
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Figure 1.5. Regulation of pluripotency. (a) Pluripotent embryonic stem cells are derived from the inner 
cell mass of blastocysts. Human and mouse differential extrinsic requirements for the maintenance of the 
undifferentiated state in culture are indicated. (b) The Oct4, Sox2, and Nanog transcription factors (blue) 
occupy actively transcribed and silent genes. At this latter set of genes, RNA polymerase II (POL2) is 
present but not active due to the repressive action of PcG proteins. The interconnected autoregulatory 
loop, where Oct4, Nanog, and Sox2 bind together at each of their own promoters, is shown (bottom left). 
(c) The promoters encoding a range of non-transcribed developmental genes bear a combination of 
“conflicting” histone modifications that are normally associated with either active chromatin states (H3K9ac 
and H3K4me) or inactive chromatin states (H3K27me). During differentiation, “bivalent” chromatin profiles 
are generally resolved, leading to transcriptional activation of tissue-specific genes and silencing of loci 
associated with alternative developmental pathways. ES cells that are deficient for Polycomb repressor 
complex 2 (such as Eed–/– cells) do not have the capacity for H3K27me and, consequently, many tissue-
specific genes that are bivalent in wild-type cells are derepressed (adapted from Jaenisch and Young, 
2008 & Spivakov and Fisher, 2007). 
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Notably, Eed-deficient cells are more prone to differentiate, suggesting a direct 
functional link between PRC2, gene silencing and the maintenance of the pluripotent 
state (Montgomery et al., 2005). Interestingly, the promoters of many inactive genes 
are marked in ES cells by both repressive and active modifications – a so-called 
“bivalent domain” (consisting of H3K27me3 associated with H3K4me3) (Azuara et al., 
2006; Bernstein et al., 2006) (Figure 1.5c). It has been suggested that ‘bivalent’ 
chromatin may allow tissue-specific regulator loci to remain untranscribed (or non-
productively transcribed) in pluripotent cells, but ‘primed’ for the rapid activation in 
response to developmental cues (Giadrossi et al., 2007; Spivakov and Fisher, 2007). 
Interestingly, this “priming” has been shown to correlate at the molecular level with the 
presence of poised RNA polymerases (not elongating) at bivalent gene promoters in 
ES cells (Stock et al., 2007). In ES-derived neural progenitors, as well as 
haematopoietic cells, bivalent chromatin profiles at many developmental genes were 
found to be resolved as lineage-appropriate genes became activated and depleted for 
H3K27me3, while lineage-inappropriate genes lost histone acetylation and H3K4m3 
(Bernstein et al., 2006; Mikkelsen et al., 2007). For example, in myoblasts Suz12 is no 
longer found at the promoters of muscle-specific genes including the key regulator of 
muscle differentiation MyoD (Boyer et al., 2006). Polycomb protein binding was, 
however, still observed in differentiated cells, including neural progenitors, myoblasts 
and T cells, indicating that in addition to pluripotency PcG proteins are involved in gene 
repression at different stages of development (Barski et al., 2007; Lee et al., 2006; 
Mikkelsen et al., 2007). 
 
The increasing knowledge of how the undifferentiated state is maintained in 
embryo-derived stem cell lines provided valuable clues for the understanding how re-
orchestration of pluripotency occurs during reprogramming (Jaenisch and Young, 
2008). Several experimental reprogramming strategies to convert somatic cells to 
pluripotency (both directly an indirectly) have been outlined including nuclear transfer, 
cell fusion and the forced expression of factors (Figure 1.6). Apart from the potential 
value for regenerative medicine, these approaches are instrumental for dissecting the 
re-establishment of pluripotency in a somatic cell at the cellular and molecular level 
(Hochedlinger and Jaenisch, 2006; Yamanaka, 2008). 
 
1.2.2.2. Somatic cell nuclear transfer 
 
Evidence of successful nuclear reprogramming of somatic cells was provided 
by the live birth of animals cloned by injection of differentiated somatic nuclei into eggs 
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(Figure 1.6). This demonstrates that terminally differentiated cells retain cell plasticity 
and can be reprogrammed to produce an adult cloned animal (Gurdon, 1962; 
Hochedlinger and Jaenisch, 2002; Wilmut et al., 1997). Successful nuclear transfer 
was first reported in 1952 by Briggs and King, who showed that nuclei from blastula 
stage embryos injected into enucleated Rana pipiens eggs resulted in normal hatched 
tadpoles (Briggs and King, 1952). In 1962 Gurdon successfully generated adult, fertile 
Xenopus laevis by nuclear transplantation of differentiated tadpole intestinal cells, but 
partial embryo cleavage of cloned embryos was far more frequent than complete 
cleavage (Gurdon, 1962). However, it has been found that the cells of the partial 
blastulae can be used as donors for a second, serial set of nuclear transfers to 
enucleated eggs. When this is done with partial blastulae derived from intestinal 
epithelium cells of Xenopus, it is found that many of the serial nuclear transplant 
embryos develop remarkably well (Gurdon et al., 2003). More than 30 years later, 
“Dolly” the sheep became widely recognised for being the first successfully cloned 
mammal (Wilmut et al., 1997). About a dozen other mammalian species have been 
cloned since (Gurdon and Byrne, 2003; Vajta and Gjerris, 2006). It remained a formal 
possibility, however, that donor nuclei which gave rise to the rarely observed clones 
were actually derived from tissue stem cells, which represent a small proportion of 
adult tissues. Herein, the successful generation of cloned mice from lymphocytes 
(Hochedlinger and Jaenisch, 2002; Inoue et al., 2005) unambiguously demonstrated 
(as lymphocytes undergo irreversible recombination of immunoglobulin or T-cell 
receptor) that terminal differentiation does not restrict the potential of the nucleus to 
support development. Cloning from terminally differentiated donor cells is, however, 
hugely inefficient and in many instances was only successful when a ‘‘two-step’’ 
procedure, that involved the generation of cloned ES cells was used as an intermediate 
(Hochedlinger and Jaenisch, 2003). These observations suggested that differentiation 
state may affect the efficiency of producing cloned animals. For example, blastomeres 
and ES cells show the highest success rates in direct cloning experiments (10-30%) in 
sharp contrast to more differentiated cells such as fibroblasts and cumulus cells (1-
3%). Terminally differentiated cell-types such as lymphocytes and neurons were cloned 
using the “two-step” procedure previously described (Hochedlinger and Jaenisch, 
2006). This inverse correlation between differentiation and reprogramming is consistent 
with the observation that a common problem of the cloning procedure is the faulty 
reactivation of early embryonic genes such as Oct4 (Bortvin et al., 2003; Jaenisch et 
al., 2005) and conversely the incomplete silencing of tissue-specific genes (Ng and 
Gurdon, 2005, 2008). However, because the cloning process is affected by many other 
parameters, such as cell cycle and the physical characteristics of the donor nucleus, it 
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has remained unresolved whether cloning efficiency decreases with progressive cell 
differentiation in all cases. For example, the generation of cloned ES cells from 
neurons is less efficient than that from neural stem cells (Blelloch et al., 2006; Inoue et 
al., 2007). In contrast, it has been argued that nuclei from granulocytes are more 
efficient donors than nuclei from haematopoietic stem cells (Sung et al., 2006).  
Nuclear cloning is an inefficient process resulting in the death of most clones 
soon after implantation or birth of clones with serious abnormalities (Hochedlinger and 
Jaenisch, 2003; Yang et al., 2007). Faulty reprogramming and epigenetic errors are 
most likely to be the cause of these developmental defects, since the offspring of 
cloned animals is not affected (Tamashiro et al., 2002). The dynamics of murine Oct4 
mRNA expression by mouse thymocyte nuclei after transfer to Xenopus eggs supports 
the requirement for complete epigenetic reprogramming (Simonsson and Gurdon, 
2004). Chemical removal of thymocyte chromatin proteins substantially accelerated 
Oct4 transcript accumulation from 96 hours to 40 hours. Consistent with the 
observation, injection of unmethylated plasmid DNA containing the genomic Oct4 
region resulted in detection of transcripts within few hours; the authors demonstrated 
that thymocyte derived Oct4 transcription was dependent on active chromatin 
remodelling and DNA demethylation. Following transplantation into an oocyte, somatic 
nuclei undergo global changes, including nuclear swelling (Barry and Merriam, 1972; 
Byrne et al., 2003), chromatin re-distribution, induction of DNA synthesis and 
movement of proteins from the egg cytoplasm into the somatic nucleus (Gurdon, 2006; 
Merriam, 1969; Tamada et al., 2006). It therefore became important to determine 
whether faulty reprogramming would affect the therapeutic utility of patient-specific ES 
cells derived by nuclear transfer. Experiments in mice showed no molecular or 
biological differences when ES cells derived from fertilised embryos or by nuclear 
transfer were compared (Brambrink et al., 2006; Wakayama et al., 2007), indicating 
that nuclear transfer ES cells are as useful for therapeutic application as ES cells 
derived from fertilised embryos. 
Regardless of the recent advances in primate embryo cloning (Byrne et al., 
2007), the generation of cloned human embryos remains limited by the availability of 
oocytes and ethical issues. One approach to overcoming this limitation is to use 
oocytes from other species such as cow or rabbit. One report (Chen et al., 2003) has 
documented the establishment of ES cells from rabbit/human inter-species blastocysts. 
Although these results were not independently reproduced yet, those ES cells 
phenotypically resembled human ES cells except from carrying human and rabbit 
mitochondria. In summary, nuclear transfer holds promise for the creation of tailored 
stem cells for regenerative medicine however, alternative, more amenable approaches 
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are needed to uncover the molecular mechanisms underlying reprogramming for 
pluripotency. 
 
 
Figure 1.6. Four strategies to induce reprogramming of somatic cells to pluripotency. Nuclear 
transfer involves the injection of a somatic nucleus into an enucleated oocyte, which, upon transfer into a 
surrogate mother, can give rise to a clone (‘‘Reproductive cloning’’), or upon derivation and expansion in 
culture can give rise to genetically matched ES cells (‘‘Customized ES cells”). Cell fusion of somatic cells 
with ES cells results in the generation of tetraploid hybrid cells that show all features of pluripotent ES 
cells. Explantation of somatic cells in culture selects for immortal cell lines that may be pluripotent or 
multipotent. At present, spermatogonial stem cells are the only source of pluripotent cells that can be 
derived from postnatal animals. Transduction of somatic cells with defined factors can initiate 
reprogramming to a pluripotent state. The promises and challenges associated with each of the strategies 
are indicated (adapted from Jaenisch and Young, 2008). 
 
1.2.2.3. Cell fusion 
 
Cell fusion has been used to demonstrate the dominant conversion of somatic 
cells to “early” pluripotent stages (Figure 1.6). Miller and Ruddle showed, in 1976, that 
the fusion of pluripotent teratocarcinoma cells with primary thymocytes resulted in the 
formation of pluripotent hybrids that shared all their features with the parental EC cells, 
including the potential to induce tumors (Miller and Ruddle, 1976). Importantly, the 
dominance of pluripotent cells over differentiated cells has also been shown in 
spontaneous (Terada et al., 2002; Ying et al., 2002) and experimental hybrids made 
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between somatic cells and murine EG (Tada et al., 1997)  and ES (Tada et al., 2001) 
cells. Hybrid cells contribute to the three primary germ layers of chimeric embryos and 
transplantation into immunodeficient mice results in formation of teratomas. The ability 
to reprogram somatic cells seems to be conserved in human ES cells (Cowan et al., 
2005; Yu et al., 2006) and analysis of mouse and human hybrid cell transcriptome 
revealed global patterns of gene expression reminiscent of ES cells (Ambrosi et al., 
2007; Cowan et al., 2005). A central question raised by these experiments is whether 
the chromosomes of the somatic cell had been reprogrammed to pluripotency, or 
whether they were silenced and carried along with the pluripotent genome. To study 
reprogramming in heterokaryons, hybrid (tetraploid) cells and in nuclear transfer 
experiments it is important to be able to distinguish and verify events that occur in the 
donor nucleus from those of the recipient. This can be achieved using at least 3 
different approaches (a) using a transgene marker (b) intra-specific polymorphic 
differences and (c) using differences between species. Activation of silent pluripotency-
associated transgenes such as Oct4-GFP (Tada et al., 2001) and Rex1-GFP (Cowan 
et al., 2005), or reactivation of the inactive somatic X-chromosome (Kimura et al., 
2002) provided some molecular evidence for reprogramming of the somatic genome in 
hybrid cells. In addition, endogenous genes such as Cripto (Cowan et al., 2005), Oct4 
and Sox2 (Flasza et al., 2003; Han et al., 2008) were also shown to be initiated in the 
somatic cell nucleus upon cell fusion. In another paper form the T. Tada laboratory, the 
authors studied the chromatin events that accompany the reprogramming process by 
fusing ES cells (M. musculus domesticus) with thymocytes (M. musculus molossinus) 
(Kimura et al., 2004). By monitoring changes in chromatin structure of thymocyte nuclei 
upon ES hybridisation the authors observed global and locus-specific (at the Oct4 
promoter region) hyperacetylation of histones H3 and H4 and di- and tri- methylation of 
H3K4, consistent with the chromatin configuration in ES cells. The stability of DNA 
methylation states has also been explored in embryonic hybrids. Interestingly, there are 
striking changes in methylation in the somatic nucleus, in which several imprinted, non-
imprinted genes (such as Oct4) and repetitive DNA were shown to be demethylated 
(Cowan et al., 2005; Tada et al., 1997; Tada et al., 2001). The somatic DNA 
methylation pattern at the imprinted H19/Igf2r locus is maintained in somatic-ES 
hybrids, unlike hybrids formed between somatic and EG cells (in which the differential 
methylation is erased). Thus, ES cells have the capacity to selectively reset certain 
epigenetic modifications of somatic cells. 
Little is known about the molecular mechanisms underlying reprogramming by 
fusion with ES cells. The factors implicated may reside in the nucleus or in the 
cytoplasm. This question was initially addressed by separating the nuclear 
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compartment (karyoplast) from the cytoplasmic compartment (cytoplast) of an ES cell; 
these elements were then individually fused with neuronal cells isolated from 
neurospheres (Do and Scholer, 2004). In hybrids produced with the ES-cell 
karyoplasts, reactivation of an Oct4–GFP transgene was detected. In contrast, the GFP 
signal was not detected when neurosphere cells were fused with ES-cell cytoplasts, 
suggesting that nuclear factors are essential for molecular reprogramming. This 
conclusion is consistent with cloning experiments in amphibians (Byrne et al., 2003) 
and mice (Wakayama et al., 1998), which indicate that successful reprogramming 
depends on direct injection of nuclei into the germinal vesicle or into a metaphase 
oocyte, where nuclear factors are available in the cytoplasm. However, a recent report 
suggested that the cytoplasm could be enough for reprogramming (Strelchenko et al., 
2006). Smith and colleagues observed a marked increase in reprogrammed cell 
colonies when they fused neural stem cells with ES cells that overexpress the 
transcription factor Nanog (Silva et al., 2006). The same phenomenon was observed 
for the transcription factor Sall4 (Wong et al., 2008), previously identified as a 
pluripotency-associated factor that regulates Oct4 in ES cells (Zhang et al., 2006). Also 
chromatin-associated factors seem to affect reprogramming efficiency since knocking-
down G9a, a H3K9 HMT, or over-expressing the H3K9 demethylase Jhdm2a in 
somatic cells was shown to facilitate reprogramming (Ma et al., 2008). Other questions 
that have emerged are whether DNA replication and cell division are critical for 
reprogramming. The time required for Oct4 activation upon cell fusion (approximately 
24 hours) can be correlated with the timing of cell cycle completion in ES cells 
(approximately 22 hours), suggesting that DNA replication may be essential for 
reprogramming (Han et al., 2008; Wong et al., 2008). However, nuclear transfer 
experiments indicated the presence of replication-independent mechanisms. Whether 
DNA replication, genome inter-mixing and cell division play an important role in 
reprogramming is unknown. 
In addition to providing an in vitro system to test the requirements of 
reprogramming, cell fusion is a potentially attractive approach to generate tailored cells 
for therapy without relying on nuclear transfer (Cowan et al., 2005). However, for this 
approach to be viable, the ES-cell nucleus needs to be removed from the heterokaryon 
in order to generate diploid customised cells for transplantation therapy (Pralong et al., 
2005). Although selective elimination of some ES cell-derived chromosomes after 
hybrid formation is possible (Matsumura et al., 2007), it may be difficult to generate 
diploid reprogrammed cells in this way due to the risk of generating large-scale 
genomic instability. If DNA replication and cell division are required for complete 
reprogramming the applications of this method are limited. In addition, there has been 
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no convincing functional evidence showing that the somatic donor nucleus has re-
gained the potential to sustain pluripotency in the absence of the ES-cell genome.  
 
1.2.2.4. Reprogramming by cell extracts, culturing and overexpression of 
defined factors 
 
Using cell-free systems to study reprogramming is an alternative to nuclear 
transfer or cell fusion. In addition, extracts might allow the purification of protein 
complexes involved in reprogramming. For example, Allan Wolffe’s laboratory 
subjected permeabilised Xenopus tadpole-derived epithelial cells to S-phase Xenopus 
egg extracts (Kikyo et al., 2000). Within two hours donor nuclei lost over 85% of 
radioactively labelled proteins, concomitant with morphologically visible de-
condensation of chromatin and uptake of proteins from the egg cytoplasm. Chromatin 
de-condensation was shown to be specifically dependent on the ATP-dependent 
nucleosome remodelling enzyme ISWI, which reversed TATA-binding protein mediated 
attachment of chromatin domains to the nuclear matrix. In a different set of 
experiments, human cells were exposed to Xenopus cell extracts and Oct4 
transcription was initiated following treatment (Hansis et al., 2004). However, no stable 
reprogramming was seen in reversibly permeabilised somatic cells that were 
subsequently passaged in culture, suggesting that a continuous supply of factors might 
be required for functional reprogramming to a pluripotent state. Xenopus egg extracts 
have proved useful in solving an old enigma in frog cloning: why cloning efficiency was 
markedly increased when somatic nuclei underwent serial transplantations (Gurdon 
and Byrne, 2003). Lemaitre and colleagues showed that efficient chromatin remodelling 
of differentiated nuclei depends on their exposure to mitotic egg extract, thereby 
facilitating embryonic DNA replication. Indeed pre-incubation of erythrocyte nuclei with 
Xenopus mitotic extract caused DNA replication, origin periodicity to decrease from 
about 120 Kb to 25 Kb (in early embryos these intervals are around 23 Kb). The 
authors also provided evidence that the enzyme topoisomerase II is required for 
chromatin re-organisation and origin recognition complex recruitment (Lemaitre et al., 
2005). Mammalian cell extracts were also shown to induce reprogramming. 
Permeabilised human 293T cells were exposed for 1 hour to extracts from human EC 
cells, and Oct4 expression and chromatin remodelling was detected (Freberg et al., 
2007; Taranger et al., 2005). However, since human EC cells express Oct4, these data 
cannot exclude the possibility that gene products were detected from the cells that 
were used to prepare the extracts. To circumvent this problem human 293T cells were 
permeabilised and incubated in extracts of mouse ES cells. The specific detection of 
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human pluripotency-associated transcripts occurred 1-8 hours after extract exposure 
(Bru et al., 2008). 
Donor cells from the germ cell lineage such as PGCs or spermatogonial stem 
cells are known to be unipotent in vivo, but it has been shown that pluripotent ES-like 
cells, can be isolated after prolonged in vitro culture from post-natal spermatogonial 
stem cells (Kanatsu-Shinohara et al., 2004). Spermatogonial stem cell-derived cells are 
pluripotent, as they were able to form postnatal chimeras and contribute to the 
germline. More recently, multipotent adult spermatogonial stem cells were derived from 
testicular spermatogonial stem cells of adult mice (Guan et al., 2006), and these cells 
were able to differentiate in vitro and to generate teratomas in vivo, but unable to form 
chimeras. A concern for any therapeutic application of cells derived from the germ line 
is their impact on genomic imprinting. It remains an open question whether somatic 
stem cells derived from adults can be converted to pluripotency by expansion in 
culture. 
Takahashi and Yamanaka recently achieved a significant breakthrough in 
directly reprogramming somatic cells back to an ES-like state (Takahashi and 
Yamanaka, 2006). They successfully reprogrammed mouse embryonic and adult 
fibroblasts to pluripotent ES-like cells after viral-mediated transduction (Figure 1.6) of 
the four transcription factors Oct4, Sox2, c-Myc, and Klf4. These were coined “iPS” (for 
induced pluripotent stem) cells and were shown to be pluripotent by their ability to form 
teratomas, although they were unable to generate live chimeras. The original isolation 
of iPS cells was based on drug-dependent selection for Fbx15, a gene targeted by 
Oct4 and Sox2, and expressed in pluripotent ES cells. When activation of Oct4 or 
Nanog genes was used as a more stringent selection criterion for pluripotency, the 
resulting Oct4-iPS or Nanog-iPS cells, in contrast to Fbx15-iPS cells, were fully 
reprogrammed to pluripotency. Importantly, Oct4- and Nanog-iPS cells generated 
postnatal chimeras, contributed to the germ line (Maherali et al., 2007; Okita et al., 
2007; Wernig et al., 2007), and generated late-gestation embryos through tetraploid 
complementation (Wernig et al., 2007), the most stringent test for developmental 
potency. In addition, iPS cells were shown to be transcriptionally and epigenetically 
indistinguishable from ES cells. iPS cells showed reactivation of somatically silenced X-
chromosome, DNA demethylation of pluripotency-associated genes and acquisition of 
chromatin structure that closely resemble ES cells (Maherali et al., 2007; Okita et al., 
2007; Wernig et al., 2007). The kinetics of events of reprogramming to iPS was 
recently addressed. Pluripotency markers such as alkaline phosphatase (3 days), 
SSEA1 (9 days), and Oct4 or Nanog (20 days) appear sequentially after viral 
transduction (Brambrink et al., 2008; Stadtfeld et al., 2008a; Wernig et al., 2007). Also, 
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evidence obtained by using inducible lentivirus-based vectors indicated that the four 
factors must be expressed for more than 12 days in order to generate iPS cells 
(Brambrink et al., 2008). Expression of the reprogramming factors in fibroblasts 
appears to initiate a sequence of events that eventually leads to the conversion of a 
small percentage of cells. In addition, similarly to what observed in nuclear transfer 
experiments, iPS reprogramming seems to be influenced by donor cell-type. The same 
cocktail of 4 transcription factors has been shown to drive mouse hepatocytes, 
stomach cells (Aoi et al., 2008), pancreatic beta-cells (Stadtfeld et al., 2008a) and 
immature B-lymphocytes to iPS, whereas adult mouse B-lymphocytes (Hanna et al., 
2008) required the additional expression of C/EBPα or silencing of the B-cell specific 
factor Pax5. Conversely, just 2 factors (Oct4 and Klf4) were sufficient to reprogram 
adult neural stem cells, which endogenously express Sox2 and c-Myc (Di Stefano et 
al., 2008; Eminli et al., 2008; Kim et al., 2008b). 
Reprogramming of human fibroblasts has also been achieved in a parallel 
approach using Oct4, Sox2 and either Nanog plus Lin28 (Yu et al., 2007) or Klf4 plus 
c-Myc (Lowry et al., 2008; Park et al., 2008c; Takahashi et al., 2007). Human iPS cells 
have been obtained by exposing fibroblasts only to Oct4, Sox2, and Lin28 (Yu et al., 
2007), although less efficiently. To date, human cell types converted to iPS include 
foetal fibroblasts, adult dermal fibroblasts, bone-marrow-derived mesenchymal cells 
and keratinocytes. In order to reprogram keratinocytes a combination of 5 factors 
(Oct4, Sox2, Klf4, c-Myc and Nanog) was required (Maherali et al., 2008). Thus, it 
remains unknown whether the same factors are sufficient to reprogram more 
specialised cell types such as mature human lymphocytes. Interestingly, generation of 
human iPS cells was dependent on FGF2 (Park et al., 2008b) rather than LIF (required 
to generate mouse iPS). Derivation of human iPS cells in mouse ES cell media with LIF 
was fruitless (Takahashi et al., 2007). 
Isolation of iPS cells has been based on retrovirus-mediated transduction of 
oncogenes and drug-dependent selection for reprogrammed cells. These experimental 
requirements hinder the eventual medical application of this in vitro reprogramming 
approach. Mice derived from iPS cells frequently developed cancer due to transgene 
re-activation (Okita et al., 2007) and the isolation of human iPS cells cannot be based 
on genetically modified donor cells. In an effort to reduce the risk of tumors in iPS cell-
derived chimeras, more recent experiments showed that c-Myc is dispensable for 
reprogramming (Nakagawa et al., 2008; Wernig et al., 2008; Yu et al., 2007), though 
the reprogramming process was significantly delayed and less efficient in the absence 
of this oncogene. While mice derived from these iPS cells will not develop c-Myc-
induced tumors (Nakagawa et al., 2008; Wernig et al., 2008), it is not clear whether the 
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transduction of other retrovirus-transduced transcription factors such as Oct4  will also 
cause tumors at later stages (Hochedlinger et al., 2005). In any case, new technologies 
must be developed to avoid the use of retrovirus. To address the second problem, iPS 
cells were isolated from genetically unmodified mouse fibroblasts based only on 
morphological criteria (Blelloch et al., 2006; Meissner et al., 2007).  
These pioneering studies have illustrated the importance of several factors for 
iPS, but also suggested by their low efficiency that additional ones may be needed for 
efficient conversion to pluripotency. Less than 1% of the cells that have incorporated 
the four retroviruses can become iPS cells. The identification of the missing factor(s) 
may enable more efficient and retrovirus-free generation of iPS cells. The big challenge 
is to adapt what is known for the direct conversion of adult somatic cells to pluripotency 
to allow the production of genetically matched cells for the study and treatment of 
human disease (Nishikawa et al., 2008). Recently, a patient with amyotrophic lateral 
sclerosis was used to successfully generate iPS cells that possess properties of ES 
cells which could be directed to differentiate into motor neurons, the cell-type destroyed 
in this disease (Dimos et al., 2008). In addition, a variety of other disease-specific iPS 
cells were recently generated for research (Park et al., 2008a). Proof-of-principle 
studies have also shown that disease-specific ES cells produced by somatic cell 
nuclear transfer or iPS, in combination with gene correction, could be used to cure 
immunological disorders or sickle cell anemia in mice (Hanna et al., 2007; Rideout et 
al., 2002). Nonetheless, major drawbacks of reprogramming strategies lay in the low 
efficiency of the process, the use of virus and ethical concerns, which limit medical 
applications. It is likely that complex transcriptional and epigenetic events are required 
for efficient conversion to pluripotency. Therefore one of the most pressing objectives is 
to increase our knowledge about the reprogramming process, i.e. systematically define 
the constellation of ‘‘reprogramming factors’’ and interactions that convert the 
epigenome of a somatic cell into that of an embryonic stem cell.
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1.3. Aims of this study 
 
Conversion of one cell-type to another involves the establishment of the novel 
program of gene expression and the coordinated silencing of lineage inappropriate 
genes. The molecular mechanisms that control this processes and prevent the 
expression of lineage inappropriate gene programs (phenotypic exclusion) remain 
poorly understood. The overall aim of this study is to dissect the epigenetic events and 
factors required for lineage conversion. For this I will use experimental inter-species 
heterokaryons as a tractable approach to monitor the progression of reprogramming of 
human somatic cells. 
 Initially, I will focus on the characterisation of the epigenetic events of 
reprogramming of human somatic cells to muscle identity. Experimental cell fusion will 
be used to reprogram human B-lymphocytes through the formation of stable 
heterokaryons with mouse myotubes. With this approach I will address large scale 
events of reprogramming such as changes in nuclear organisation and the importance 
of chromatin mechanisms for lineage inappropriate gene extinction. Further, I will 
expand the heterokaryon approach for the reprogramming of somatic cells to 
pluripotency. Mouse ES cells will be fused to human B-lymphocytes and the 
requirements/stability of the reprogramming process will be addressed. This approach 
will also be used to uncover the individual role of factors previously implicated in 
reprogramming and finally, address the contribution of Polycomb repression in ES cells 
for somatic cell reprogramming. 
This study might contribute to both an increased understanding of the molecular 
basis of cell identity conversion as well as helping to develop potential applications of 
nuclear reprogramming in cell replacement therapy. 
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CHAPTER 2. MATERIALS AND METHODS 
 
 
2.1. Materials 
 
2.1.1. Antibodies 
 
hLamin A/C Mouse monoclonal anti-human Lamin A/C (VP-L550; Vector Laboratories Inc., 
Burlingame, CA). Does not cross-react with mouse Lamin A/C. Used for 
immunofluorescence (IF) at 1:100 dilution. 
GFP Rabbit polyclonal anti-green fluorescent protein (GFP) (A11122; Molecular Probes, 
Eugene, OR). Used for IF at 1:200 dilution. 
SSEA4 Mouse monoclonal anti-human SSEA4 (MC-813-70; Developmental Hybridoma Studies 
Bank, Iowa City, IA). Used for IF and fluorescence activated cell sorting (FACS) at 1:3 
dilution. 
TRA-1-60 Mouse monoclonal anti-human TRA-1-60 (MAB4360; Chemicon/Milipore, Temecula, 
CA). Used for IF at 1:12 dilution. 
TRA-1-81 Mouse monoclonal anti-human TRA-1-81 (MAB4381; Chemicon). Used for IF at 1:20 
dilution. 
hNestin Rabbit polyclonal anti-human Nestin (ab28944; Abcam Ltd., Cambridge, UK). Does not 
cross-react with mouse Nestin protein. Used for IF at 1:100 dilution. 
hNanog Rabbit polyclonal anti-human Nanog (ab21624; Abcam). Does not cross-react with 
mouse Nanog protein. Used for IF at 1:100 dilution. 
mOct4 Goat polyclonal anti-mouse Oct4 (sc-8628; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA). Used for western blot at 1:2000 dilution. Mouse monoclonal anti-Oct4 (611202; BD 
Biosciences, San Jose, CA). Used for IF at 1:100. 
mSox2 Rabbit polyclonal anti-mouse Sox2 (ab15830; Abcam). Used for western blot at 1:1500 
dilution. 
mLamin B Goat polyclonal anti-mouse Lamin B antibody (sc-6216; Santa Cruz Biotechnology). 
CREST  Human CREST (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, 
sclerodactyly, telangiectasia) autoimmune serum. A Gift from G. Brown, University of 
Birmingham Medical School, UK. Used for IF at 1:200 dilution. 
mMyogenin Mouse monoclonal anti-mouse Myogenin (M3559; DakoCytomation, Denmark). Used for 
IF at 1:100. 
5.1H11 Mouse anti-human NCAM (neural cell adhesion molecule) (5.1H11 supernatant, 
Developmental Studies Hybridoma Bank). Does not cross-react with mouse NCAM 
protein. Used for IF at 1:2 dilution. 
mEed Mouse monoclonal anti-mouse Eed. Antibody kindly provided by A. Otte (University of 
Amsterdam, The Netherlands). Used for western blot at 1:200 dilution. 
mSuz12 Rabbit polyclonal anti-mouse Suz12 (CS-029-050; Diagenode SA, Liège, Belgium). 
Used for western blot at 1:1000 dilution. 
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mEzh2 Rabbit polyclonal anti-mouse Ezh2 (CS-039-050; Diagenode). Used for western blot at 
1:1000 dilution. 
FLAG Mouse monoclonal anti-FLAG epitope (F3165; Sigma-Aldrich Company Ltd., Gillingham, 
UK). Used for western blot at 1:2000 dilution. 
H3 Rabbit polyclonal anti-histone 3 carboxy terminal (ab1791; Abcam). 
H3K9Ac Rabbit polyclonal anti-histone 3 lysine 9 acetylation (07-352; Upstate Biotechnology 
/Milipore, Lake Placid, NY). 
H3K9me3 Rabbit polyclonal anti-histone 3 lysine 9 trimethylation (07-442; Upstate). 
H3K27me3 Rabbit polyclonal anti-histone 3 lysine 27 trimethylation (07-449; Upstate). 
H3K27m1 Rabbit polyclonal anti-histone 3 lysine 27 monomethylation (07-448; Upstate). 
H3K27m2 Rabbit polyclonal anti-histone 3 lysine 27 dimethylation (07-452; Upstate). 
H4K20m3 Rabbit polyclonal anti-histone 4 lysine 20 trimethylation (07-463; Upstate). 
H3K4m3 Rabbit polyclonal anti-histone 3 lysine 4 trimethylation (ab8580; Abcam). 
H4Ac Rabbit polyclonal anti-histone 4 acetylation (06-866; Upstate). 
BrdU Mouse monoclonal anti-BrdU antibody (347580; BD Biosciences). 
Methyl-C Mouse monoclonal anti-MethylCytidine (33D3; Eurogenetec, Belgium). 
 
2.1.2. Cell lines 
 
C2C12 C2C12 is a subclone from a myoblast cell line (C2) established from normal adult mouse 
leg muscle; genetic background C3H (Yaffe and Saxel, 1977). 
hB Human Epstein-Barr Virus transformed adult B cell clones obtained from E. Eden (MRC 
Clinical Sciences Centre, London, UK) (Eden et al., 2002). 
hB Puror Human Epstein-Barr Virus transformed adult B cells where the puromycin resistance 
gene was inserted by electroporation. 
HFM 16806 Human foetal muscle derived myoblast cell line. 
E14tg2A Hprt deficient mouse ES cell line derived from Lesch-Nyhan embryos (Hooper et al., 
1987); feeder-independent; 129 genetic background. 
OS25  The E14tg2A-derivative was obtained from Austin Smith (Wellcome Trust Centre for 
Stem Cell Research, Cambridge, UK). This cell line was previously subjected to 
sequential gene targeting to integrate βgeo into the Sox2 locus and hygromycin-
thymidine resistance gene into the Oct4 locus (Billon et al., 2002); feeder-independent; 
129 genetic background. 
ZHBTc4 Genetically engineered mouse ES cell line carrying a tetracycline-regulatable Oct4 
transgene replacing endogenous Oct4 alleles (Niwa et al., 2000); feeder-independent; 
129 genetic background. 
2TS22c Genetically engineered mouse ES cell line carrying a tetracycline-regulatable Sox2 
transgene replacing endogenous Sox2 alleles (Masui et al., 2007); feeder-independent; 
129 genetic background; a kind gift from Dr. H. Niwa (RIKEN Centre for Developmental 
Biology, Japan). 
2O1 Sox2 deficient ES cells constitutively overexpressing Oct4 (Masui et al., 2007); feeder-
independent; 129 genetic background; a kind gift from Dr. H. Niwa (RIKEN Centre for 
Developmental Biology, Japan). 
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CCE Mouse ES cell line; feeder-dependent; genetic background 129; a gift from Dr. Vasso 
Episkopou (MRC Clinical Sciences Centre, London, UK). 
19G / 23G Mouse embryonic germ cell lines derived from 11.5 dpc genital ridges; 129/Sv-Rosa26 
genetic background; feeder-dependent; a gift from Prof A. Surani (The Gurdon institute, 
Cambridge, UK). 
F9 Mouse embryonic carcinoma cell line; feeder-independent; genetic background 129. 
P19 Mouse embryonic carcinoma cell line; feeder-independent; genetic background C3H.  
B1.3 / G8.1 Eed-/- mouse ES cell lines (Azuara et al., 2006), derived from eed3354SB mutant mice 
obtained from the Oak Ridge National Laboratory; feeder-dependent; C5Bl/6 genetic 
background. 
B1.3BAC Rescued Eed deficient mouse ES cell line (B1.3) with a bacterial artificial chromosome 
(BAC) carrying Eed and neomycin resistance gene (see section 2.2.4); feeder-
dependent; C5Bl/6 genetic background. 
B1.3Neo Eed-/- mouse ES cell line (B1.3) carrying the neomycin resistance gene (see section 
2.2.4); feeder-dependent; C5Bl/6 genetic background. 
B1.3-Oct4 Eed-/- mouse ES cell lines overexpressing Oct4 protein (see section 2.2.4); feeder-
dependent; C5Bl/6 genetic background. 
ESL32 Eed-/- mouse ES cell line derived from Eed deficient embryos (Wang et al., 2001); 
feeder-dependent; 129/C5Bl/6 mixed genetic background. 
ESL12 Eed+/- mouse ES cell line; feeder-dependent; 129/C5Bl/6 mixed genetic background. 
ESL21 Eed+/+ mouse ES cell line, matching wild-type control for ESL32; feeder-dependent; 
129/C5Bl/6 mixed genetic background; ESL cell lines were kindly provided by N. 
Brockdorff and M. Casanova (MRC clinical Sciences Centre, London, UK). 
Suz12KO Suz12-/- mouse ES cell line (Fujimura et al., 2006); feeder-dependent; a gift from H. 
Koseki (RIKEN Yokahama institute, Japan). 
Suz12WT Wild-type mouse ES cell line; matching control for Suz12 -/- ES cells; feeder-dependent; 
a gift from H. Koseki (RIKEN Yokahama institute, Japan). 
Ezh2-1.3 Mouse ES cell line Ezh2flx/flx expressing Cre-ERT2 recombinase which activation is 
inducible by tamoxifen. Mice with both Ezh2 alleles (SET domain) flanked by loxP sites 
(Su et al., 2003) were crossed with mice carrying Cre-ERT2 cassette (Seibler et al., 
2003). ES cells were then derived and clones isolated, characterised and kindly 
provided by S. Sauer (MRC clinical Sciences Centre, London, UK); feeder-independent. 
ES-ERT2 Mouse ES cell line Ring1A-/-, Ring1Bflx/flx expressing Cre-ERT2 recombinase which 
activation is inducible by tamoxifen (Endoh et al., 2008; Stock et al., 2007); feeder-
dependent; a gift from H. Koseki (RIKEN Yokahama institute, Japan). 
Oct4-GFP B Abelson transformed mouse pre-B cell lines derived from the transgenic mice 
GOF18ΔPE (Palmieri et al., 1994) bone marrow; C5Bl/6 genetic background. 
MEFs Mouse embryonic fibroblasts isolated from wild type embryos (E13.5). 
SNLs Clonally derived cell line from a STO cell line (mouse embryonic fibroblasts) that stably 
expresses LIF and neomycin-resistance gene. 
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2.2. Methods 
 
2.2.1. Cell culture 
 
All tissue culture reagents were from Invitrogen (Invitrogen Ltd, Paisley, UK), 
unless stated otherwise. C2C12 cells were maintained as undifferentiated myoblasts in 
growth medium (GM) [Dulbecco’s modified medium (DMEM) supplemented with 20% 
(v/v) foetal calf serum (FCS; Globepharm, Esher, UK), 4 mM L-Glutamine and 
antibiotics (10 µg/ml Penicillin and Streptomycin)], and routinely dissociated with 
trypsin-EDTA. The formation of multinucleated differentiated myotubes was induced in 
a mitogen poor medium (DM): DMEM, 2% Horse Serum (HS; Globepharm), 4 mM L-
Glutamine and antibiotics. After one day in DM, the cells were replated on gelatin 
coated dishes at 3.104 cells per cm2. To eliminate proliferating cells 10-5 M Ara-C 
(Cytosine β-D arabino furanoside; Sigma) was added to the differentiating cultures. 
HFM 16806 cells were maintained as undifferentiated myoblasts in Ham F10 media 
supplemented with 20% FCS, 4 mM L-glutamine and antibiotics. MEFs and SNLs were 
cultured in DMEM supplemented with 10% FCS, 2 mM L-Glutamine and antibiotics, 
grown until confluence, dissociated with trypsin-EDTA, irradiated with γ-irradiation (300 
rad) and frozen for future use in 10% dimethyl sulfoxide (DMSO), 90% FCS. 
EBV-transformed hB clones were maintained in RPMI-1640 supplemented with 
10% FCS, 2 mM L-Glutamine and antibiotics. The Oct4-GFP B-cell line was grown in 
RPMI-1640 supplemented with 20% FCS, non-essential amino acids, 2 mM L-
glutamine, 50 µM β-mercaptoethanol, antibiotics and interleukin (IL)-7 (5 ng/ml; R&D 
systems, Minneapolis, MN).  
ES cells were grown and maintained undifferentiated either on irradiated 
MEF/SNL feeder layers or directly on 0.1% gelatin-coated surfaces (Sigma), and 
dissociated with trypsin-EDTA. Feeder dependent ES cells were grown in KO-DMEM 
medium plus 10% FCS (PAA Laboratories Gmbh, Pasching, Austria), non-essential 
amino acids, L-Glutamine, β-mercaptoethanol, antibiotics and 1000 U/ml of LIF (Esgro, 
Chemicon/Millipore). Feeder-free ES cells were grown on 0.1% gelatin-coated flasks 
(Fisher Scientific UK Ltd, Leicestershire, UK) in Glasgow’s Minimal Eagle medium 
(GMEM-BHK 21) supplemented with 10% FCS (PAA Laboratories Gmbh), non-
essential amino acids, 1 mM sodium pyruvate, 0.075% sodium bicarbonate, antibiotics, 
0.1 mM β-mercaptoethanol and LIF (1000 U/ml). Doxycycline (1 µg/ml, Sigma), retinoic 
acid (10-6 M, Sigma), 4-hydroxy-tamoxifen (800 nM, Sigma), cycloheximide (0.1 µg/ml, 
Sigma) were added to the media when indicated. Human ES cell lines H1, H7 and H9 
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cells (Thomson et al., 1998) were cultured in medium conditioned by mitotically 
inactivated MEFs supplemented with 8 ng/ml of bFGF (FGF2; Peprotech, London, UK) 
on matrigel-coated plates (BD Biosciences), as previously described (Xu et al., 2001). 
Cells were routinely passaged at a 1:3 dilution by treatment with 200 U/ml collagenase 
IV and mechanical dissociation. All cells were maintained at 37°C and 5% (v/v) CO2. 
 
2.2.2. Cell fusion and experimental heterokaryons 
 
2.2.2.1. Muscle-lymphocyte heterokaryons 
 
Heterokaryons were produced by fusing mouse C2C12 myotubes and human B 
cells with 50% polyethylene glycol, pH 7.4 (PEG 1500, Roche Diagnostics, Mannheim, 
Germany), according to Chiu and Blau protocol (Chiu and Blau, 1984). C2C12 
myoblasts were induced to differentiate (as described in section 2.2.1) and 2 days after 
the onset of differentiation, non-adherent hB-lymphocytes were plated in serum free 
DMEM (7.106 cells for 35 mm dish) and centrifuged (400 g for 15 min) to allow them to 
get in contact with the differentiating muscle culture. The cells were fused with 1 ml of 
polyethylene glycol (PEG 1500) for 1 min, rinsed three times in serum-free media (1 
ml) at 37°C and maintained in differentiation media, in presence of 10-5 M Ara-C and 
10-5 M Ouabain (g-strophanthin, Sigma) to eliminate proliferating cells and unfused hB 
cells, respectively. Heterokaryons cultures were maintained for 2-8 days in DM. Where 
stated, cells were treated immediately after fusion with HDAC inhibitors, 20 nM TSA or 
1 mM VPA. 
 
2.2.2.2. ES-lymphocyte heterokaryons 
 
ES cells and hB-lymphocytes were respectively labelled with VibrantTM 1,1’-
dioctadecyl-3, 3, 3’, 3’ tetramethylindodicarbocyanine (DiD) and 1,1'-dioctadecyl-3, 3, 
3', 3'-tetramethylindocarbocyanine perchlorate (DiI) cell labelling solutions (Molecular 
Probes). Cells were resuspended at 1.106 cells/ml in DMEM and labelled with 5 µl/ml of 
dye at 37°C, 15 min. ES and hB were then mixed at an appropriate ratio (mES:hB ratio 
1:1, Figure 2.1; ES:Oct4-GFP B ratio 1:5), and washed twice in phosphate buffered 
saline (PBS). The supernatant was completely removed and 1 ml of PEG at 37°C was 
added to the pellet of cells over 60 sec and incubated at 37°C for 90 sec with constant 
stirring. Then, 4 ml of serum-free medium (DMEM) were carefully added over a period 
of 3 min, followed by 10 ml of DMEM and incubation at 37°C for 3 min. After 
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centrifugation (1350 rpm, 5 min), the pellet was allowed to swell in complete medium 
for 3 min. Cell mixtures were then resuspended and cultured under conditions 
promoting the maintenance of undifferentiated mouse ES cells at 0.5.106 cells/cm2. To 
eliminate unfused hB cells Ouabain (10-5 M) was added to the medium. Proliferating ES 
cells were eliminated by the addition of 10-5 M Ara-C 4-6 hours after fusion and then 
removed after 16 hours. When Hprt-/- ES cells were used, HAT (20 µM hypoxanthine, 
0.08 µM aminopterine and 3.2 µM thymidine; Sigma) was added to the medium 24 
hours after fusion. 
 
 
      
Figure 2.1. Impact of varying cell ratio in fusion efficiency. Inter-species heterokaryons (mESxhB) 
were generated by cell fusion of mouse embryonic stem cells (mES) with human B-lymphocytes (hB) in the 
presence of polyethylene glycol. hB and mES cells were respectively labelled with the cell membrane dyes 
DiI and DiD and analysed by flow cytometry. Fusion efficiency was assessed by FACS analysis as the 
percentage of double-labelled cells (upper right quadrant of dot plots). Cell fusion with different mES:hB 
ratios are shown. 
 
 
 
2.2.2.3. Embryonic hybrid clones  
 
Embryonic hybrid cells were produced by fusion of Oct4-GFP B lymphocytes 
with either ZHBTc4 or 2TS22c ES cells. ESxB-lymphocyte hybrids were selected using 
HAT for 8-12 days. GFP positive colonies were identified under a fluorescence 
microscope Leica DM IRE2. Colonies were isolated with a pipette, dissociated with 
trypsin-EDTA, and cultured in mouse ES cell conditions. 
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2.2.3. Reverse transcription (RT) polymerase chain 
reaction (PCR) 
 
2.2.3.1. RNA extraction and cDNA synthesis 
 
RNA extraction was performed using RNA-BEE reagent (Tel-Test Inc., 
Friendswood, TX) and residual DNA was eliminated using the DNA-free kit (Ambion, 
Austin, TX) according to manufacturer’s instructions. RNA was then reverse 
transcribed using SuperscriptTM First-Strand Synthesis system (Invitrogen). 3 µg of total 
RNA was diluted in Rnase free water to a final volume of 11 μl and supplemented with 
1 μl of 10 mM dNTP mix (invritogen) and 1 μl of oligo (dT)12-18 (Invitrogen). The mixture 
was incubated at 65°C for 5 min and put on ice for 1 min, when 1 μl of 0.1 M DTT, 4 μl 
of 5X first strand buffer, 1 μl of RnaseOUT (Invitrogen) and 1 μl of 200 U/μl Superscript 
III were added. A reaction mixture without the enzyme was also set up as a control 
(designated “-RT”). The mixture was incubated at 25°C for 5 min, 50°C for 1 h and at 
75°C for 15 min. cDNAs of interest were then detected by semi-quantitative PCR or 
real-time PCR. 
  
2.2.3.2. Semi-quantitative PCR analysis 
 
Semi-quantitative PCR analysis was performed in 50 µl using 0.4 µM primers, 
1.25 U of HotStarTaqTM DNA polymerase (reference 203205, Qiagen, Valencia, CA) 
with the following program: 95°C for 15 min, then cycles of 94°C for 15 sec, 60°C for 30 
sec, 72°C for 30 sec. PCR products were separated by electrophoresis on 1% agarose 
gels and visualised by ethidium bromide staining. A fifth of the PCR product was 
loaded and separated on 1.5% agarose gels. Blotted on Hybond-N nylon membrane 
(Amersham Pharmacia Biotech, Little Chalfont, UK), and hybridised with 32P-labelled 
probes. Blots were washed and signals quantified using a phosphoimager. Probes 
were derived from cDNA preparation by PCR and 32P-labelled using random priming 
(Prime-Lt II kit, Stratagene, La Jolla, USA). The primers and conditions used for this 
analysis can be found in Appendix I, Table A1. For each reaction of PCR amplification, 
conditions were maintained within the dynamic range (i.e. non-saturating). 
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2.2.3.3. Real-time quantitative PCR analysis (qPCR) 
 
Real-time PCR analysis was carried out on a OpticonTM DNA engine using 
Opticon Monitor 3 software (MJ Research Inc., Waltham, MA), under the following 
cycling conditions: an initial denaturating step at 95°C for 15 min, 40 cycles of 
denaturation at 94°C for 15 sec, annealing at 60°C for 30 sec, elongation at 72°C for 
30 sec at which point the fluorescence was read at 72°C, 75°C, 78°C and 83°C. The 
melting curve was determined from 70°C to 90°C, at 0.2°C intervals. PCR reactions 
included 2X Sybr-Green PCR Mastermix (Qiagen), 300 nM primers and 2 µl of 
template in a 35 µl reaction volume. A reaction without DNA was included to control for 
the formation of primer dimers and each measurement was performed in triplicate. The 
analysis of the qPCR data was performed with the Opticon Monitor 3 software and the 
relative abundance of sequences was calculated using the ΔΔC(T) method (Pfaffl et al., 
2001). When the amplification efficiency is close to 2, the relative amount of PCR 
products between reactions 1 and 2 can be calculated as 2-ΔC(T)1/2-ΔC(T)2, being C(T) the 
threshold cycle at which fluorescence due to PCR products becomes detectable above 
background. Gapdh was generally used for gene expression data normalisation. Primer 
sequences can be found in Appendix I, Table A2. 
 
2.2.3.4. Primer design and testing for quantitative PCR 
 
Primers were designed with the Primer Express software (Applied Biosystems, 
Warrington, UK), using sequences from the mouse and human database from 
EnsEMBL. The following design criteria were used: amplicon size of 100-200 bp, GC 
content of 40-60%, melting temperature 55-65°C. All primer pairs were tested for 
predicted products within the mouse and human genome using in silico PCR tools such 
as PUNS (http://okeylabimac.med.utoronto.ca/PUNS) or the UCSC genome browser 
(http://genome.ucsc.edu). Primers yielding a single predicted PCR product of the 
correct size were ordered from Sigma Genosys (the sequences for the primers are 
shown in their 5’ to 3’ orientation). 
The efficiency of amplification for each primer pair was determined by qPCR 
with sequential 2-fold dilutions of cDNA or genomic DNA (Pfaffl et al., 2001). Primers 
yielding poor linear fits of the C(T) versus logarithm of concentration (R2<0.99) or 
efficiencies lower than 1.8 or greater than 2.2 were discarded. When species specificity 
was required (i.e. analysis in inter-species heterokaryons), primers were designed to 
specifically amplify the human sequences but not the mouse orthologs and them tested 
in human and mouse positive control cDNA. 
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2.2.4. Genomic PCR 
 
2.2.4.1. Genomic DNA extraction 
 
Genomic DNA was isolated from cells by overnight incubation in 500 μl of lysis 
buffer (200 mM NaCl, 100 mM Tris-HCl pH 7.4, 5 mM EDTA, 0.2% SDS, 250 μg 
Proteinase K) at 55ºC and subsequent phenol/chlorophorm/isoamylalcohol and 
chlorophorm/isoamylalcohol extractions. DNA was then precipitated with isopropanol 
(50%), followed by 70% ethanol wash, and ressuspension in Tris-EDTA (TE; 10 mM 
Tris-Hcl pH 8.0, 1 mM EDTA). DNA concentration was quantified by 
spectrophotometry. 
 
2.2.4.2. Genomic PCR  
 
PCR analysis was performed in 50 µl using 0.4 µM primers, 1.25 U of 
HotStarTaqTM DNA polymerase with the following program: 95°C for 15 min, then 
cycles of 94°C for 15 sec, 60°C for 30 sec, 72°C for 30 sec. PCR products were 
separated by electrophoresis on 1% agarose gels and visualised by ethidium bromide 
staining. Presence of rearranged DNA of the IgH locus (D-J region) was checked by 
PCR using with the following primers: IgH-F: 5’-TTCAAAGCACAATGCCTGGCT-3’ IgH-R: 5’-
GTCTAGATTCTCACAAGAGTCCGATAGACCCTGG-3’. 
 
2.2.5. Cloning and DNA delivery into ES cells 
 
2.2.5.1. Engineering of protein expression and RNAi constructs 
 
The mouse Oct4 open reading frame (ORF) was amplified from ES cells by RT-
PCR (see section 2.2.3.2) with the linker primers 5’- CGTATCGGTACCATGGCTGGACACCTG 
GCTTC-3’ and 5’- CCTTACGAATTCTTAACCCCAAAGCTCCAGGT 3’, which introduced flanking 
restriction sites for KpnI and EcoRI (underlined). The PCR product was ligated into the 
KpnI-EcoRI sites of the pDFLAG-cDNAIII vector (a gift from Dr. B Cobb) using the 
procedures described on section 2.2.5.2 and sequence verified (MRC Clinical Sciences 
Centre sequencing facility). To generate a eukaryotic expression construct, the 
2xFLAG-Oct4 sequence was subcloned into pCBA (a gift from Dr. Amy Tang) using 
BglII-EcoRV sites. In the pCBA vector, expression was driven by the chicken β-actin 
promoter and selected with neomycin resistance gene (Figure 2.2a). 
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Short hairpin RNA sequences targeting mouse Oct4 transcript only (and not the 
human ortholog) were 5′-GATCCCCGAAGGATGTGGTTCGAGTATTCAAGAGATACTCGAACCACA 
TCCTTCTTTTTA-3’ and 5′-AGCTTAAAAAGAAGGATGTGGTTCGAGTATCTCTTGAATACTCGAACCA 
CATCCTTCGGG-3’ (Chew et al., 2005). A short hairpin with no predictable targets in both 
human and mouse was included as a control 5’-GATCCCCGCGCGCTTTGTAGGATTCGTTCA 
AGAGACGAATCCTACAAAGCGCGCTTTTTA-3’ and 5’-AGCTTAAAAAGCGCGCTTTGTAGGATTCGT 
CTCTTGAACGAATCCTACAAAGCGCGCGGG-3’, designed with the following on-line software 
(http://jura.wi.mit.edu/bioc/siRNAext/home.php). Together, these primers constituted a 
double-stranded BglII-HindIII fragment coding for a short hairpin RNA. This fragment 
was cloned into the pSUPERneo+GFP vector (VEC-PBS-0005; OligoEngine, Inc, 
Seattle, WA) using the BglII-HindIII restriction sites (Figure 2.2b). 
 
    
 
Figure 2.2. Expression vectors used in this study. (a) Vector used for overexpression of tagged Oct4 
protein in ES cells (DFLAGOct4-pCBA). Double FLAG Oct4 ORF sequence was cloned downstream the 
chicken β-actin promoter. Neor – Neomycin resistance gene. pSV40 – SV40 promoter. Oct4 ORF – mouse 
Oct4 open reading frame. (b) Vector used for expression of short hairpin RNA (shRNA) in ES cells. 
Hairpins were cloned downstream the H1 promoter (Polymerase III dependent H1 promoter). EGFP – 
enhanced green fluorescence protein. PGK – murine phosphoglycerate kinase promoter. 
 
For Eed reconstitution, a bacterial artificial chromosome (BAC) was inserted in 
Eed deficient ES cells (B1.3 clone). The Eed containing BAC clone was called RP23-
370F10 and includes the 97076839-97260535 region of the forward DNA strand of 
mouse chromosome 7. The BAC clone was ordered in the supplied vector (BACPAC 
resources, Oakland, CA) which contains a chloramphenicol acetyltransferase (CAT) 
gene for selection in bacteria. The CAT gene was replaced with the neomycin 
resistance cassette from the pL452 plasmid (NCI, Frederick, MD) by recombineering. 
The CAT gene is 660 bp, 330 bp of the 5' and 330 bp of the 3' regions were PCR-
amplified and cloned into the pL452 plasmid, 5' and 3' respectively of the neomycin 
resistance cassette. Recombination was induced by the transformation (as described in 
section 2.2.5.2) of the recombineering competent bacterial strain SW102 (NCI, 
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Frederick, MD) (Warming et al., 2005) with the BAC clone and posterior introduction of 
the pL452 plasmid by electroporation. 
 
2.2.5.2. Plasmid construction and bacterial transformation 
 
Enzymes and buffers were from New England Biolabs (New England Biolabs 
Ltd, Herts, UK). 1 μg of insert and 1 μg of vector were digested with appropriate 
restriction enzymes following manufacturer’s instruction. Digestion products were run 
on 1% agarose gels with the 100 bp or 1 Kb ladders and bands of correct size were 
purified using QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s 
instructions. 50 ng of vector and a three-molar excess of insert were ligated with 1 μl 
(400 U) of T4 DNA ligase overnight at 14°C. DNA was added to 20 μl of 5X KCM buffer 
(0.5 M KCL, 0.15 M CaCl2, 0.25 M MgCl2) and the total volume adjusted to 100 μl with 
H2O. The mixture was added to 100 μl of competent DHS5α cells (Invitrogen), 
incubated on ice for 20 min, 35 sec at 42°C and on ice for 2 min. Transformed cells 
were then plated into Lysogeny Broth (LB) agar supplemented with 50 μg/μl of 
ampicillin and incubated overnight at 37°C. Individual colonies were picked into LB 
broth with 50 μg/μl of ampicillin and incubated overnight at 37°C with agitation. DNA 
was extracted from exponentially growing cultures with the Miniprep or Maxipreps kits 
(Qiagen) according to manufacturer’s instructions and final DNA diluted in double 
distilled water. 
 For short hairpin RNA constructions the synthetic primer pairs (HPLC purified 
by Sigma) were treated separately with T4 polynucleotide kinase for 30 min at 37°C in 
a mix containing 1 μl of enzyme, 2 μl of 10x ligase buffer and 8.5 μl of 100 mM of each 
of the two primers. The reaction was then diluted with 180 μl of buffer A (10 mM Tris 
pH7.4, 50 mM NaCl), incubated at 95°C for 5 min and allowed to cool slowly to room 
temperature for primer annealing. 2 μl of annealed primers were then ligated to BglII-
HindIII digested pSUPERneo+gfp. Bacterial clones were then picked, grown and DNA 
extracted and sequenced (MRC Clinical Sciences Centre sequencing facility). 
 
2.2.5.3. DNA delivery into ES cells 
 
 DNA delivery into ES cells was performed using lipofectamine 2000 
(Invitrogen). 1.106 ES cells were plated in a well of a 6-well plate and 24 h later cells 
were transfected. 4 μg DNA were diluted in 400 μl of OptiMEM (Invitrogen) while 
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lipofectamine was also diluted 1:40 in OptiMEM. After mixing for 5 min both solutions 
were combined and left at room temperature for 20 min. The mixture was then added 
to the cells and incubated at 37°C for 4.5 h. Finally, the transfection mix was replaced 
for 2 ml of complete ES cell culture medium. The DNA BAC clone was delivered into 
ES cells by electroporation. ES cells plus DNA (30 μg) were transferred into a cold 
electroporation cuvette (Gene Pulser Cuvette, 165-2088, Bio Rad Laboratories Inc., 
Waltham, MA) and left on ice for 5 min before electroporation (200V, 960 μF, BioRad). 
Cells were incubated on ice for an additional 5 min for recovery and cultured in 
complete ES cell medium. When required selection was applied 24 h after transfection 
(G418, 400 μg/ml; Invitrogen) and resistant ES cell colonies manually isolated after 10 
days. 
 
2.2.6. Fluorescence activated cell sorting (FACS) analysis 
 
Cell fusion efficiency was assessed using VibrantTM DiD and DiI cell labelling 
solutions (Molecular Probes; emission spectra: DiI λ=565nm, DiD λ=665nm). B-
lymphocytes and ES cells were labelled with DiI and DiD detected using the FL2 and 
FL4 detection channels, respectively. 
Analysis of the SSEA4 surface antigen was performed as follows: 1.106 cells 
were washed twice in FACS buffer (PBS, 3% FCS), resuspended in anti-SSEA4 
antibody (diluted 1:3 in FACS buffer) and incubated 30 min at room temperature. The 
cells were then washed twice in FACS buffer and incubated for an additional 30 min 
with a FITC-labelled secondary antibody (1:100 dilution; Jackson Laboratory, Bar 
Harbor, ME). Finally, cells were washed twice and then resuspended in 100 μl of FACS 
buffer and analysed in a FACScalibur (BD Biosciences) with CellQuest software. FACS 
purification was performed using a FACSAria cell sorter (BD Biosciences). 
 
2.2.7. Immunofluorescence (IF) analysis 
 
hB-lymphocytes were attached to glass coverslips pre-coated with poly-L-lysine 
(Sigma). Heterokaryons were cultured in 0.5% gelatin-coated Thermanox® coverslips 
(Nalge-Nunc Inc., Rochester, NY). Mouse and human nuclei were distinguished in the 
resulting heterokaryons by counterstaining with 4,6-diamidino-2-phenylindole (DAPI) 
and/or human-specific Lamin A/C staining (Figure 2.3). Shared cytoplasm was 
confirmed by F-actin staining (Phalloidin; A12380, Molecular Probes). 
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At appropriate time points coverslips were removed, washed in PBS and fixed 
in 2% paraformaldehyde (PFA) in PBS for 20 min. Fixed samples were washed in PBS 
and, for intracellular staining, permeabilised with 0.4% Triton X-100 for 5 min. Samples 
were incubated sequentially in blocking solution [2.5% bovine serum albumin (BSA), 
0.05% Tween20, 10% Normal Goat Serum (Vector) in PBS] for 30 min and in primary 
antibody diluted in blocking solution (2 h at room temperature) in a humid chamber. 
Coverslips were washed in wash buffer (0.2% BSA, 0.05% Tween20 in PBS; 3x5 min) 
and incubated with secondary antibodies coupled with appropriated fluorophores 
(Molecular Probes) diluted in blocking solution for 45 min. Finally, cells were washed 
twice in wash buffer (5 min), once in PBS (3 min) and mounted in Vectashield (Vector) 
with DAPI (0.1 µg/ml). Staining with the antibody 5.1H11 was performed on unfixed 
samples labeled for 1 h at 37°C. 5.1H11-labelling was revealed using biotin coupled 
with anti-mouse IgG antibody (1 h at 37°C; Vector) followed by Texas-Red-coupled 
avidin (15 min at 37°C; Vector). All washes were performed at room temperature in 
DM. 5.1H11-labelled samples were fixed in 2% PFA for 20 min. For alkaline 
phosphatase assays, hybrid colonies 8 days after cell fusion were stained with alkaline 
phosphatase assay kit (Sigma) according to manufacturer’s instructions. 
Samples were visualised using a TCS SP5 Leica laser-scanning confocal 
microscope. Images were processed using Leica Confocal software and Adobe 
Photoshop CS2. Microscope settings and laser power were kept constant between the 
controls and samples. To estimate nuclear volumes, z-stacks spanning individual 
nuclei were collected on the laser scanning confocal microscope. The volume of each 
section was obtained by multiplying the xy-surface of each confocal plane by the 
thickness of sections along the z-axis. To investigate chromocentre organisation, 
image processing software (Leica Confocal Software and Metamorph 4.0) were used to 
perform 3D reconstructions and maximal projections of z-series collected through 
individual nuclei after CREST immunostaining. The number of chromocentres, the 
number of centromeric signals per chromocentre, and the total number of individual 
signals per nucleus were analysed in reconstructed projections. Images of live GFP 
fluorescent colonies and alkaline phosphatase staining were collected using a Leica 
DM IRE2 microscope running Metamorph software. 
 
 74
         
Figure 2.3. Distinction of human and mouse nuclei within heterokaryons. Human and mouse nuclei 
were distinguished in the resulting heterokaryons by immunoflorescence with human-specific Lamin A/C 
(green) staining and DAPI (blue) counterstain. Human nucleus shows a diffuse DAPI staining and positive 
labelling for laminA/C whereas mouse nucleus shows DAPI spotted pattern (with intense foci). Actin 
staining (red) delineates single cells. 
 
2.2.8. Western blot analysis 
 
Whole cell extracts were prepared by direct lysis of cells (5 min at 95°C and 
subsequent vortexing) in protein sample buffer (50 mM Tris-HCL pH 6.8, 1% SDS, 10% 
glycerol, 0.001% Bromophenol Blue, 5% β-mercaptoethanol). For western blot analysis 
of modified histones, histone proteins were isolated from whole cells by acid extraction. 
10.107 ES cells were pelleted and resuspended in 1 ml PBS (4°C), centrifuged (500g 
for 5 min) and the supernantant removed. Cell pellets were resuspended in 180 μl of 
ice cold lysis buffer (100 mM HEPES pH 7.9, 1.5 mM MgCl2 10 mM KCl, 0.5 mM DTT 
and 1.5 mM PMSF), 20 μl of 2M HCl and incubated on ice for 30 min. Following acid 
lysis the solution was centrifuged 11,000g for 10 min at 4°C, the supernantant of acid 
soluble proteins collected and sequentially dialyzed against 0.1 M acetic acid (twice for 
1 hour) and water (1 hour, 3 hours and overnight, respectively). The protein solution 
was quantified and stored at -70°C. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out with the Bio-Rad minigel system. 20 μg of protein sample and the 
benchmark pre-stained protein ladder (Invitrogen) were loaded on an acrylamide 
(BioRad) stacking gel [5% (w/v) acrylamide, 0.125 M Tris (pH 6.8), 0.1% (w/v) SDS, 
0.1% (w/v) ammonium persulphate, and 0.1% (v/v) N,N,N’,N’-
tetramethylethylenediamine] and separated in a 10% acrylamide resolving gel [10% 
(w/v) acrylamide, 0.4 M Tris (pH 8.8), 0.1% (w/v) SDS, 0.1% (w/v) ammonium 
persulphate, and 0.1% (v/v) N,N,N’,N’-tetramethylethylenediamine] using Tris-glycine 
electrophoresis buffer [1.5% (w/v) Tris, 7.2% glycine, 0.5% (w/v) SDS]. Resolved 
acrylamide gels were blotted to a Protan nitrocellulose transfer membrane (Schleicher 
& Schuell Bioscience, Dassel, Germany) in transfer buffer (48 mM Trizma base, 39 mM 
glycine, 0.037% (w/v) SDS and 20% (v/v) methanol) using the trans-blot semi-dry 
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electrophoretic transfer apparatus (BioRad). The membranes were incubated for 30 
min with blocking buffer [5% (w/v) fat free milk powder (Marvel), 1.2 g/L Tris pH7.4, 
8.75 g/L NaCl], followed by primary antibody incubation diluted in blocking buffer for 2 h 
at room temperature, with agitation. After washing 3 times in wash buffer [1.2 g/L Tris 
pH7.4, 8.75 g/L NaCl] for 5 min, blots were incubated with horseradish peroxidase-
coupled secondary antibodies (anti-rabbit and anti-mouse were from Amersham and 
used at 1:5000 and 1:2000 dilutions, respectively; anti-goat used at 1:2000 dilution 
from Santa Cruz) in blocking buffer for 1 h at room temperature. Detection was done 
with the ECL-Plus western blotting detection kit (Amersham) following manufacturer’s 
instructions and using Kodak X-Omat photographic films. 
 
2.2.9. Fluorescence in situ hybridisation (FISH) 
 
2.2.9.1. Probe labelling 
 
DNA probes for DNA and RNA FISH were labelled with either digoxygenin-11-
dUTP (DIG) or biotin-16-dUTP nick translation kit (Roche) according to manufacturer’s 
instructions. First, 1 μg of DNA was pre-treated with RNaseA (20 μg/ml) for 30 min at 
37°C to remove RNA impurities and subsequently subjected to nick translation for 2 h 
at 15°C. The reaction was then stopped on ice and fragment size was determined by 
agarose gel electrophoresis. The labelled probe was then purified via columns 
(included in the kit) and 50 ng plus 10 μg of salmon sperm DNA (Invitrogen) were used 
per slide. 
 
2.2.9.2. DNA FISH 
 
Mouse γ-satellite (major-satellite) probe was directly labelled with Fluoro-RED 
and used in combination with digoxygenin-11-dUTP (DIG)-coupled human α-satellite 
probe (Q-Biogen, Illkirch, France). α-satellite signal was detected with anti-DIG 
fluorescein isothiocyanate (AD-FITC) raised in sheep (Boehringer, Mannheim, 
Germany), followed by anti-sheep FITC (Vector). 
Cells were hypotonically treated in 75 mM KCl for 5 min at room temperature 
before fixation in ice-cold methanol: acetic acid 3:1. Slides were denatured for 2.5 min 
at 75°C in 70% formamide and 2xSSCP (10xSSC, 0.2M NaH2PO4, pH 7.0), 
immediately passed through an ice-cold ethanol series (70, 90 and 100%) and allowed 
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to air-dry. The probes were resuspended in 15 μl hybridization solution (2xSSC, 50% 
formamide, 10% dextran sulphate, 1% Tween-20), denatured at 75°C for 3 min, pre-
annealed at 37°C and hybridization occurred overnight at 37°C in a humid chamber 
after sealing with parafilm and vulcanizing rubber solution (Weldtite, UK). Slides were 
washed as follows: 50% formamide and 2xSSC (0.3M NaCl, 30 mM sodium citrate pH 
7) at 45 °C (3 x 5 min), 0.5xSSC (60°C, 3 x 5 min) and SSCT (4xSSC, 0.05% 
Tween20; Room temperature, 1 x 5 min). Slides were blocked in 5% (w/v) fat free milk 
powder (Marvel) in SSCT for 30 min at 37°C in humid chamber. Two layers of DIG and 
biotin detection were performed with 3 washes (SSCT) in between and afterwards, 
followed by a final wash in PBS and mounting in DAPI containing Vectashield. 
 
2.2.9.3. RNA FISH 
 
RNA-FISH was performed as described previously by Lawrence et al. 
(Lawrence et al., 1989) with probes synthesised by PCR. hCD20 (a 6.1 kb genomic 
DNA fragment spanning the last 6 exons of the human CD20 gene) was labelled with 
DIG, and detected as described in section 2.2.9.2. hNCAM (a 5.6kb genomic DNA 
fragment spanning exon 2 to exon 7 of the human NCAM gene) probe was labelled 
with biotin-16-dUTP and detected with Avidin-Texas-Red (Vector), followed by a 
biotinylated goat anti-avidin antibody (Vector) and Avidin-Texas-Red antibody 
(Invitrogen). 
Cells were permeabilised for 7 min on ice cold CSK (cytoskeletal) buffer (100 
mM NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM PIPES, 0.5% Triton X-100, 1 mM 
EGTA, 2 mM Vanadyl Ribonucleoside for RNase inhibition) and subsequently fixed in 
4% PFA in PBS for 10 min on ice. Coverslips were washed for 3 min in SSCT and 
blocked with 4 mg/ml BSA in SSCT (blocking buffer) for 30 min at room temperature. 
After washing, 10 μl of labeled FISH probe in 150 μl of hybridization solution (2XSSC, 
50% formamide, 10% dextran sulphate, 2 mM Vanadyl Ribonucleoside) was added 
and the coverslip was sealed with parafilm and vulcanizing rubber solution and 
hybridization occurred overnight at 37°C in a humid chamber. In next day, 3 washes (5 
min each) in 2xSSC containing 50% formamide were performed followed by 3 washes 
in 2xSSC, all at 42°C. Slides were transferred into wash buffer and subsequently 
blocked in blocking buffer for 30 min at 37°C in humid chamber. Next, two layers of 
DIG and biotin detection were performed with 3 washes (SSCT) in between and 
afterwards, followed by a final wash in PBS and mounting in DAPI containing 
Vectashield. 
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2.2.10. Replication timing analysis 
 
2.2.10.1. BrdU labelling and cell cycle fractionation by flow cytometry 
 
All reagents used were from Sigma unless stated otherwise. Non-synchronized, 
exponentially growing hB cells were incubated with 50 μM 5‘-bromodeoxyuridine 
(BrdU) for 30 min at 37°C, washed in cold PBS, fixed in 70% ethanol and stored at 4°C 
in the dark for at least overnight. Ethanol was removed by washing the cells twice with 
PBS and collected by centrifugation at 1700 rpm for 7 min, 4°C. BrdU-labelled cells 
were resuspended in staining buffer (40 mM Tris pH 7.4, 0.8% NaCl and 21 mM MgCl2) 
supplemented with 0.05% NP-40, propidium iodide (50 μg/ml) and RNAse A (1 mg/ml), 
carefully disaggregated by syringing trough a 25G needle and allowed to stain in the 
dark for 30 minutes prior to separation into different phases of the cell cycle on a 
FACSAria cell sorter (BD Biosciences). 50,000 cells were collected for each of six 
fractions (G1, S1, S2, S3, S4 and G2/M) into lysis buffer (1 M NaCl, 10 mM EDTA, 50 
mM Tris-HCL pH 8.0, 0.5% SDS, 0.2 mg/ml proteinase K, 0.25 mg/ml denatured, 
sheared salmon sperm DNA) and stored at -20°C following incubation for 2 h at 50°C. 
 
2.2.10.2. Isolation of BrdU-labelled DNA by immunoprecipitation 
 
BrdU-labelled DNA from Drosophila melanogaster Schneider cells was added 
to each fraction (6 ng per 10,000 sorted cells). DNA was purified by phenol, 
chloroform/isoamyl alcohol extraction and ethanol precipitation. Precipitated DNA was 
dissolved in 480 μl of TE with 0.2 mg denatured, sheared salmon sperm DNA 
(Invitrogen) at 37°C for 1 hour and stored at 4°C in the dark. Samples were then 
sonicated (VC 130 PB, Sonics & Materials, Inc, Newtown, USA) to generate fragments 
of an average size of 700 bp (range 250 bp - 2 kb). After denaturation for 3 min at 95°C 
and cooling down on ice for 2 min, samples were adjusted to 10 mM sodium phosphate 
(pH 7.0), 0.14 M NaCl, and 0.05% Triton X-100 and then incubated with 80 μl of mouse 
anti-BrdU antibody (25 μg/ml) for 30 min at room temperature with constant rotation. 
Secondary antibody (rabbit anti-mouse IgG, Sigma) was added in excess (35 μg) and 
incubated at room temperature with constant rotation for additional 30 min. DNA-
protein complexes were collected by centrifugation at 15000 rpm for 20 min at 4°C, 
washed once with washing buffer (10 mM sodium phosphate buffer pH 7.0, 0.14 M 
NaCl, 0.05% Triton X-100) and resuspended in 200 μl lysis buffer (50 mM Tris-HCL pH 
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8, 10 mM EDTA, 0.5% SDS, 0.25 mg/ml proteinase K) and incubated overnight at 
37°C. BrdU-labelled DNA was then extracted by phenol/chloroform/isoamyl alcohol and 
ethanol precipitation before resuspension in TE. The abundance of newly replicated 
DNA in each cell-cycle fraction was determined by qPCR (see section 2.2.3.3). Primer 
pairs used for this analysis are listed in Appendix I, Table A3. 
 
2.2.11. Chromatin immunoprecipitation analysis 
 
2.2.11.1. Preparation of extracts from cell lines 
 
All reagents used were from Sigma unless stated otherwise. Approximately 
1.108 exponentially growing hB cells were harvested, washed twice in PBS and 
crosslinked with 1% PFA for 10 min at room temperature. After quenching of PFA with 
glycine at a final concentration of 125 mM for an additional 10 min at room 
temperature, the cells were washed twice with ice-cold PBS containing protease 
inhibitor cocktail (Roche) and lysed in 1 ml of ice cold lysis buffer (50 mM Tris-HCL pH 
8.1, 10 mM EDTA pH 8.0, 1% SDS) with protease inhibitor cocktail. Using a 
BioruptorTM 200 (Diagenode), the chromatin was sonicated on ice to an average size of 
300 to 500 bp running the settings: output-high, 30 sec on, 30 sec off, for 15 min. 
Sonication efficiency was tested by running 4 μl of sonicated chromatin (supplemented 
with 2 μl 5% N-Lauroylsacrosine, 2 μl methyl-orange DNA loading buffer and 2 μl of 
PBS) on a 1.5% agarose gel. Sonication was repeated until the fragment size was 
approximately 500 bp. Insoluble proteins were discarted after centrifugation of the 
lysate at 15,000 rpm for 15 min at 18ºC and DNA concentration quantified by 
spectrophotometry (NanoDrop® ND-1000, Wilmington, USA). 
 
2.2.11.2. Bead preparation 
 
0.2 g of protein A-sepharose beads (P3391; Sigma) per sample were rinsed 
twice with 2 ml of ice cold dilution buffer (1% Triton X-100, 2 mM EDTA pH 8.0, 150 
mM NaCl, 20 mM Tris-HCL pH 8.1 and protease inhibitor cocktail) and blocked 
overnight, at 4ºC with the same solution supplemented with 10 μl of BSA (New England 
Biolabs, 10 mg/ml) and 4 μl salmon sperm DNA (10 mg/ml), on a spinning wheel. After 
this blocking step, the beads were washed twice in dilution buffer and stored up to 6 
weeks at 4ºC in dilution buffer and lysis buffer in a 10:1 ratio. 
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2.2.11.3. Immunoprecipitation 
 
Fragmented chromatin (140 μg) was diluted 1/10 in dilution buffer with protease 
inhibitors (Roche). 30 μl of the blocked beads were added per sample and incubated at 
4ºC for 2h, on a spinning wheel, to pre-clear the solution of any non-specific binding to 
the beads. The chromatin solution was then filtered to remove the beads. Fragmented 
chromatin was subjected to immunoprecipitation with 5 μg of the following antibodies: 
anti-H3K9Ac, -H4Ac, -H3K4m3, -H3K9m3, -H3K27m3, -H4K20m3, rabbit anti-mouse-
IgG antiserum (negative-control; DakoCytomation) and anti-H3-carboxy terminal 
antibody, left incubating overnight at 4ºC, on a spinning wheel. Afterwards, 30 μl of 
beads were once again added to the chromatin solutions and left immunoprecipitating 
2 h on a spinning wheel, at 4ºC, after which they were washed as follows: 4 times in 1 
ml of ice-cold wash buffer (20 mM Tris-HCl pH 8.1, 2 mM EDTA pH 8.0, 150 mM NaCl, 
0.1% SDS, 1% Triton X-100) and collected by centrifugation at 4,000 rpm for 1 min at 
4°C, and washed once in final wash buffer (20mM Tris-HCl pH 8.1, 2 mM EDTA pH 
8.0, 500 mM NaCl, 0.1% SDS, 1% Triton X-100) on ice. After adding elution buffer (1% 
SDS, 0.1M NaHCO3) to elute the immunocomplexes from the beads, these were 
treated with RNase and proteinase K, 2 h at 37ºC and 6 h of incubation at 65ºC to 
reverse the cross-links. Finally, the DNA was sequentially extracted with 
phenol/chloroform/Isoamylalcohol and precipitated in 50% isopropanol containing 5 
mM NaAc and 20 μg of glycogen carrier (Glycoblue, Ambion). After purification, DNA 
was resuspended in 80 μL of TE. Quantification of precipitated DNA was performed 
using qPCR amplification (section 2.2.3.3) and the primers listed on Appendix I, Table 
A3. Histone’s modification levels were normalised against input DNA and total H3 
detected, and the ratio of modified-H3 to total H3 was denoted as relative abundance. 
 
2.2.12. DNA methylation analysis 
 
2.2.12.1. Bisulfite genomic sequencing 
 
Genomic DNA was isolated from cells as described in section 2.2.4.1. Bisulfite 
modification of genomic DNA was carried out with the EZDNA methylation kit 
(Zymogenetics Inc., Orange, CA) according to the manufacturer’s recommendations. 2 
μg of genomic DNA was converted at 50ºC (protected from light) with CT conversion 
reagent and column purified (provided in the kit). DNA was then eluted in 10 μl and 2 μl 
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of recovered DNA was used for PCR amplification (section 2.2.4.2). PCR primers were 
designed to recognise bisulfite-converted human DNA only using MethPrimer 
(http://www.urogene.org/methprimer/index.html) and tested in silico using MethBLAST 
(http://medgen.ugent.be/methBLAST/welcome.html). Primer pairs used in this analysis 
can be founding Appendix I, Table A4. Amplified products were cloned (see section 
2.2.5.2) into pCR2 (Invitrogen) and ten bacterial clones were randomly picked, cultured 
overnight with LB at 37ºC with agitation. Next day DNA was extracted and sequenced 
(MRC Clinical Sciences Centre sequencing facility). 
 
2.2.12.2. Methyl DNA immunoprecipitation (mDIP) 
 
mDIP was carried out in hB genomic DNA as described (Weber et al., 2005). 
Genomic DNA was sonicated (VC 130 PB, Sonics & Materials, Inc) to produce random 
fragments ranging in size from 300 bp to 1000 bp. 4 μg of fragmented DNA was used 
for the mDIP assay. After denaturation for 10 min at 95°C and cooling down on ice for 
2 min, samples were immunoprecipitated for 2 h at 4°C with 10 μl of anti-methylcytidine 
antibody in a final volume of 500 μl of IP buffer (10 mM sodium phosphate pH 7.0, 0.14 
M NaCl, and 0.05% Triton X-100) with constant rotation. The mixture was then 
incubated with 30 μl of Dynabeads with M-280 sheep antibody against mouse IgG 
(Dynal Biotech, Oslo, Norway) for 2 h at 4°C and washed three times with 700 μl of IP 
buffer. Beads were then treated with proteinase K for 3 h at 50°C and methylated DNA 
recovered by phenol-chloroform extraction followed by ethanol precipitation. The 
abundance of methylated DNA was determined by qPCR amplification (see section 
2.2.3.3) with 25 ng of input DNA and 1/30 of the immunoprecipitated methylated DNA. 
Primer pairs used in this analysis are listed in Appendix I, Table A3. 
 
2.2.13. Genomic context analysis 
 
For GC content and LINE density calculations, 200 Kb of surrounding DNA (100 
Kb upstream and downstream of the transcription start position) were analysed, based 
on the May 2004 human genome assembly of the University of California, Santa Cruz, 
genome browser (http://genome.ucsc.edu/) (Hiratani et al., 2004). The number of 
transcriptional units surrounding the middle position of the gene (500 Kb of surrounding 
DNA) was counted for gene density calculations. 
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CHAPTER 3. LYMPHOCYTE REPROGRAMMING TO 
MUSCLE IN STABLE HETEROKARYONS 
 
 
3.1. Reprogramming human lymphocytes in muscle 
heterokaryons 
 
The generation of multinucleated heterokaryons in which different parental cells 
are fused to generate polyploid cells where nuclei share the same cytoplasm but 
remain spatially discrete has been demonstrated between myotubes and cells of an 
unrelated lineage (Blau et al., 1983; Terranova et al., 2006). Upon heterokaryon 
formation changes in somatic cell identity are induced by muscle cells. For instance, 
cells derived from the three main germ layers (mesoderm, endoderm and ectoderm) 
can be dominantly reprogrammed to express muscle-specific genes in heterokaryons 
(Blau et al., 1985). Here, I will analyse in detail the kinetics of nuclear events that 
accompany reprogramming of human B lymphocytes (hB) by the mouse myoblast cell 
line C2C12 (see section 2.1.2 for cell line details). These experiments were performed 
in collaboration with Remi Terranova. Proliferating C2C12 myoblasts were induced to 
differentiate by exposure to low mitogen media. After 2 days lymphocytes were added 
to the myotube cultures and fused in the presence of PEG (Figure 3.1a). In inter-
species heterokaryons it is possible to discriminate human nuclei (using selective 
primers for human genes; α-satellite DNA) from mouse nuclei (γ-satellite DNA). Human 
and mouse nuclei within the resulting myotubes (analysed 0-8 days after cell fusion) 
were distinguished by FISH using differentially labelled probes that selectively 
recognise human γ-satellite or mouse α-satellite DNA. α-satellite DNA (green) was 
present in the nuclei of human B cells before (Figure 3.1b) and after cell fusion with 
mouse myotubes (Figure 3.1c) and allowed them to be readily discerned from mouse 
C2C12 nuclei (labelled red with γ-satellite probe). Human lymphocyte-derived nuclei 
were also identified by counter-staining with DAPI (Figure 3.1c right panel, arrow), 
which highlights AT-rich regions that surround mouse centromeres and generates 
punctuate labelling that is selective for mouse nuclei. Human nuclei, in contrast, show 
diffuse DAPI labelling (illustrated in Figure 3.2a, arrowed). 
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Figure 3.1. Heterokaryon formation between human B-lymphocytes and C2C12 myotubes. (a) 
Shows the protocol used to generate inter-species (hBxC2) heterokaryons. Mouse C2C12 myoblasts were 
differentiated into myotubes and fused with human B-lymphocytes (hB). Heterokaryons were then 
analysed from 0 to 8 days after cell fusion. Mouse and human nuclei were distinguished by FISH using 
probes that were specific for mouse γ-satellite DNA (red) or human α-satellite DNA (green), or by DAPI 
staining (blue). (b) Shows a confocal image of hB nuclei prior to fusion and (c) shows confocal images of a 
myotube containing a human (arrowed) and a mouse nucleus. Scale bars, 10 μm. 
 
 
 
As an indicator of reprogramming, expression of the human muscle marker NCAM 
(detected using the monoclonal antibody 5.1H11, Figure 3.2a, labelled in red) that 
recognises human, but not mouse NCAM (Chiu and Blau, 1984) was monitored over 
time using immunofluorescence labelling. Approximately 37% of heterokaryons 
expressed human NCAM two days after fusion, 59% after four days and 72% after 
seven days (Figure 3.2b), consistent with previously reported estimates of the 
reprogramming of mesoderm-derived cells by C2C12 myotubes (Blau et al., 1985). 
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Figure 3.2. Reprogramming human B-lymphocytes in C2C12 heterokaryons. (a) Confocal section of a 
reprogrammed heterokaryon identified by human NCAM expression (detected with 5.1H11 antibody by 
immunofluorescence, red). One mouse (DAPI intense foci) and one human nucleus (arrowed) are seen 
(scale bar, 10 µm). (b) Expression kinetics of human NCAM (5.1H11 antibody) by lymphocyte-derived 
nuclei (means +/- standard deviations, n = 3 with 50 nuclei per experiment). 
 
 
3.2. Increased nuclear volume and re-distribution of 
heterochromatin are early events in the reprogramming of 
lymphocytes to muscle 
 
Two days after fusion the global morphology of the lymphocyte-derived nuclei 
(in terms of both size and shape) changed, becoming similar to that of neighbouring 
C2C12 nuclei. This result suggests that the reprogramming of human B-lymphocytes is 
associated with global changes in nuclear architecture (Figure 3.3a). To investigate this 
further, I documented the change in the size of human lymphocyte-derived nuclei upon 
heterokaryon formation. The volume of human B cell nuclei, estimated by 
immunofluorescence (materials and methods, section 2.2.7), increased from 
approximately 600 µm3 prior to fusion to 1500 µm3 and 1800 µm3 two and four days 
after heterokaryon formation, respectively (Figure 3.3b). The distribution of constitutive 
heterochromatin within these nuclei was analysed by immunofluorescence with CREST 
(calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, 
telangiectasia) autoimmune serum. Human CREST antiserum was found to recognise 
three constitutive centromeric proteins CENP-A, -B, and -C (Earnshaw et al., 1986; 
Moroi et al., 1980).  
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Figure 3.3. Nuclear reorganisation is an early event in lymphocyte reprogramming. (a) Single optical 
section showing lamin A/C immunofluorescence labelling of human B-lymphocyte nuclei (hB) before (d0) 
and three days after fusion with C2C12 myotubes (d3). (b) The volume of hB nuclei before (d0), 2 and 4 
days after heterokaryon formation (d2, d4) compared to C2C12 myotubes 2 and 4 days after serum 
withdrawal and differentiation (d2, d4). Nuclear volume was estimated as described in materials and 
methods (section 2.2.7) (means +/- standard deviations, n = 3 with 50 nuclei per experiment). (c) CREST 
antiserum reveals the centromere distribution (green) in hB nuclei (d0) and two days after heterokaryon 
formation (d2), where individual chromocentres are indicated (arrowed). Confocal images are maximal 
projections of multiple optical z-sections. (d) Distribution of constitutive heterochromatin in hB nuclei before 
(d0, open bars) and 2 days after fusion in hNCAM expressing (black bars) and hNCAM negative (not yet 
reprogrammed) heterokaryons (grey bars) was compared by assessing the number of discrete CREST 
signals and number of chromocentres per nucleus (n = 100). Scale bars, 10 µm. 
 
 
Prior to fusion, human centromeres were clustered to form 5-8 chromocentres per 
nucleus detected by CREST labelling (one chromocentre was defined as three or more 
closely juxtaposed CREST signals; Figure 3.3c, green) (Alcobia et al., 2000; Brown et 
al., 2001; Weierich et al., 2003). Two days after heterokaryon formation, the number of 
chromocentres per nucleus was markedly reduced (Figure 3.3c, d) as well as CREST 
spatially discrete signals (Figure 3.4, middle panel). This reorganisation mimicked the 
spatial distribution of constitutive heterochromatin seen in neighbouring C2C12 nuclei 
(Figure 3.4, right panel) and occurred rapidly as no further major changes occurred at 
later time points (between day 2 and day 7, Figure 3.4). 
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Figure 3.4. Early redistribution of heterochromatin in hBxC2 heterokaryons. CREST immunostaining 
was used to compare the distribution of constitutive heterochromatin in human B-lymphocyte (hB) -derived 
nuclei prior to fusion (d0), two (d2), and seven (d7) days after hBxC2 heterokaryon formation and 
successful reprogramming (5.1H11 positive heterokaryons). The number of chromocentres and the 
number of discrete CREST signals was assessed using 3D-reconstructed sequential z-series spanning 
100 individual nuclei for each time point. Differentiating C2C12 cultures (0, 2 and 7 days) were analysed 
as controls (right panel).  
 
Changes in nuclear size and architecture were evident prior to the expression of 
hNCAM (Figure 3.3d, comparison between hNCAM positive and negative 
heterokaryons; black and grey bars, respectively), suggesting that nuclear 
reorganisation may precede overt human muscle reprogramming. This rapid timing of 
response implicates transacting factors derived from mouse myotubes in the nuclear 
remodelling of lymphocytes. Consistent with this possibility, mouse Myogenin protein 
was detected in many human nuclei as early as 24 hours after heterokaryon formation 
(Figure 3.5), several days before endogenous human myogenin transcripts were 
expressed (Figure 3.6). 
 
Figure 3.5. Rapid translocation of 
mouse Myogenin to human nuclei. 
Immunofluorescence detection of 
Myogenin protein (green) in a human 
nucleus (arrowed) 24 hours after cell 
fusion. Human and mouse nuclei were 
distinguished on the basis of diffuse and 
spotted DAPI staining (blue), respectively. 
Images show single confocal optical 
sections. Scale bar, 10 µm. 
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3.3. Reprogramming initiates a temporally ordered 
activation of genes encoding human myogenic regulatory 
factors by lymphocyte-derived nuclei 
 
To determine the kinetics of gene activation and silencing induced by 
heterokaryon formation and reprogramming of human lymphocytes, we analysed the 
expression of a panel of human muscle- and B cell-associated genes using RT-PCR 
and primer combinations that were designed to amplify specifically human transcripts 
only (listed in Appendix I, Table A1). As a control, mouse C2C12 cDNA was included at 
all times to confirm the specificity of each primer combinations to human transcripts 
(C2, Figure 3.6). This analysis showed that muscle gene expression was efficiently 
initiated in human B cell nuclei two days after heterokaryon formation (Figure 3.6). 
Interestingly, human MRFs were expressed in a sequence that accurately reflects their 
normal temporal order during myogenic differentiation (Pownall et al., 2002), so that 
hMyf5 was transiently expressed at days 2-3, followed by hMyogenin (day 3 onwards) 
and hMrf4 later (day 4 onwards). 
 
 
 
Figure 3.6. Ordered expression of human myogenic genes by lymphocyte-derived nuclei. 
Expression of human muscle-specific (hMyf5, hMyogenin, hMrf4) and human lymphocyte-specific (hCD45, 
hPax5) genes detected by RT-PCR before (hB) and after cell fusion (day 1 to 8). Prior to fusion, hB 
expressed hGapdh, hCD45 and hPax5, but not muscle-specific genes. Following heterokaryon formation, 
human Myf5, Myogenin and Mrf4 expression was initiated and the expression of human lymphocyte-
specific genes CD45 and Pax5 declined. Mouse C2C12 samples (C2) were used as negative controls to 
confirm the specificity of primers to human transcripts and hGapdh was used to standardise input. 
 
The establishment of a novel gene program by human B cell-derived nuclei was 
accompanied by declining expression of the B cell-specific regulator hPax5 and the 
leukocyte-associated gene hCD45. Expression of human Gapdh, a ubiquitously 
expressed gene, remained constant throughout these analyses. This observation 
suggests that silencing and activation of gene expression programs are coordinated 
during reprogramming. 
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3.4. HDAC activity is required for the silencing of lineage 
inappropriate genes during reprogramming 
 
To assess whether HDAC activity is required to dominant reprogramming of 
lymphocytes to muscle, we treated heterokaryons with the HDAC inhibitor TSA. 
Application of low doses of TSA to differentiating C2C12 or to primary cultures of 
mouse muscle has been shown to increase histone H3K9 and H4K20 trimethylation at 
pericentric DNA and prevent centromeric clustering (Terranova et al., 2005), 
suggesting a role for HDACs in the formation of repressive heterochromatin 
environments during terminal differentiation. To assess their importance during lineage 
conversion, heterokaryons established between human B-lymphocytes and C2C12 
cells were treated with low doses of TSA (20 nM). This did not affect the success rate 
of heterokaryon formation or the proportion of hNCAM positive reprogrammed nuclei 
seven days after fusion (79 ± 6.7%, compare with 72 ± 8.7% in absence of TSA), 
although a slightly enhanced induction of hNCAM expression was seen in the presence 
of TSA (Figure 3.7a). 
 
 
 
Figure 3.7. HDAC inhibition does not impair the activation of muscle gene expression program. (a) 
Expression kinetics of human NCAM (assessed by 5.1H11 immunofluorescence) in hBxC2 heterokaryons 
in the presence (solid line) or absence (broken line) of TSA (20 nM). For each time point, 100 
heterokaryons were analysed in two separate experiments, values shown are the mean and standard 
deviation. (b) RT-PCR analysis of hMyogenin, hMrf4, hMyf5 and hGapdh gene expression in human B-
lymphocytes (hB) and in day 4 (d4) and day 7 (d7) hBxC2 heterokaryons cultured in the presence (+) or 
absence (-) of 20 nM TSA. Differentiating human muscle was used as positive control (hC+) and mouse 
C2C12 cells (C- mC2) as negative control for RT-PCR analysis. hGapdh was used to standardise input. 
(c) Immunofluorescence analysis of day 5 heterokaryons (hBxC2 day5) showed increased histone H3 
lysine 9 (H3K9) acetylation in human nuclei in response to treatment of heterokaryons with 20 nM TSA (+ 
TSA). Confocal microscope settings and laser power were kept constant so that the relative abundance of 
H3K9 acetylation could be directly compared (and quantified, right hand panel) to untreated control 
(means +/- standard deviations, 50 nuclei per experiment). Scale bar, 10 µm. 
 
A comparison of Myf5, Myogenin and Mrf4 expression in heterokaryons that were 
treated with TSA or untreated (Figure 3.7b) confirmed that acquisition of muscle gene 
expression by human lymphocyte-derived nuclei was not compromised. Myogenin 
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expression was detected at days 4 and 7, Mrf4 was most abundant at later stages 
while Myf5 was only detected early after heterokaryon formation (days 2-3). TSA 
treatment resulted in a slight advance in the timing of hMrf4 expression, a result that is 
consistent with a global increase in histone acetylation (Figure 3.7c) and chromatin 
accessibility induced by TSA and a previous report that showed precocious expression 
of mMrf4 in primary mouse muscle treated with HDAC inhibitors (Terranova et al., 
2005). 
TSA did however have a dramatic effect on the temporal extinction of human 
lymphocyte gene expression in inter-species heterokaryons (Figure 3.8). Whereas 
expression of hCD45, hPax5, hCD20 and hCD37 was extinguished (or significantly 
diminished in the case of hCD45) in heterokaryons by day 7, sustained expression of 
these genes was evident in TSA treated heterokaryons (highlighted in green, compare 
left and right panels, Figure 3.8). Human Gapdh, a gene that is expressed in all human 
tissues, was detected throughout in both TSA-treated and untreated cultures and is 
shown for comparison.  
 
 
Figure 3.8. HDAC inhibition prevents the shutdown of lymphocyte-specific genes during 
reprogramming. RT-PCR analysis showed the impact of 20 nM TSA treatment on the expression of 
hCD45, hPax5, hCD20 and hCD37 in inter-species hBxC2 heterokaryons 0 (hB) to 7 days after cell fusion 
(d1-d7). hGapdh was used to standardise input. Green boxes highlight that lymphocyte-associated genes 
were not extinguished following TSA treatment (right hand panel). 
 
To evaluate the selectivity of this TSA response in heterokaryons, we analysed 
the expression of other human genes including hPax6, hRex1, hTert, hNanog and 
hOct4. Most genes were not significantly upregulated in heterokaryons upon TSA 
treatment (Figure 3.9a), with the exception of hOct4 which was transiently activated 
(Figure 3.9a, hB x C2 d4) upon cell fusion. Similarly, TSA treatment of mouse 
myoblasts and mouse myotubes did not induce the inappropriate expression of 
lymphocyte-associated and neural-associated genes (Figure 3.9b) although 2 of the 11 
tested (mEngrailed and mCD4) showed slight up-regulation. This result is consistent 
with estimates that approximately 10% of genes may be sensitive to HDAC inhibition in 
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myoblasts (Iezzi et al., 2004), and suggests that HDAC inhibition in experimental 
heterokaryons selectively targets the silencing of lymphocyte associated gene 
expression program. This claim is also supported by the finding that hPax5 extinction in 
heterokaryons is not associated with reduced expression of Pax5-upstream regulators 
(such as hE2A and hEbf) and that hPax5 (but not hE2A or hEbf) was sensitive to TSA 
treatment (Figure 3.10), as confirmed by quantitative RT-PCR (primers listed in 
Appendix I, Table A2). The expression of hE2A and hEbf in heterokaryons showed a 
similar pattern to the one seen in differentiating human muscle cultures (right panel), 
confirming that these transcriptional regulators are not silenced in the muscle lineage. 
 
 
 
 
Figure 3.9. TSA treatment does not result in the mis-
activation of other lineage related genes. (a) RT-PCR 
gene expression analysis of hPax6, hRex1, hTert, hNanog 
and hOct4 in human B-lymphocytes (hB) and in day 4 (d4) 
and day 7 (d7) hB x C2 heterokaryons cultured in the 
presence (+) or absence (-) of 20 nM TSA. Human 
embryonic stem cell (for hOct4, hNanog, hRex1, hTert) 
and human neuronal progenitor cells (for hPax6) were 
used as positive controls (hC+) and mouse C2C12 cells 
(C- mC2) and mouse ES cells (C- mES) as negative 
controls for RT-PCR analysis. hGapdh was used to 
standardise input. (b) RT-PCR analysis of mouse 
transcripts for mMash1, mNeuroD, mNurr1, mPax2, mEngrailed1, mShh (neural-associated) and mCD45, 
mRag1, mCD4, mLambda-5, mCD19 (lymphocyte-associated) in mouse myoblasts and myotubes cultured 
in the presence or absence of 20 nM TSA. Mouse brain and foetal liver (mC+) were used as positive 
controls for this analysis. mHPRT was used to standardise input. 
 
 
 
 90
 
 
Figure 3.10. hPax5 extinction in heterokaryons is not associated with a decline in the expression of 
hE2A and hEbf. Quantitative RT-PCR analysis of human hPax5, hE2A and hEbf expression in hBxC2 
heterokaryons treated with 20 nM TSA (white bars) or untreated (black bars), 0 (hB) to 10 days (d1-10) 
after cell fusion. Expression of hE2A and hEbf was compared with control cultures of differentiating human 
HFM (Human Foetal Muscle) cells (grey bars). Mouse C2C12 samples (C2) were used as negative 
controls to confirm the specificity of primers for human transcripts and the data were normalised to 
hGapdh expression. 
 
3.5. Inhibition of HDAC activity results in the co-
expression of hCD20 and hNCAM in individual reprogrammed 
nuclei 
 
The observation that TSA prevents the silencing of lymphocyte-associated 
genes but allows the acquisition of muscle gene expression predicts that TSA treated 
heterokaryons would contain nuclei that simultaneously express lymphocyte and 
muscle associated genes. To verify this at the level of individual nuclei, RNA FISH was 
performed to simultaneously detect human muscle- (hNCAM) and lymphocyte- 
(hCD20) specific transcripts in TSA treated experimental heterokaryons. To verify the 
specificity of probes used to detect human CD20 (hCD20-DIG) RNA transcripts, the 
detection hCD20 signals (green) in human B-lymphocyte nuclei were sensitive to 
RNAse but not to DNAase or TSA treatment (Figure 3.11a). Human NCAM (hNCAM-
biotin) was not detected in any of these conditions in human B-lymphocytes (Figure 
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3.11a) but two hNCAM signals (red) were seen in human myoblasts (Figure 3.11b), 
consistent with gene expression patterns.  
 
 
Figure 3.11. Co-expression of lymphocyte- and muscle-specific genes in individual nuclei treated 
with the HDAC inhibitors TSA and VPA. (a) Human B-lymphocytes were analysed for hCD20 (green) 
and hNCAM (red) transcripts using RNA FISH. Two foci of hCD20 signal were evident in hB cell nuclei that 
were removed by pre-treatment of samples with RNAse A (+RNase), but not DNAse (+DNase). Application 
of 20 nM TSA did not impair hCD20 signal detection (+TSA). (b) Human NCAM transcripts (red) were 
detected in human myoblast nuclei but not in lymphocytes. (c) RNA FISH showing examples of nuclei that 
express hCD20 transcripts alone (green) and hNCAM transcripts alone (red) or both (red/green, arrowed) 
in lymphocyte-derived nuclei within day5 hBxC2 heterokaryons. Confocal images are maximal projection 
of multiple optical z-sections (scale bars, 10 µm). (d) The proportion of nuclei expressing hNCAM (red), 
hCD20 (green), or both hNCAM and hCD20 (red/green) signals in heterokaryons cultured in the absence 
(untreated) or presence of 20 nM TSA (+TSA) or 1 mM VPA (+VPA) is expressed as a proportion of 
human nuclei in which RNA transcripts were detected. 
 
Using these probes, RNA-FISH analysis was used to score nuclei expressing the 
muscle gene hNCAM alone, the lymphoid gene hCD20 alone, or co-expressing both 
hNCAM and hCD20 within individual nuclei in heterokaryons at day 5 (illustrated in 
Figure 3.11c; quantification is shown in Figure 3.11d and Table 3.1). In untreated 
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heterokaryons in which human RNA signals were found, most nuclei (75%) expressed 
hNCAM and only a minority (32%) expressed hCD20. Nuclei in which both transcripts 
were detected simultaneously were rare (7%), and may reflect nuclei “in transit” from 
the lymphoid to muscle program. Addition of TSA or the structurally unrelated HDAC 
inhibitor VPA did not affect muscle-specific hNCAM signals (red histograms) but had a 
dramatic effect on the proportion of lymphocyte-derived nuclei that retained hCD20 
expression (green histograms, Figure 3.11d). Consequently, and in contrast to 
untreated cultures, many lymphocyte-derived nuclei within TSA- or VPA-treated 
heterokaryons co-expressed both hCD20 and hNCAM (28 and 29%, respectively; 
red/green histograms, Figure 3.11d). These results confirm that HDAC activity is 
important for the silencing of lymphocyte-specific genes during reprogramming. 
 
 
Table 3.1. RNA FISH detection of hCD20 and hNCAM transcripts in day-5 heterokaryons. 
 
Sample 
Nuclei with 
hNCAM signals 
only 
Nuclei with 
hCD20 
signals only 
Nuclei with both 
hCD20/hNCAM 
signals 
Sample 
size No signal 
Untreated   
exp. 1 20 5 1 56 30 
exp. 2 29 10 2 72 31 
exp. 3 20 10 4 60 26 
+ TSA (20 nM)   
exp. 1 20 18 15 75 22 
exp. 2 16 17 12 60 15 
+ VPA (1 mM)  
exp. 1 15 16 17 77 29 
exp. 2 17 21 11 69 20 
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3.6. Discussion and future perspectives 
 
Demonstrations of somatic cell reprogramming by nuclear transfer and in 
experimental heterokaryons have shown that many types of differentiated cells retain a 
flexible lineage potential (Baron and Maniatis, 1986; Blau et al., 1983; Gurdon, 1962; 
Hochedlinger and Jaenisch, 2002; Wilmut et al., 1997) [reviewed by DiBerardino 
(DiBerardino, 1988) and Surani (Surani, 2001)]. Here the epigenetic plasticity of human 
B-lymphocytes was assessed in stable C2C12-derived muscle heterokaryons. I show 
that dominant conversion of human lymphocytes to muscle is a multi-step process that 
includes changes in nuclear size, architecture and gene activity. In muscle 
heterokaryons, where chromosome replication is precluded (Chiu and Blau, 1984), 
these steps can be distinguished on the basis of their timing and the requirement for 
HDAC activity. Within the first 48 hours of heterokaryon formation, lymphocyte nuclei 
increase in size and heterochromatin domains are redistributed to mimic the spatial 
arrangement of neighbouring mouse myocytes. Importantly, this reorganisation 
appears to precede the activation of endogenous human muscle-specific genes. It is 
possible that these changes in nuclear architecture are the result of physical 
constraints, or that dominant factors within the myotubes impose a muscle-specific 
organisation on the introduced nucleus. As cycling and non-cycling lymphocytes 
display different constitutive heterochromatin organisation (Brown et al., 1999; Solovei 
et al., 2004) and cell cycle withdrawal is a characteristic feature of myogenic 
differentiation (Ait-Si-Ali et al., 2004; Shen et al., 2003; Walsh and Perlman, 1997), it is 
also possible that nuclear reorganisation is a consequence of imposing cell cycle 
arrest. Previous studies have shown that fusion of nucleated chicken erythrocytes with 
rat myoblasts results in pronounced nuclear enlargement and chromatin redistribution 
prior to gene reprogramming (Dupuy-Coin et al., 1976). Similar effects have been 
reported for mouse lymphocytes injected into Xenopus oocytes (Byrne et al., 2007) and 
bone marrow cells that form stable heterokaryons with Purkinje neurons (Weimann et 
al., 2003). Chromatin redistribution in developing muscle has also shown to be 
dependent on the methyl-CpG binding proteins MeCP2 and MBD2 (Brero et al., 2005). 
MeCP2 interacts with HP1 to modulate heterochromatin association (Agarwal et al., 
2007). Taken together, these results suggest that myogenic regulators and chromatin 
remodelling machinery are both likely to have important roles in conveying dominant 
cell-type-specific nuclear organisation during reprogramming. 
Trans-acting factors derived from mouse myotubes, that are implicated in 
nuclear remodelling during the myogenic conversion of lymphocytes, have yet to be 
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characterised. The MRFs: MyoD, Myf5, Myogenin, and Mrf4, are conserved bHLH 
transcription factors present in vertebrates (Weintraub et al., 1991), that have the 
remarkable ability to convey muscle-associated properties to many non-muscle cell 
types (Aurade et al., 1994; Choi et al., 1990; Davis et al., 1987; Ohkawa et al., 2006). 
Ectopic expression of Myogenin in fibroblasts, induces muscle differentiation in a 
manner dependent on the chromatin-remodelling enzyme Brg1 (Ohkawa et al., 2006). 
These results suggest that MRFs convey the muscle identity by cooperating with the 
SWI/SNF chromatin remodelling machinery to alter chromatin structure (de la Serna et 
al., 2001). Consistent with this possibility, mouse Myogenin protein (myotube-derived) 
was detected in human nuclei (lymphocyte-derived) as early as 24 hours after 
heterokaryon formation. However, to carefully elaborate which factors are required and 
sufficient to establish muscle-specific identity, will require additional experiments. For 
example, using inter-species heterokaryons treated with drugs that inhibit the activity of 
specific enzymes, or using RNA interference to silence mouse myotube-specific genes 
and alter trans reprogramming. 
My results show that de novo expression of an endogenous muscle gene 
program by lymphocyte-derived nuclei begins two days (hMyf5) after heterokaryon 
formation. The activation of hMyf5 is then followed by hMyogenin (day 3 onwards) and 
hMrf4 later (day 4 onwards) (summarised in Figure 3.12). The pattern of expression of 
the MRFs (MyoD, Myf5, Myogenin and Mrf4) genes in vertebrates provided evidence 
that these regulators are involved in both the specification and differentiation of 
myogenic progenitor lineages (Pownall et al., 2002). Myf5 and MyoD are expressed in 
proliferative myoblasts (Emerson, 1990), and in tissue culture cells this expression is 
stably maintained through autoregulation (Thayer et al., 1989), which implicates Myf5 
and MyoD in the establishment and maintenance of muscle progenitor lineages. 
However, Myogenin and Mrf4 are activated during myoblast differentiation (Brownell et 
al., 1996; Rhodes and Konieczny, 1989; Wright et al., 1989) and likely have functions 
later for the activation of genes associated with muscle contractile proteins (Lassar et 
al., 1991). Interestingly, human MRFs genes were activated in a lymphoid cell type 
upon cell fusion in a sequence that accurately reflects their temporal order during 
normal muscle differentiation. In agreement with my findings, the activation of hMyoD, 
one of the earlier markers of myogenic commitment, was also shown to occur rapidly 
(transcriptional activation between day 1 and 3) in heterokaryons generated between 
human keratinocytes and mouse muscle cells (Zhang et al., 2007). 
 
 95
 
Figure 3.12. Kinetics of events involved in the multi-step reprogramming of lymphocytes to muscle 
in heterokaryons. Trans acting factor (mMyogenin) migration to human nuclei and nuclear re-organisation 
(nuclear size and re-distribution of heterochromatin domains) are early events of reprogramming (day 1 
and 2, respectively). Activation of endogenous human muscle markers begins at day 2 (hMyf5) and is 
followed by hMyogenin (day 3 onwards) and hMrf4 later (day 4 onwards). These events are indicated by 
the green arrows. Reduction of lymphocyte-specific gene expression (hCD45, hPax5, hCD20 and hCD37) 
begins after 2-3 days and continues over a 7-day period (red boxes). 
 
Activation of muscle-specific genes in lymphocyte-derived nuclei was 
accompanied by the extinction of several lymphoid-associated genes (hCD45, hPax5, 
hCD20, hCD37). Reduced expression of leukocyte-specific genes began 2-3 days after 
cell fusion and continued over a 7-day period (Figure 3.12). These kinetics were similar 
to the reported shut-down of human albumin expression during hepatocyte 
reprogramming to muscle (Miller et al., 1988). Thus reprogramming to muscle identity 
appears to be coordinated with the silencing of lineage-inappropriate genes in 
heterokaryons. 
Throughout development, cellular differentiation is characterised by the 
coordinated activation and extinction of genes at specific times. In developing 
lymphocytes, the regulated expression and silencing of the terminal deoxynucleotidyl 
transferase locus, Dntt, provides a particularly well studied example (Wernig et al., 
2007). Dntt is expressed by immature lymphocytes but is transcriptionally silenced in 
response to signalling through the T- or B-cell receptor. A temporal analysis of the 
chromatin modifications that accompany stable silencing showed that silencing is 
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nucleated at the promoter by the ordered deacetylation of histone H3 Lysine 9, loss of 
methylation at H3 Lysine 4 and methylation at H3 Lysine 9. This was followed by 
repositioning of the Dntt locus to pericentric heterochromatin (Brown et al., 1999) and 
the bidirectional spreading of repressive histone modifications (Kimura et al., 2004). 
The importance of histone deacetylation for initiating the assembly of silent chromatin 
is underscored by a requirement for Ikaros, a DNA binding factor that is essential for 
lymphocyte development, that interacts with HDAC-containing nucleosome remodelling 
NuRD complex (Koipally et al., 1999) and is required for the appropriate stage-specific 
silencing of many lymphocyte-associated genes (Sabbattini et al., 2001; Su et al., 
2004). Remarkably, my results show that in experimental heterokaryons, inhibition of 
HDAC activity by low doses of TSA or VPA blocked the silencing of lineage 
inappropriate genes without affecting ongoing conversion to muscle. Accordingly, upon 
HDAC inhibition, approximately 30% of individual human nuclei in heterokaryons were 
seen to co-express two different lineage-associated gene programs. The RNA-FISH 
approach used to address gene expression in individual nuclei provides “snapshots” of 
local transcription at a given time point. Since gene activity has been shown to occur 
not continuously but in bursts of transcription (Cai et al., 2006; Golding et al., 2005; Raj 
et al., 2006) and there are massive variations in the number of local mRNA molecules 
when a gene “transits” from inactive to active state (Raj et al., 2006), it is even possible 
that the number of co-expressing nuclei is underestimated. 
My results underscore the importance of HDACs for correctly extinguishing the 
gene expression program of nuclei undergoing reprogramming and conversion to 
muscle. To date, 18 HDACs have been identified in human and categorised in several 
classes based on their homology with yeast HDACs (Blander and Guarente, 2004; de 
Ruijter et al., 2003). Moreover, HDACs are not redundant in function, as different 
classes of HDACs associate with different co-repressors and activators (Bolden et al., 
2006; Marks and Dokmanovic, 2005; Xu et al., 2007). Whether a specific HDAC 
protein(s) or family is involved in gene extinction during reprogramming of lymphocytes 
to muscle remain an open question. In my experiments I have used broad HDAC 
inhibitors such as TSA and VPA which inhibit both class I and class II HDACs by 
binding to their zinc containing catalytic domain (HDACs class III, or sirtuins are NAD+ 
dependent and therefore not inhibited by these compounds). However, it has been 
reported that class II HDACs are five times less susceptible to inhibition by VPA than 
class I HDACs (Gottlicher et al., 2001). Since the failure of lymphocyte-specific gene 
extinction was similar in TSA and VPA treated heterokaryons, it is tempting to 
speculate that class I HDACs may be involved in gene extinction. In the future, this 
could be further investigated using more selective inhibitors such as depsipeptide 
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(Furumai et al., 2002), SK7041 and SK7068 (Kim et al., 2003), which specifically 
inhibits some Class I HDACs or using RNAi-based approaches. 
Collectively, these results underscore the importance of gene silencing in 
reprogramming but also show that the establishment of muscle gene expression and 
the extinction of lymphocyte identity are distinct and mechanistically separable 
components of lineage conversion. 
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CHAPTER 4. HETEROKARYON-BASED 
REPROGRAMMING OF LYMPHOCYTES FOR 
PLURIPOTENCY 
 
 
4.1. Generation of inter-species heterokaryons between 
human B-lymphocytes and mouse embryonic stem cells 
 
Spontaneous and experimental cell fusion of differentiated cells with pluripotent 
ES cells induces the expression of pluripotency-associated markers in the hybrid cells 
(Cowan et al., 2005; Tada et al., 2001; Ying et al., 2002), re-activation of the silent X-
chromosome (Tada et al., 2001) and DNA de-methylation and chromatin remodelling at 
specific sites in the somatic cell genome (Cowan et al., 2005; Kimura et al., 2004). 
While these data show that reprogramming occurs through the epigenetic resetting of 
gene expression programs in the differentiated cell (Simonsson and Gurdon, 2004; 
Surani, 2001), it has been unclear whether genome duplication is required for 
conversion to pluripotency (Han et al., 2008). Here I asked whether reprogramming to 
pluripotency occurs in heterokaryons and investigated the requirements for the 
dominant reprogramming of human B cells by fusion with mouse ES cells. 
The protocol used for “transient” heterokaryon formation is illustrated in Figure 
4.1a. Unlike the muscle syncytia detailed in Chapter 3, embryonic stem cell lines do not 
generate multinucleated cells, and the resulting heterokaryons are transient rather than 
stable. Human B cells were fused with mouse ES cells using PEG and the nuclear 
events in fused cells were monitored by fluorescence microscopy and quantitative RT-
PCR. To facilitate the identification of fused cells, mouse E14tg2A ES cells were pre-
labelled with DiD and human B cells with DiI. The two labelled cell populations were 
mixed in a 1:1 ratio and inter-species heterokaryons were generated in suspension by 
PEG-mediated cell fusion. Dual-stained cells were purified by FACS (typically 10-15% 
of cells, Figure 4.1b) and cultured under conditions promoting the maintenance of 
undifferentiated mES cells. 
 99
 
Figure 4.1. Generation of embryonic inter-species heterokaryons through cell fusion. (a) Shows the 
experimental strategy used to generate inter-species heterokaryons (hB x mES). Human B-lymphocytes 
(hB) and mouse embryonic stem cells (mES) were fused in the presence of polyethylene glycol (PEG) and 
monitored over time. (b) Human B-lymphocytes (hB) and mouse embryonic stem cells (mES) were 
respectively labelled with the cell membrane dyes DiI and DiD and fused in the presence of PEG. Fused 
cells (double-labelled, upper right quadrant) were FACS sorted and cultured under conditions promoting 
the maintenance of undifferentiated mES cells. 
 
 
4.2. Reprogramming of gene expression is initiated in ES 
cell heterokaryons prior to nuclear fusion 
 
 Human (B cell-derived) and mouse (ES cell-derived) nuclei were distinguished 
on the basis of DAPI and human-specific lamin A/C labelling, and the proportion of 
cells containing two discrete (heterokaryons) or conjoined nuclei (hybrids) was 
assessed over time (Figure 4.2a). Up to 2 days following cell fusion 98 – 99% of dual 
labelled cells were identified as heterokaryons in which a single human and a single 
mouse nuclei were evident (illustrated in Figure 4.2a, central image). The kinetics of 
nuclear fusion were also confirmed by FISH analysis in which probes specific for 
mouse chromosomes (γ-satellite, red) or human chromosomes (α-satellite, green) were 
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used to detect nuclei containing solely human or solely mouse chromosomes or both 
(indicative of hybrid formation, Figure 4.2b). 
 
 
Figure 4.2. Heterokaryons can be maintained up to two days before nuclear fusion. (a) 
Immunofluorescence analysis of the kinetics of heterokaryon (cells in which parental nuclei share the 
same cytoplasm but remain discrete) and hybrid formation (where both parental genomes occupy the 
same nucleus) following PEG-induced fusion. hB-derived nuclei were distinguished from mouse nuclei on 
basis of DAPI (blue) and human Lamin A/C staining (green), and actin staining (red) delineates individual 
cells. In the lower panels confocal sections showing a hB cell prior to fusion (left, day 0), a heterokaryon 
[one mouse (with DAPI intense foci) and one human nucleus (hLamin A/C positive)] (middle, day 2) and a 
hybrid cell (right, day 3) are shown. n = 100 (b) Mouse and human nuclei were distinguished by FISH 
using probes specific for mouse γ-satellite DNA (red) or human α-satellite DNA (green) along with DAPI 
(blue). Confocal sections of human B cells (hB) and mouse ES cells (mES) before and after cell fusion (hB 
x mES) are shown. Heterokaryons were identified up to 2 days after fusion, but by day 3 hybrid formation 
was detected. Scale bars, 10 µm. 
 
 The expression of pluripotency-associated and lymphocyte-associated genes 
by human B cell-derived nuclei was assessed by RT-PCR, using primers that were 
designed to selectively amplify each of the human transcripts. This analysis showed 
that hOct4 and hNanog transcripts arise from hB-derived nuclei, two days after 
heterokaryon formation (Figure 4.3a, left panel). The establishment of a new gene 
expression program by hB nuclei was accompanied by a reduction in expression of the 
lymphocyte-associated genes hCD20 and hCD37 (Figure 4.3a, right panel).  
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Figure 4.3. Reprogramming of human B-lymphocytes to embryonic state by mouse ES cells does 
not require nuclear fusion. (a) Expression of human ES-specific (hOct4, hNanog) and human 
lymphocyte-specific (hCD20, hCD45) transcripts detected by RT-PCR using human-specific primers. Prior 
to fusion, hB cells expressed hGapdh, hCD20 and hCD45 but not embryonic stem cell-specific genes. 
Following heterokaryon formation (hB x mES d2), human pluripotency-associated genes hOct4 and 
hNanog were expressed (left panel) and hCD20 and hCD45 were extinguished (right panel). mES, -RT 
and H2O were used as negative controls and human embryonic stem cells (hES) as a positive control. 
hGapdh was used to standardise input. (b) The expression of hES-specific genes (hOct4, hNanog, 
hCripto, hDnmt3b, hTle1, hRex1 and hTert) was assessed by quantitative RT-PCR analysis 0 to 8 days 
after cell fusion. Positive (hES-NCL1, black bars) and negative (hB, mES) controls for this analysis were 
included. The constitutively expressed gene hHprt remains detectable at identical levels at all time points. 
(c) Activation of embryonic genes is accompanied by silencing of lymphocyte-specific genes (hCD19, 
hCD37, hCD20, hCD45 and hPax5). Data were normalised to hGapdh expression. Error bars indicate the 
s.d. of 3 independent experiments.  
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The kinetics of gene activation was then assessed by qRT-PCR with primers 
recognising a panel of human ES-associated gene products, including transcription 
factors, DNA modifiers and signalling molecules. The expression of human Oct4, 
Nanog, Cripto, Dnmt3b and Tle1 was detected in cells as early as 1 day after fusion 
and human Rex1 after 2 days (Figure 4.3b). Expression of hTert was detected from 
day 4 onwards (Figure 4.3b). Although the expression levels were low in heterokaryons 
(<1% of that detected in human ES cells, cell line NCL1), these increased over time 
and were undetectable in non-fused (or self-fused, not shown) human B cells or control 
mouse ES cells. Mouse lymphocyte-specific gene transcripts (mCD19, mCD37 and 
mCD45) were not detected throughout the analysis (not shown), confirming ES cell 
dominance in conversion (Cowan et al., 2005; Tada et al., 2001). The increased 
expression of human pluripotency-associated genes over this 8-day period was 
mirrored by a reduction in expression and extinction of several human lymphocyte-
associated genes within the second (hCD45, hCD37 and hCD19) or third day (hCD20 
and hPax5) of heterokaryon formation (Figure 4.3c). hHprt expression was equivalent 
at all stages, as anticipated (Figure 4.3b). Collectively these data show that upon 
dominant reprogramming, activation and silencing of tissue-specific gene programs 
begins ahead of, and therefore does not require, nuclear fusion and cell division. In 
addition, since these results examine gene expression at the population level, it is 
possible that gene expression varied between individual heterokaryons and hybrid 
cells. 
 As the reprogramming of somatic cell has been previously shown to result in 
altered DNA methylation at specific loci (Cowan et al., 2005; Freberg et al., 2007; 
Simonsson and Gurdon, 2004; Tada et al., 2001), we examined changes in the 
methylation status of the human Oct4 gene promoter (Deb-Rinker et al., 2005) and as 
a control, the Igf2/H19 imprinting control region (ICR) (Ulaner et al., 2003). As 
illustrated in Figure 4.4, human B cells prior to fusion showed high levels of DNA 
methylation throughout the hOct4 promoter and across a single Igf2/H19 allele. 
Following cell fusion, DNA methylation of hOct4 in reprogrammed B cells declined, 
consistent with a trend towards a hypomethylated state as seen in the human ES cell 
line H1. Demethylation of the hOct4 promoter was rapid, detected prior to nuclear 
fusion and cell division (heterokaryons at day2) and maintained throughout the 
experiment (d2-d8), a result that is consistent with active chromatin remodelling of the 
locus prior to expression. In addition, a mosaic pattern of demethylation was observed 
(some DNA clones completely demethylated while others remain largely methylated) 
suggesting that only a proportion of heterokaryons are being successfully 
reprogrammed. This pattern of demethylation was also observed in human 293T cells 
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upon exposure to ES-cell extract (Freberg et al., 2007) at the human Oct4 and Nanog 
promoter regions. No changes in DNA methylation at Igf2/H19 ICR were detected over 
this period, consistent with its imprinted status and the lack of ability of ES cells to 
erase imprints (Tada et al., 2001; Ulaner et al., 2003). 
 
 
Figure 4.4. The human Oct4 promoter is 
demethylated in heterokaryons. Bisulfite 
genomic sequencing analysis of DNA 
methylation at the human Oct4 promoter 0, 
2, 4 and 8 days after cell fusion with mES 
cells. Human ES cells (hES, cell line H1; 
lower panel) are shown as controls. The 
methylation pattern of Igf2/H19 imprinting 
control region (ICR) was analysed as a 
control. The position of CpG sites relative 
to the transcriptional start site (TSS) is 
indicated. Open circles represent 
unmethylated cytosines, black closed 
circles represent methylated cytosines and 
gray closed circles represent constitutively 
methylated cytosines. Region 1, 2 and 3 
indicate CpG sites that are part of the 
same PCR product. 
 
 
 
 
 
 
4.3. Induction of a human ES-specific gene expression 
profile and multi-lineage potential 
 
 A comparison of the relative abundance of gene-specific transcripts in 
reprogrammed human B cells (Figure 4.5a, right-hand column), showed a strong 
similarity with the gene expression profiles of several human ES cell lines [NCL1 
(Stojkovic et al., 2004), H1, H7, H9 (Thomson et al., 1998); Figure 4.5a, left-hand 
column]. For example, while Oct4 was abundantly expressed in all human and mouse 
ES cell lines, Nanog and Cripto expression was consistently much lower than Oct4 
(100-1000 fold) for each of the mouse ES cell lines analysed (OS25, CCE, E14, 
ZHBTc4; Figure 4.5a, middle panel). In human ES cell lines however, Oct4, Nanog and 
Cripto transcripts were similarly abundant, a result that was mirrored in reprogrammed  
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Figure 4.5. Reprogrammed lymphocytes are comparable to human ES cells rather than mouse ES 
cells. (a) Quantitative RT-PCR analysis of the relative levels of gene expression in several human (NCL1, 
H1, H7 and H9), mouse (OS25, CCE, E14 and ZHBTc4) ES cell lines and in reprogrammed lymphocytes 
(hB x mES) at 0, 2, 4 and 8 days after cell fusion. Human ES lines (left panel) and hB x mES (right panel) 
gene expression data was normalised to hGapdh. Mouse ES lines (middle panel) gene expression data 
was normalised to mGapdh. Error bars indicate the s.d. of 3-4 independent experiments. (b) Expression of 
Fgfr1, Fgfr2, Fgf2, Bmp4, Lifr and Jak3 was assessed by qRT-PCR in human ES cells (hES, NCL1), 
mouse ES cells (mES) and human B-lymphocytes (hB). Fgfr1, Fgfr2 and Fgf2 were uniquely expressed by 
human ES cells. (c) After cell fusion, the expression of genes involved in the maintenance of 
undifferentiated human ES cells (hFgfr1, hFgfr2 and hFgf2; highlighted with green box) and genes 
selectively expressed by mouse ES cells (hBmp4, hLifr and hJak3) was analysed by qRT-PCR. Data were 
normalised to hGapdh expression. Error bars indicate the s.d. of 3 independent experiments. 
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human B cells. Expression of some pluripotency-associated genes, for example Sox2, 
was variable and often required more time (>8 days) to be detected in hB x mES 
cultures (not shown). 
 
 
Figure 4.6. Reprogrammed cells express the human ES marker SSEA4. (a) Heterokaryons resulting 
from human B cell and mouse ES cell fusions (hB x mES) were stained for SSEA4 at 0, 2, 4 and 8 days 
and expression was analysed by flow cytometry. The results showed that 13.5% (day 2), 16.6% (day 4) 
and 15.8% (day 8) of total heterokaryons expressed SSEA4, as delineated by the rhomboid gates. Mean 
intensity fluorescence of positive cells is indicated. (b) FACS analysis showed that >90% of hES cells (H1 
cell line) expressed SSEA4, while hB and mES did not (2.1% and 1.5% respectively). A proportion of 
heterokaryons showed SSEA4 expression (15.8%) 8 days after cell fusion (hB x mES d8). (c) FACS 
sorting of SSEA4 positive cells co-purifies reprogrammed cells that express hOct4, hNanog and hCripto, 
as assessed by qRT-PCR. Data were normalised to hGapdh expression. 
 
Similarities between gene expression profiles of human ES cell lines and hB x 
mES fused cells prompted us to examine additional markers that are expressed solely 
by either human or mouse ES cells (Ginis et al., 2004; Pera and Trounson, 2004; Sato 
et al., 2003; Xu et al., 2005). These included fibroblast growth factor receptors (Fgfr1 
and Fgfr2) and Fgf2 (expressed by human ES cells, Figure 4.5b), LIF receptor (Lifr) 
and Bmp4 (expressed by mouse ES cells) and SSEA4, a surface glycoprotein 
selectively expressed by human ES cells (Thomson et al., 1998). This analysis 
revealed that reprogrammed cells expressed increasing amounts hFgfr1, hFgfr2 and 
hFgf2, but did not express hBmp4 or hLifr or upregulate the downstream kinase hJak3 
(Figure 4.5c). Thus, these data show that although dominant conversion is driven by 
mouse ES cells that express Bmp4 and Lifr prior to fusion (Figure 4.5b), reprogrammed 
heterokaryons and hybrid cells have a remarkably different expression profile that 
resembles human, rather than mouse ES cell lines. Consistent with this, fusion of 
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mouse ES cells and human B cells resulted in SSEA4 expression by a proportion of 
cells (13-16%, days 2-8 as shown in Figure 4.6a and 4.6b) and the isolation of SSEA4-
positive cells co-purified successfully reprogrammed cells that express hOct4, hNanog 
and hCripto (Figure 4.6c), while SSEA4-negative cells were not reprogrammed. The 
observation that only a proportion of heterokaryons are successfully reprogrammed, as 
judged by hOct4 DNA demethylation and SSEA4 expression, might partly explain why 
the levels of transcripts encoding pluripotency factors are lower in reprogrammed 
cultures than established hES cell lines.  
To ask whether the reprogramming of human B cells by mouse ES cells resets 
multi-lineage potential, hB x mES cultures were treated with retinoic acid (RA) 6-8 days 
after cell fusion in order to induce differentiation. Prior to RA treatment, hybrid colonies 
expressed several pluripotency-associated markers, including hNanog protein 
(detected using a human Nanog-specific antibody) and the human embryonic-specific 
antigens SSEA4, TRA-1-60 and TRA-1-81 (Thomson et al., 1998) (Figure 4.7).  
 
 
Figure 4.7. Expression of human-specific embryonic markers in hybrid cells. Human B cells (hB) and 
mouse ES cells (mES) were fused and the resulting colonies (hB x mES, day 8) were analysed by 
immunofluorescence. Detection of hNanog protein (red) and the human ES-specific antigens SSEA4, 
TRA-1-81 and TRA-1-60 (green) with human-specific antibodies is shown. Control hB cells did not express 
any of the markers. DAPI staining is shown in blue. Images are single confocal sections. Scale bar, 50 µm. 
 
In addition, most cells in hB x mES colonies showed alkaline phosphatase (AP) activity 
(Thomson et al., 1998) (Figure 4.8a), as well as the expression of human AP 
transcripts (hALPL, Figure 4.8b). Following treatment with RA, AP activity and 
expression of hOct4, hNanog and hRex1 was reduced (Figure 4.8a and 4.8c), while 
morphological heterogeneity within colonies increased.  
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Figure 4.8. Multi-lineage potential is reset in reprogrammed human lymphocytes. (a) Alkaline 
phosphatase activity assay of hybrid colonies (hB x mES, day 8) resulting from fusion of human B cells 
(hB) and mouse ES cells. Hybrid colonies showed alkaline phosphatase activity (pink) that was reduced 
upon retinoic acid treatment (+RA, day 6). Images are bright field pictures. (b) qRT-PCR analysis of 
human alkaline phosphatase (hALPL) gene expression upon cell fusion. (c) qRT-PCR analysis of gene 
expression upon RA treatment of hybrid cells (blue line) showed that levels of pluripotency genes (hOct4, 
hNanog and hRex1) declined while differentiation-associated genes were upregulated [extra-embryonic 
(hCdx2, hHand1 and hGata6), endoderm (hSox7, hHnf4 and hCollagenIVαI), mesoderm (hMixl1, hEbf and 
hMyoD) and ectoderm (hNestin)]. Unfused hB cells were included as controls (black line). Data were 
normalised to hGapdh expression. (d) Immunostaining of ectodermal differentiating colonies 6 days after 
RA exposure with anti human-specific Nestin antibody (green). Nuclei were visualised with DAPI staining 
(blue). Scale bars, 50 µm. (e) Bisulfite genomic sequencing analysis of DNA methylation at the human 
Oct4 promoter and the Igf2/H19 imprinted control region (ICR) 8 days after RA treatment. The position of 
CpG sites relative to the transcriptional start site (TSS) is indicated. Open circles represent unmethylated 
cytosines, black closed circles represent methylated cytosines and gray closed circles represent 
constitutively methylated cytosines. 
 
Detection of extra-embryonic (hCdx2, hHand1 and hGata6), endoderm (hSox7, hHnf4 
and hCollagenIVαI), mesoderm (hMixl1, hEbf and hMyoD) and ectoderm (hNestin) 
associated transcripts in RA treated hB x mES cultures, but not in RA treated hB cells 
(Figure 4.8c, blue and black lines respectively), confirmed a selective response of 
reprogrammed cells to multiple differentiation pathways. In addition, cells expressing 
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hNestin protein were detected (using an anti-human Nestin-specific antibody) at the 
edge of colonies after RA treatment (Figure 4.8d). Differentiation also resulted in 
increased DNA methylation of the hOct4 promoter (Figure 4.8e), similar to levels seen 
in differentiated human B cells (Figure 4.4). Taken together, these results show that 
reprogramming of human B-lymphocytes by mouse ES cells resets gene expression 
and multi-lineage potential. 
 
4.4. Genes not easily re-activated in heterokaryons 
display heterochromatic features 
 
The observation that genes such as hSox2 and hTert, that were not re-activated 
in day-2 heterokaryons, could reflect the fact that they require a higher threshold of 
activators for overt expression, or that these genes are subject to multiple layers of 
repressive epigenetic modifications in B cells, including DNA and histone methylation 
(Jenuwein and Allis, 2001; Lande-Diner and Cedar, 2005) and late replication (Gilbert, 
2002). This possibility prompted us to examine the epigenetic status of these and 
additional loci in hB-lymphocytes prior to cell fusion (results summarised in Figure 4.9). 
My results showed that many silent endogenous genes in hB cells can be re-
activated in heterokaryons at day 2 (hOct4, hDppa5, hCripto, hDnmt3b, hNanog, 
hGdf3, hGbx2 and hTle1; Figure 4.9c, white boxes) albeit at low levels (hFoxd3 and 
hRex1; Figure 4.9c, grey boxes). However, expression of some genes was not 
detected (hTert, hSox2 and hDppa4; Figure 4.9c, black boxes). I assessed the 
replication timing of these genes in hB cells, as there is a correlation between 
replication timing and heritably repressed chromatin (Gilbert, 2002). The timing that 
each locus replicates during S-phase was analysed by a PCR-based method (Azuara 
et al., 2006) and genes ordered them from the earliest (hOct4, green) to the latest 
(hRex1, red) replicating gene (Figure 4.9a; see Appendix II, Figure A1 for detailed 
analysis). Four out of five ES-associated genes analysed (hSox2, hFoxd3, hDppa4 and 
hRex1) that were not easily re-activated in heterokaryons were among the late-
replicating cohort of genes (Figure 4.9, highlighted by the red open box). This subset of 
genes was also preferentially located within isochores with low GC content, high 
frequency of LINE elements (Figure 4.9d, upper panel) and gene poor regions (Figure 
4.9d, lower panel), as previously reported (Hiratani et al., 2004). 
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Figure 4.9. Some genes not easily re-activated in heterokaryons show heterochromatic features. (a) 
The replication timing of each gene (hOct4, hDppa5, hCripto, hDnmt3b, hTert, hNanog, hGdf3, hFoxd3, 
hGbx2, hSox2, hDppa4, hTle1 and hRex1) was defined accordingly to its peak abundance in G1-S1 phase 
(early, green), S2 phase (middle-early, dark green), S2-S3 phase (middle, yellow), S3 phase (middle-late, 
orange) or S4-G2 (late, red), determined in two independent experiments with a PCR-based assay 
(Azuara et al., 2006) in hB-lymphocytes. Genes are ordered according to their replication timing. α-Globin 
and β-Amylase were included as control genes. (b) The abundance of active (H4Ac, H3K9Ac and 
H3K4me2) and repressive (H3K9m3, H3K27m3 and H4K20m3) histone modifications was assessed in hB-
lymphocytes using chromatin immunoprecipitation and qPCR. The colour code for different histone marks 
is indicated. Controls for active (hIkaros) and repressive (α-satellite and hMyoD) histone modifications 
were included. The enrichment indicates the ratio of modified H3 to unmodified H3 detected at each 
promoter region normalised to input DNA. Error bars indicate the s.d. of 3 independent experiments. (c) 
Heterokaryons were generated by cell fusion of mouse ES cells (E14tg2A or OS25 cell line) with hB-
lymphocytes and each of the human ES-associated transcripts was quantified by qRT-PCR two days after 
fusion. Detectable (white boxes), detectable at low levels (grey boxes) and not detectable (black boxes) 
genes were categorised based on three independent experiments. (d) The genomic context of each gene 
was analysed and GC content, long interspersed nuclear elements (LINE) and gene density are indicated 
(see material and methods for details). In the upper panel black boxes highlight region which GC content is 
less than 43% and LINE density greater than 6% (Hiratani et al., 2004). In the lower panel, black boxes 
indicate gene poor regions which contain less than 10 genes in the surrounding 500Kb. (e) The 
abundance of CpG DNA methylation at each promoter region was assessed in hB-lymphocytes using 
methyl-DNA immunoprecipitation (MDIP) (Weber et al., 2005) and qPCR. Controls for unmethylated 
(hIkaros) and methylated (hH19; hH19/Igf2 imprinting control region) regions were included. The 
enrichment indicates the ratio of methylated DNA over input DNA. The red open box highlights the late 
replicating cohort of genes which includes 4 out 5 not easily re-activated genes in heterokaryons. 
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Furthermore, active histone modifications (H4Ac, H3K9Ac and H3K4me2; Figure 4.9b, 
upper panel) as assessed by chromatin immunoprecipitation were absent from the 
majority of these loci (with exception of hDnmt3b and hFoxd3) consistent with 
transcriptional repression of these genes in hB-lymphocytes. Repressive histone 
modifications (H3K9m3, H3K27m3 and H4K20m3; Figure 4.9b, lower panel) were also 
enriched preferentially at these late replicating genes. The hTert gene, however, 
showed high levels of H3K27m3 despite being early-replicating. This may provide an 
explanation for the lack of hTert expression in heterokaryons. Finally, no correlation 
was observed between the re-activation potential and the abundance of DNA 
methylation at the promoter regions of the genes (Figure 4.9e) as assessed by methyl-
DNA immunoprecipitation (MDIP) (Weber et al., 2005). These results suggest there is a 
tendency for genes that replicate later in S-phase, with repressive histone 
modifications, being more difficult to re-activate in heterokaryons. However some 
genes, such as hTle1 and hGbx2, rapidly reactivated in heterokaryons, are late-
replicating and highly enriched for repressive histone marks. This suggests that while 
the epigenetic status of genes influences their re-expression potential, this is not the 
only constraint to activate genes in heterokaryons. The right combination and/or the 
levels of “trans” acting factors are also likely to have an important role in conveying ES-
specific gene expression. 
 
4.5. Inter-species reprogramming of human B cells 
requires mOct4 but not mSox2 
 
Oct4 is part of the core regulatory circuitry in ES cells (Boyer et al., 2005) and it is 
essential for pluripotency and self-renewal (Niwa et al., 2000). To assess the potential 
role of mouse-derived Oct4 as a dominant “trans” acting factor within inter-species 
heterokaryons, we generated ES cells expressing Flag-tagged mouse Oct4 protein 
(Figure 4.10a) and fused these with human B lymphocytes (Figure 4.10b). Flag-tagged 
Oct4 protein (derived from mouse ES cells) was seen to accumulate within human 
nuclei 3 to 6 hours after cell fusion (Figure 4.10b; complete kinetics shown in Figure 
4.10c). In addition, Oct4 protein was present in human heterokaryon nuclei by 3 hours, 
before transcription of endogenous hOct4 was initiated (at 24 hours). Thus the 
translocation of the ES-derived Oct4 protein into human lymphocyte nuclei occurs prior 
to overt reprogramming. This experiment was done in collaboration with Kelly Morris. 
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Figure 4.10. Oct4 migration to human nuclei precedes reprogramming. (a) Mouse ES cells 
expressing a tagged Oct4 protein (Flag-mOct4) were generated by insertion of Flag-tagged mouse Oct4 
cDNA in E14tg2A ES cells (parental cell line). Western blotting with anti-Oct4 and anti-Flag antibodies 
confirmed the presence of Flag-tagged Oct4 protein by transduced cells. Equivalent protein loading is 
shown with mouse Lamin B detection. (b) Flag-mOct4 ES cells were fused to hB cells and 
immunofluorescence analysis of cultured heterokaryons 6 hours after cell fusion showed the presence of 
ES cell-derived Oct4 (Flag-Oct4, green) in a human nucleus (arrowed). Human nuclei were distinguished 
from mouse nuclei on basis of diffuse versus punctuate DAPI staining (blue), respectively. Actin labelling 
(red) delineates the cell membrane. Images are confocal sections of heterokaryons containing a single 
mouse (with DAPI intense foci) and a single human nucleus. (c) Immunofluorescence kinetic analysis of 
cultured heterokaryons at 0, 1, 3, 6, 9 and 12 hours with Oct4 or Flag antibodies (green). Heterokaryons 
were scored according to the following Oct4 distribution: Oct4 protein not detected (Negative), stronger 
staining in mES-derived nucleus than hB nucleus (mES>hB), nuclei equally labelled (mES = hB), stronger 
in the human nucleus (mES<hB). Confocal sections of representative heterokaryons from each of the 
categories are shown (upper panels). Human nuclei were distinguished from mouse nuclei on basis of 
diffuse versus punctuate DAPI staining (blue), respectively. Actin labelling (red) delineates the cell 
membrane. Scale bars, 10 µm. n = 100. 
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 Reprogramming of human fibroblasts to ES-like cells has been shown to require 
the activation of at least four factors including Oct4, Sox2 and either Nanog plus Lin28 
(Yu et al., 2007) or Klf4 plus c-Myc (Masui et al., 2007). Recently it was shown that 
mouse ES cells that lack Sox2, a factor thought to be vital for preventing extra-
embryonic differentiation, can remain pluripotent if provided with additional Oct4 (Masui 
et al., 2007). To investigate the relative importance of Oct4 and Sox2 in 
reprogramming, mouse ES cells that are inducible null (Tet-off) for mOct4 [ZHBTc4 
(Niwa et al., 2000)] or for mSox2 [2TS22C (Masui et al., 2007)] were used as fusion 
partners with human B cells. These inducible null ES cell lines were kindly provided by 
H. Niwa and have been characterised previously (Masui et al., 2007; Niwa et al., 2000). 
Both cell lines display a rapid (within 24 hours) and complete elimination of Oct4 or 
Sox2 gene/protein expression upon doxycycline (+Dox) treatment. In my hands, pre-
treatment of ZHBTc4 cells with Dox for 6 and 12 hours, resulted in a progressive 
decrease in mOct4 gene expression (Figure 4.11b), without significantly affecting the 
expression of several other pluripotency-associated genes or the efficiency with which 
the ES cells fuse with human B cells (Figure 4.11a). Successful reprogramming, as 
judged by induction of several human genes (Oct4, Nanog, Cripto, Dnmt3b, Sox2, 
Tle1, Tert and Rex1) was however reduced (+6 hours) or eliminated (+12 hours) by 
pre-treatment of ZHBTc4 cells with Dox (Figure 4.11c, a complete kinetic analysis is 
provided in Appendix II, Figure A2). This result showed that mOct4 expression is 
critically important for initiating successful reprogramming, in keeping with previous 
reports (Maherali et al., 2007; Masui et al., 2007; Takahashi and Yamanaka, 2006; 
Wernig et al., 2007; Yu et al., 2007). The extinction of human lymphocyte-specific 
genes was however not impaired by Oct4 removal (Appendix II, Figure A2), a result 
that may support the previous findings that the activation and silencing of gene 
expression programs in heterokaryons are mechanistically distinct processes (Chapter 
3). 
 Eliminating mSox2 expression in mouse ES cell (Figure 4.12a, 2TS22C cell line) 
had, in contrast, a relatively mild effect on reprogramming efficiency (Figure 4.12b, 
compare values at 0, 12 and 24 hours of Dox treatment). Furthermore, reprogramming 
was fully restored in fusions using 2O1 cells, a Sox2-deficient mES cell line in which 
mOct4 expression is up-regulated (Masui et al., 2007) (Figure 4.12b, values shown in 
red and complete kinetics shown in Appendix II, Figure A3). 
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Figure 4.11. Oct4 is required for successful reprogramming. (a) ZHBTc4 [untreated or treated with 
doxycycline (Dox) for 6 and 12 hours] and hB cells were labelled (with DiD and DiI, respectively) and PEG-
fused. Fusion efficiencies (14.1%, 10.6% and 18.6%) were obtained by FACS, as a percentage of double-
labelled cells. (b) In ZHBTc4 ES cells endogenous Oct4 was replaced by an inducible transgene 
(Oct4βgeo) which can be downregulated by addition of Dox (Niwa et al., 2000). Quantitative RT-PCR 
analysis showed that 6 hours (+6) and 12 hours (+12) after Dox treatment, mOct4 was progressively 
downregulated, while expression of other pluripotency-associated genes (mNanog, mCripto, mRex1 and 
mSox2) was largely unaffected. (c) ES cells expressing normal levels of Oct4 (-), partially reduced (Dox+6) 
or lacking Oct4 expression (Dox+12) were fused to hB-lymphocytes. Successful reprogramming was 
assessed by quantifying the abundance of human ES-associated transcripts (hOct4, hNanog, hCripto, 
hDnmt3b, hSox2, hTle1, hTert and hRex1), two days after fusion by qRT-PCR. Data were normalised to 
Gapdh expression. Error bars indicate the s.d. of 2-3 independent experiments. 
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 These data show that Oct4, but not Sox2, is critical for the dominant 
reprogramming activity of mouse ES cells. Interestingly, using 2O1 cells we observed 
the enhanced induction of hSox2 (Figure 4.12b, red arrow), a result that suggests that 
mouse-derived Oct4 levels may be important for initiating hSox2 expression from 
lymphocytes in these transient heterokaryons. 
 
 
Figure 4.12. Sox2 is dispensable for reprogramming. (a) In 2TS22C ES cells endogenous Sox2 is 
replaced by an inducible transgene (Sox2Zeo) which can be downregulated by addition of doxycycline 
(Dox) (Masui et al., 2007). Quantitative RT-PCR analysis showed that 12 hours (+12) and 24 hours (+24) 
after Dox treatment, mSox2 was downregulated while expression of other pluripotency-associated genes 
(mNanog, mCripto, mRex1 and mOct4) continued to be expressed. 2O1 ES cells are Sox2-deficient mES 
cells (asterisk) in which mOct4 expression is up-regulated (red bars). (b) ES cells expressing Sox2 (-), 
Sox2 depleted cells (Dox+12, Dox+24) and 2O1 cells were fused to hB-lymphocytes. Successful 
reprogramming was assessed by quantifying the abundance of human ES-associated transcripts (hOct4, 
hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and hRex1), two days after fusion by qRT-PCR. An 
elevated induction of hSox2 using 2O1 cells as a fusion partner is highlighted by an arrow (red). All data 
was normalised to Gapdh expression and error bars indicate the s.d. of 2-3 independent experiments. 
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4.6. ES-derived factors are dispensable for maintaining 
the reprogrammed status of somatic cells 
 
 To assess whether gene expression by the reprogrammed cell is stable (self-
sustaining) or requires the continuous supply of factors provided by the mouse ES cell, 
I generated hybrid cells between B-lymphocytes and ES cells in which Oct4 expression 
could be conditionally withdrawn following fusion (ZHBTc4, experimental outline shown 
in Figure 4.13a). 
In these experiments, fusions were performed between mouse lymphocytes 
carrying a silent, Oct4-driven GFP transgene (GOF18ΔPE) and mouse ZHBTc4 ES 
cells. This allows successfully reprogrammed hybrid cells to be identified on the basis 
of GFP re-expression (for example by day 10, Figure 4.13a). Hybrid clones contained a 
rearranged IgH locus, confirming their derivation from mouse B cells (Figure 4.13c) and 
displayed twice the DNA content of diploid cells (4n, Figure 4.13b) consistent with their 
tetraploid status. As anticipated, hybrid cells expressed ZHBTc4-derived Oct4βgeo 
transcripts (Figure 4.14a) and several pluripotency-associated genes, but did not 
express B cell markers such as CD19, Pax5 and Ly108 (Figure 4.13d). Two hybrid 
clones were selected for study, hybrid 4 and 12. These were treated with Dox to 
selectively ablate expression of ZHBTc4-derived Oct4βgeo (Figure 4.14; Figure 4.14a 
shows the strategy for the specific detection of Oct4βgeo transgene). Withdrawal of 
ZHBTc4-derived Oct4 did not alter the expression of mNanog and mSox2 in 
reprogrammed cells (Figure 4.14b), and did not precipitate differentiation. For example, 
the trophectoderm associated genes mCdx2 and mHand1 were not induced by mOct4 
removal in hybrid cells (Niwa et al., 2000) (Figure 4.14c); while removal of Oct4 from 
the parental ZHBTc4 line resulted in mCdx2 and mHand1 expression (Figure 4.14c, 
right hand panel). In addition, characteristic events of ES cell differentiation such as 
morphological changes and loss of Oct4 protein (or Oct4 promoter-driven GFP signal) 
were not observed in hybrid cells upon Dox treatment (Figure 4.14d and Appendix II, 
Figure A4). These cells could maintain self-renewal for at least for 15 passages in the 
presence of Dox without detectable differentiation (not shown). 
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Figure 4.13. Derivation and characterisation of embryonic hybrids. (a) To address whether 
reprogramming is stable or subject to reversion, we ablated Oct4 expression after hybrid formation. 
ZHBTc4 ES cells [mES with endogenous Oct4 replaced by an inducible transgene (Oct4βgeo) which can 
be downregulated by addition of doxycycline (Dox) (Niwa et al., 2000)] were fused with mouse B-
lymphocytes (mB) carrying a GFP transgene under the control of Oct4 promoter (GOF18ΔPE). 
Reprogramming of mB results in the re-activation of GFP in hybrid colonies (d10, lower panels). Kinetic 
analysis of single cells (upper panels) showed that transgene re-activation occurs in heterokaryons (day 2, 
2 arrows), and hybrid cells (day3, arrowhead). mB cells are shown as negative controls. Nuclei were 
visualised with DAPI staining (blue). Scale bars, 10 µm. (b) Hybrid clones (mES x mB, 4n) that re-
expressed GFP were isolated and analysed by FACS. mES, mB and mES x mB hybrid cells unstained (left 
panel) or stained with propidium iodide (right panel) to assess GFP expression and DNA content, 
respectively. (c) Contribution of the lymphocyte genome within hybrid cells was confirmed by detection of a 
rearranged IgH locus (D-J region). IgH rearrangement was seen in B-lymphocytes (mB), hybrid cells (mES 
x mB) but not in mES cells. The rearranged DNA can be detected by PCR amplification and visualised on 
the gel as a 750 bp band. (d) Lymphocyte-specific genes (mCD19, mPax5 and mLy108) were not detected 
in hybrid cells although ES-specific genes (mOct4, mNanog, mSox2, mRex1 and mUtf1) remain detectable 
by RT-PCR. 
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Similar results were observed following withdrawal of ES-derived Sox2 in hybrid 
cells (hybrid cells generated between B-lymphocytes and 2TS22C ES cells in which 
Sox2 expression could be conditionally withdrawn, Figure 4.15a). No change in mOct4 
or mNanog expression (Figure 4.15b), or trophectoderm differentiation as mHand1 
expression (Masui et al. 2007) (Figure 4.15c) was not precipitated by the loss of Sox2 
protein from hybrid cells (Figure 4.15d). These data show that reprogramming of 
mouse lymphocytes by mouse ES cells induces an epigenetically stable (and heritable) 
resetting of gene expression in the lymphocyte nucleus. 
 
 
Figure 4.14. Reprogramming is self-sustaining and can be maintained in the absence of ES-derived 
Oct4. (a) Specific detection of Oct4βgeo transgene by RT-PCR with primers within βgeo cassette, which 
specifically amplify ZHBTc4-derived Oct4 but not endogenous mOct4. mES and mB cells were included as 
controls. mGapdh was used to standardise input. (b) Hybrid clones (4 and 12) were treated with 
doxycycline (Dox) to ablate ES-derived Oct4, and qRT-PCR confirmed downregulation of Oct4βgeo 
transcript (upper panels). Removal of mES-derived Oct4βgeo in hybrid clones did not affect gene 
expression of pluripotency-associated transcripts (lower panels; mOct4, mNanog and mSox2) after 96 
hours of Dox treatment. (c) No differentiation was observed after Oct4 removal in hybrid cells. mRex1 
expression was retained and the extra-embryonic markers mHand1 and mCdx2 were not induced. In 
ZHBTc4 ES cells (open bars) upon Dox treatment, mHand1 and mCdx2 were induced (Niwa et al., 2000) 
and is shown for comparison. Data were normalised to mGapdh expression. Error bars indicate the s.d. of 
3 independent experiments. (d) Western blotting with anti-Oct4 antibody confirmed that Oct4 protein is 
rapidly removed after Dox treatment of ZHBTc4 ES cells (lower panel) but remains detectable at all times 
in hybrid cells (upper panels). mB cells were included as a negative control. Equivalent protein loading is 
shown with Lamin B detection. 
 
 
 118
 
Figure 4.15. Sox2 is not required to maintain the reprogrammed status of hybrid cells. (a) 2TS22C 
ES cells (mES) were fused with mouse B-lymphocytes (mB) carrying a GFP transgene under the control of 
Oct4 promoter (GOF18ΔPE) which undergoes re-activation after cell fusion and successful 
reprogramming. (b) Hybrid clones (1 and 2) were treated with doxycycline (Dox) to ablate ES-derived 
Sox2. Quantitative RT-PCR analysis showed the downregulation of Sox2Zeo transcript; in contrast, mSox2 
levels were maintained, along with other pluripotency-associated genes (mOct4 and mNanog). (c) 
Differentiation was not observed after Sox2 removal in hybrid cells. mRex1 expression was sustained and 
mHand1 was not activated. 2TS22C ES cell line (open bars) is shown for comparison where mHand1 
expression is induced upon Dox treatment (Masui et al., 2007). Data is normalised to mGapdh expression. 
Error bars indicate the s.d. of 2 independent experiments. (d) Western blotting with anti-Sox2 antibody 
confirmed that Sox2 protein is rapidly removed after Dox treatment of 2TS22C ES cells (lower panel) but 
remains detectable at all times in hybrid cells (upper panels). mB cells and 2O1 cells (Sox2 deficient cell 
line) were included as controls. Equivalent protein loading is shown with Lamin B detection. 
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4.6. Discussion and future perspectives 
 
Previous studies have shown that lymphocyte nuclei can be reprogrammed to a 
pluripotent state by injection into Xenopus (Byrne et al., 2007) or mouse oocytes 
(Hochedlinger and Jaenisch, 2002) or by forming hybrid cells with pluripotent ES, EC or 
EG cells (Do et al., 2007; Tada et al., 1997; Tada et al., 2001). 
Here I have shown that reprogramming human lymphocytes to a multi-potential 
state can be achieved by creating heterokaryons with mouse ES cells. This process 
results in the re-expression of endogenous human genes that are normally associated 
with human blastocyst development and human ES cell lines. Successful inter-species 
reprogramming is initiated in heterokaryons prior to nuclear fusion and chromosome 
intermixing, and generates cells that express human FGF signalling pathway 
components (Fgfr1, Fgfr2 and Fgf2) and human ES-specific surface molecules such as 
SSEA4, TRA-1-60 and TRA1-81. Markers that are restricted to mouse ES cells are not 
expressed by these cells (e.g. Bmp4 and LIF receptor). Conversion of human B cells 
into ES-like cells results in the re-modelling of the somatic genome with loss of DNA 
methylation at the hOct4 locus. However, a subset of ES-associated genes analysed 
which displayed heterochromatic features such as late replication and repressive 
histone marks, were not easily re-activated in heterokaryons. Using genetically 
engineered mouse ES cells I demonstrate that successful reprogramming of human 
lymphocytes occurs independently of Sox2, a factor thought to be required for iPS 
cells. In contrast, reprogramming is critically dependent upon Oct4, since Oct4 deletion 
abolishes the reprogramming capacity of mES cells. Importantly, once reprogramming 
is initiated by factors produced by the dominant (ES) nucleus, we show that the 
subsequent withdrawal of mOct4 or mSox2 does not compromise the phenotype of 
hybrid cells. This result implies that the reprogrammed state, once initiated, is both self-
sustaining and heritable (results summarised in Figure 4.16). 
My results show that activation of endogenous human ES cell gene expression 
(e.g. hOct4, hNanog, hCripto, hTle1, hDnmt3b, hDppa5, hGdf3 and hGbx2) by 
lymphocyte-derived nuclei begins very rapidly (24 hours after fusion), although the 
majority of these transcripts were not detected during the first 12 hours. Increasing 
amounts of ES-derived transcripts were detected in heterokaryons maintained in 
culture over an 8-day period of time. The observation that the percentage of SSEA4 
positive cells does not increase over time suggests that successful conversion occurs 
in a subset of heterokaryons. 
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Figure 4.16. Events underlying reprogramming of lymphocytes in embryonic heterokaryons and 
hybrid cells. Extinction (crossed arrows; hCD45, hCD37 and hCD19) or reduction (dashed arrows; 
hCD20 and hPax5) of lymphocyte-specific gene expression is initiated in heterokaryons and is maintained 
in hybrid cells. Activation of the majority of endogenous human ES markers begins in heterokaryons (solid 
arrows) and transcript detection increases (bold arrows) in hybrid cells. However, some genes were not 
activated (crossed arrow; e.g. hSox2;) or detected at low levels (dashed arrows; e.g. hRex1) in 
heterokaryons. Demethylation of the human Oct4 promoter starts in heterokaryons (in a subset of clones) 
and is maintained in hybrid cells. mOct4 but not mSox2 is required to initiate the conversion for the multi-
potent phenotype in heterokaryons. The maintenance of the reprogrammed status in hybrid cells does not 
require mouse trans acting factors such as mOct4 and mSox2. 
 
Whether the increased transcript detection was a consequence of an accumulation of 
stable mRNAs in successfully reprogrammed heterokaryons or of an increase in 
transcription rate with time, cannot be determined in the experiments reported here. 
When compared to the activation of muscle genes in muscle heterokaryons, where 
transcripts were firstly detected from B-lymphocytes two days after fusion (Chapter 3), 
gene re-activation in embryonic heterokaryons is very rapid suggesting that 
undifferentiated ES cells are potent “reprogrammers” of somatic cells. Although the 
molecular mechanisms of dominant reprogramming by ES cells is poorly understood, 
the rapid induction of gene expression could reflect the high expression levels of 
chromatin remodelling factors found in undifferentiated cells (Ramalho-Santos et al., 
2002). To support this idea there is evidence that ES cells possess “hyperdynamic 
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chromatin” (Meshorer et al., 2006) and are globally transcriptionally active (Efroni et al., 
2008) or primed (Stock et al., 2007), as compared with differentiated cells. Extinction of 
lymphocyte-specific gene expression (hCD45, hCD37, hCD19, hCD20 and hPax5) was 
achieved after 48-72 hours and was maintained in hybrid cells. This data is consistent 
with earlier work examining gene extinction in hybrid cells (Massa et al., 2000). 
Lymphoma cells fused with fibroblasts (Junker and Pedersen, 1985) results in 
immunoglobulin gene extinction very shortly after fusion. Maintenance of lymphocyte-
specific gene silencing in both inter- and intra-species hybrids is also supported by 
genome-wide analysis of gene expression in human and mouse hybrid cells (Ambrosi 
et al., 2007; Cowan et al., 2005). 
One surprising aspect of the reprogramming data shown here is the rapidity of 
gene conversion and DNA demethylation that occurs within heterokaryons. Previous 
studies have shown that reprogramming in experimental heterokaryons using adult 
cells from different lineages (Blau et al., 1985; Terranova et al., 2006) can be initiated 
before chromosome replication and cell division. In addition, heterokaryons formed by 
fusing adult mouse erythroleukemia (MEL) cells and human embryonic/foetal erythroid 
(K562) cells revealed that transcriptionally inactive mouse globin genes can be re-
activated within 24 hours in transient heterokaryons (Baron and Maniatis, 1986). Here I 
show that conversion of unipotent lymphocytes towards multipotency is achieved in 
transient heterokaryons before nuclear fusion and cell division. The rapid re-activation 
of endogenous pluripotency-associated genes seen in inter-species heterokaryons is 
consistent with transgene re-activation studies that have reported Oct4gfp expression 
(at 24 hours) by MEFs (Wong et al., 2008) or neural stem cells (Han et al., 2008) fused 
with mouse ES or EC cells. Likewise, re-activation of human Oct4 and Nanog by 
human somatic nuclei, has been shown to occur rapidly upon DNA de-methylation and 
Tpt1 activation induced by Xenopus oocytes (Koziol et al., 2007; Simonsson and 
Gurdon, 2004). My results underscore that nuclear fusion and cell division are not 
required events for reprogramming. Nevertheless, the importance of cell division, and 
in particular DNA synthesis for both establishing and maintaining programs of gene 
expression has been widely debated (Egli et al., 2008; Wolffe, 1991). It has been 
suggested that mitotic conditioning is crucial to reset the chromatin structure of 
differentiated adult donor cells for embryonic DNA replication in Xenopus eggs 
(Lemaitre et al., 2005). In agreement with this hypothesis, ES cells were shown to be 
most effective at reprogramming when they contained a high proportion of cells in the 
S and G2/M phases of the cell cycle (Sullivan et al., 2006). Landmark cell cycle 
experiments by Rao and colleagues (Rao and Johnson, 1970) established that S-
phase cells are able to induce DNA synthesis when fused to a G1 cell. Furthermore, 
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the same observation has been reported in inter-species heterokaryons (Graves, 
1972). These studies suggest that nuclear reprogramming may require an initial round 
of somatic DNA replication of silent chromatin in the presence of ES-derived factors 
produced during S and G2/M phases. With the experiments reported here I cannot 
confirm or refute the importance of DNA synthesis for reprogramming to pluripotency in 
inter-species heterokaryons. However, as successful reprogramming is only achieved 
in a proportion of heterokaryons (<13%), and mouse ES cell cultures contain >30% of 
cells in S-phase, it is possible that genome-wide DNA synthesis or partial DNA 
replication [or repair (Barreto et al., 2007)] is required for successful lymphocyte 
conversion. Further experiments will be required to elaborate on this point. 
The epigenetic remodelling of the hB-lymphocyte genome for pluripotency 
includes the loss of DNA methylation at the hOct4 promoter region as previously 
reported (Cowan et al., 2005; Freberg et al., 2007; Simonsson and Gurdon, 2004; 
Tada et al., 2001). Whether the gene-specific de-methylation observed in 
heterokaryons involves passive or active process [such as DNA repair-based 
mechanisms (Barreto et al., 2007)], is unknown. In contrast to what is observed for 
hOct4 (that is transcriptionally and epigenetically reprogrammed rapidly in 
heterokaryons), some genes may be subjected to several layers of “repression” such 
as late replication and repressive histone marks, rendering them more “resistant” to 
activation (e.g. hSox2, hTert, hFoxd3, hDppa4, and hRex1). Accordingly, when the 
expression of 10 Oct4-related genes was analysed in individual cumulus cell-derived 
mouse cloned blastocysts, only 62% correctly expressed all tested genes (Bortvin et 
al., 2003). Interestingly, Dppa4 was among the group of genes that showed variable 
expression. The repressed chromatin configuration of Dppa4 may offer an explanation 
as to why some genes are difficult to re-activate. 
Importantly, I show that by enhancing Oct4 levels in Sox2-deficient ES cells 
(ES-2O1), an elevated expression of hSox2 is induced in reprogrammed human B 
cells. Recent genome-wide studies have shown that Sox2 is a direct target of Oct4 in 
both human (Boyer et al., 2005) and mouse (Loh et al., 2006) ES cells, a fact that 
could explain why hSox2 is efficiently reprogrammed using ES cells that overexpress 
mOct4. In addition to Sox2, Oct4, Nanog and Cripto were also shown to be direct Oct4 
targets in both species. Accordingly, these genes were more sensitive to Oct4 removal 
(partial Oct4 removal after 6 hours of Dox treatment) or elevation (using ES-2O1 cells 
as fusion partner) (see Appendix II, Figure A2 and A3). Together, my results suggest 
that re-expression of silent loci can be overcome by an elevation of the appropriate 
transcriptional activator (Oct4). The exact contribution of chromatin-mediated 
repression during reprogramming is difficult to address because transcription factors 
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often recruit co-factors that alter chromatin structure. However, in our hands, 
overexpression of exogenous Oct4 in lymphocytes did not induce pluripotent 
conversion (Pereira & Terranova, unpublished results), a finding that argues that 
additional DNA-binding and chromatin remodelling factors [including those known to 
interact with Oct4 (Liang et al., 2008; Wang et al., 2006), or associated with the 
process of DNA demethylation] may be critical for successful reprogramming. In 
agreement with this, Oct4 is part of a protein interaction network in ES cells, which is 
linked to several chromatin co-factors. These include proteins associated with gene 
repression (such as the histone deacetylation complex NuRD, PcG proteins and the 
histone demethylase LSD1) and gene activation (the SWI/SNF chromatin remodelling 
complex proteins SMARCA2, SMARCA4, BAF180 and BAF155) (Liang et al., 2008; 
Wang et al., 2006). In addition, Oct4 has been shown to be required to maintain the 
chromatin structure within the extended Nanog locus in ES cells (Levasseur et al., 
2008). 
 In the experiments presented here, I have shown that reprogrammed human 
cells express a profile of transcripts, signalling molecules and surface antigens that are 
similar to those seen in human ES cells, and different from mouse ES cells. This 
suggests that an early human embryonic “program” of gene expression is initiated in 
human nuclei by trans-acting (mouse-derived) factors. Differences between the 
expression profiles of mouse ES cells and human reprogrammed nuclei probably 
reflect discrepancies in cis-acting regions between the mouse and human genomes. 
However, it is also possible that newly synthesised human regulatory factors (from hB-
derived nuclei) could be influencing the pattern of gene expression and directing the 
hES phenotype (Hardeman et al., 1986). This explanation seems unlikely as (a) the 
human-specific profile of gene expression was observed very early after cell fusion (24 
hours), and (b) the inhibition of de novo protein synthesis by treatment with 
cycloheximide D upon cell fusion did not alter the overall pattern of gene expression 
(Appendix II, Figure A5). A study in which the entire hTert gene was introduced into 
mice, showed that expression of the transgene was similar to endogenous hTert in 
humans, rather than mouse endogenous mTert (Horikawa et al., 2005). It is interesting 
to speculate that some of the differences between human and mouse ES cells (Ginis et 
al., 2004; Pera and Trounson, 2004; Sato et al., 2003; Xu et al., 2005) may indeed 
reflect intrinsic species dissimilarities, rather than temporal differences in the isolation 
of stem cells (Brons et al., 2007; Tesar et al., 2007). We show that fusion of human 
lymphocytes to mouse ES cells (that are LIF and Bmp dependent), human ES-like cells 
are generated that express FGF signalling components (and are not dependent of 
LIF/Bmp). In agreement with this data, attempts to generate human iPS cells in the 
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presence of LIF rather than Fgf2 have been unsuccessful (Takahashi et al., 2007). This 
may suggest that differences between human and mouse ES cells reflect distinct 
signalling and transcriptional networks, rather than necessarily when or where they 
were isolated during embryogenesis. It has been documented that only 9.1% of the 
total genes targeted by Oct4 are shared between human and mouse (Boyer et al., 
2005; Loh et al., 2006). Whether the hES gene expression program initiated in 
reprogrammed lymphocytes is a result of divergent transcriptional networks between 
human and mouse (Odom et al., 2007), remains to be addressed. The identification of 
mouse Oct4 genomic targets in human nuclei upon heterokaryon formation would 
potentially help address this question. For this, the mouse ES cell line constructed 
during this study (that expresses a Flag-tagged Oct4 protein, Flag-mOct4) would 
provide a valuable tool. Moreover, the introduction of genetically modified human 
somatic nuclei in embryonic heterokaryons may help to elucidate the influence of 
endogenous human factors and regulatory sequences during cis reprogramming. 
Retroviral-mediated expression of four transcriptional regulators, Oct4, Sox2, c-
Myc and Klf4, has been shown to drive mouse fibroblasts into an ES-like (iPS) state, 
albeit at very low frequency (Takahashi and Yamanaka, 2006; Wernig et al., 2007). 
Mouse hepatocytes, stomach cells (Aoi et al., 2008) and pancreatic beta-cells 
(Stadtfeld et al., 2008a) are also converted using the same strategy, whereas adult 
mouse B-lymphocytes (Hanna et al., 2008) required the additional expression of 
C/EBPα or silencing of the B-cell specific factor Pax5. Reprogramming of human 
fibroblasts has also been achieved in a parallel approach using Oct4, Sox2 and either 
Nanog plus Lin28 (Yu et al., 2007) or Klf4 plus c-Myc (Masui et al., 2007; Park et al., 
2008c). These pioneering studies have illustrated the importance of these factors for 
iPS, but also suggested that additional factors may be needed for efficient conversion 
to pluripotency. I show here that Sox2, in contrast to Oct4, is not required to convert 
human B-lymphocytes into a multi-potent state in heterokaryons. This observation 
contrasts with results obtained using iPS strategies to reprogram mouse and human 
fully differentiated cells. Whether this is because of differences relating to the 
overexpression of transcription factor cocktails used in iPS, or that reprogramming 
occurs over an extended time period [pluripotency-associated genes such as Oct4, 
Nanog , Sox2 and Tert are re-activated after 2 weeks of transduction (Brambrink et al., 
2008; Stadtfeld et al., 2008b)], is not known. However, as Sox2 was recently shown to 
be dispensable for the activation of Oct-Sox enhancers in mouse ES cells (Masui et al., 
2007), it is also possible that additional Sox family members such as Sox4, Sox11 and 
Sox15, may have redundant functions with Sox2 in reprogramming. 
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Finally, I show that withdrawal of mOct4 or mSox2 after reprogramming is 
initiated does not compromise the phenotype of hybrid cells. This result implies that the 
reprogrammed state, once initiated, is both self-sustaining and heritable. The targeted 
elimination of both copies of chromosome 6 (which harbour pluripotency-associated 
genes including Nanog) from mouse ES-somatic hybrid cells, did also not affect the 
phenotype of hybrid cells (Matsumura et al., 2007). However, it has been recently 
shown that ES can self-renew indefinitely in the permanent absence of Nanog, 
although cells are prone for differentiation (Chambers et al., 2007). Oct4, in turn, is 
essential for stem cell self-renewal and the reduction of Oct4 levels by 50% leads to 
differentiation in trophoblast lineage (Niwa et al., 2000). The observation that ES-
derived Oct4 is not required for self-renewal of hybrids provides stronger evidence that 
cell fusion-induced reprogramming is indeed stable. Similarly, withdrawal of exogenous 
Oct4 after iPS generation does compromise self-renewal (Maherali et al., 2007). Thus 
reprogramming to pluripotency seems to be a stable heritable condition that does not 
require the continuous supply of exogenous factors in order to be maintained. 
Hence, my results show that human ES-like cells are rapidly and efficiently 
generated from lymphocytes through fusion with mouse ES cells, that reprogramming 
is stable, and is achieved through the interplay between transcriptional effectors and 
unique genomic information provided by human somatic nuclei. Moreover, 
experimental embryonic heterokaryons offer a powerful experimental approach to trace 
the contribution of individual factors to the reprogramming of human somatic cells 
towards a multipotent state. 
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CHAPTER 5. ROLE OF PCG PROTEINS IN THE 
MAINTENANCE OF ES CELL REPROGRAMMING 
ACTIVITY 
 
 
5.1. Pluripotent cells reprogram human lymphocytes in 
heterokaryons 
 
The ability of ES cells to induce the expression of a pluripotency-associated 
markers from differentiated cells, is a property that is shared by other embryonic-
derived cell populations (Do et al., 2007; Miller and Ruddle, 1976; Tada et al., 1997). 
These dominant reprogramming cells include EG cells (Tada et al., 1998), which are 
derived from PGCs that colonise the genital ridges during early organogenesis (Matsui 
et al., 1992; Resnick et al., 1992), and EC cells derived from induced or spontaneous 
teratocarcinomas (Andrews et al., 2005). EG and EC cells share many features with 
ES cells, such as the ability to self-renewal and follow multiple differentiation pathways. 
However, EC cells have a more restricted lineage potential (Chambers and Smith, 
2004) and EG cells have lost allele-specific parental imprints (Labosky et al., 1994) and 
are able to reprogram imprinted genes after hybridisation with somatic cells (Tada et 
al., 1997; Tada et al., 2001). Collectively these reports have encouraged a view that 
the ability for dominant reprogramming is a shared feature of the undifferentiated state. 
Here I examine the requirements for reprogramming human lymphocytes towards 
pluripotency in heterokaryons. 
The approach used for heterokaryon formation between pluripotent cell lines 
and human B-lymphocytes is described in Chapter 4. Human B cells were fused with 
either mouse ES, EC or EG cells using PEG. Reprogramming was assessed by qRT-
PCR of the human embryonic genes hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, 
hTert and hRex1, induced 0 to 3 days after cell fusion (Figure 5.1). This experiment 
was performed in collaboration with Joana Santos. The reprogramming potential of F9 
and P19 embryonic carcinoma cell lines, that express numerous markers in common 
with ES cells, but have a narrower range of lineage potential (Chambers and Smith, 
2004), was examined (Figure 5.1; complete kinetics shown in Appendix II, Figure A6). 
Reprogramming activity, as measured by the reactivation of human embryonic genes, 
was similar between the two embryonic carcinoma cell lines (F9 and P19) and ES cells 
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(E14tg2A and OS25). However, a more detailed comparison between F9 and P19 EC 
cells revealed slight differences, such as an enhanced ability of P19 cells to initiate the 
expression of hSox2 and conversely a reduction in hRex1 induction kinetics. 19G and 
23G embryonic germ cells (Tada et al., 1998) were also able to reprogram human 
lymphocytes, albeit less efficiently (Figure 5.1; complete kinetics shown in Appendix II, 
Figure A7). Human pluripotency-associated transcripts were approximately 10-fold less 
abundant in EGxhB cultures than in ESxhB or ECxhB cultures. In addition, hRex1, a 
marker of the inner cell mass that is downregulated in the epiblast (Pelton et al., 2002; 
Rogers et al., 1991), was not detected upon cell fusion of EG cells with human 
lymphocytes. These data suggest that although differences in the reprogramming 
potential may reflect the developmental origin of cells used, all pluripotent cells share a 
dominant reprogramming capacity in heterokaryons. 
 
 
Figure 5.1. Reprogramming potential of pluripotent cell lines. Mouse embryonic stem (ES: OS25 and 
E14tg2A; yellow and orange bars, respectively), embryonic carcinoma (EC: F9 and P19; dark and light 
purple bars, respectively), embryonic germ (EG: 19G and 23G; dark and light blue bars, respectively) or 
Eed-deficient ES cells (ES Eed-/-: G8.1 and B1.3; dark and light green bars, respectively) were fused to 
human B-lymphocytes. Successful reprogramming was measured by the level of activation of human 
embryonic genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and hRex1) by qRT-PCR 3 
days after cell fusion. Data were normalised to hGapdh expression. Error bars indicate the s.d. of 2-3 
independent experiments. 
 
5.2. Eed is required for embryonic stem cell 
reprogramming activity 
 
Undifferentiated embryonic cells share many features, including self-renewal, 
pluripotency and reprogramming activity. These characteristics are translated in the 
high expression levels of pluripotency-associated transcription factors such as Oct4. 
Withdrawal of Oct4 from ES cells abolishes self-renewal, pluripotency (Niwa et al., 
2000) and reprogramming (see section 4.5). In addition, “stemness” is also reflected at 
the epigenetic level. For example, Polycomb-mediated repression by the catalysis of 
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H3K27 methylation at important lineage determinants in undifferentiated ES cells plays 
an important role keeping these genes in a repressed but primed state (Spivakov and 
Fisher, 2007). This observation together with the fact that the PcG protein Eed is 
expressed at high levels in undifferentiated ES and ex vivo PGCs (Grskovic et al., 
2007; Mak et al., 2004), prompted us to examine whether Polycomb repression is 
required for stem cell-mediated reprogramming. Reprogramming was examined using 
ES cells that were genetically deficient in Eed (see section 2.1.2 for cell line details). 
Eed as part of the PRC2 is essential for the methyltransferase activity of the complex 
and H3K27 methylation (Azuara et al., 2006; Montgomery et al., 2005; Peters and 
Schubeler, 2005). Trimethylated and dimethylated H3K27 were not detected in Eed-
null ES cells, and levels of monomethylated H3K27 were markedly reduced (Figure 
5.2a). ES cells lacking Eed retain self-renewal and can differentiate in vitro (as 
embryoid bodies) and in vivo (within chimeric embryos) into multiple lineages at a 
reduced efficiency (Chamberlain et al., 2008; Morin-Kensicki et al., 2001). In vivo 
development is compromised in Eed-deficient embryos, as these die shortly after 
gastrulation (Faust et al., 1998). Two independent Eed-deficient ES cell lines (G8.1 and 
B1.3) were fused to hB-lymphocytes and reprogramming assessed by qRT-PCR of the 
human embryonic genes hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and 
hRex1. Interestingly, both cell lines showed a severe reduction in the ability to 
reprogram hB-lymphocytes (Figure 5.1, right panel). The majority of pluripotency-
associated transcripts were either reduced or undetectable after 3 days of 
heterokaryon formation. This failure in reprogramming contrasts with the induction of 
embryonic-associated transcripts by the other pluripotent cell lines analysed (Figure 
5.1, left and central panels). To verify that compromised reprogramming is a 
consequence of Eed loss rather than a reflection of differences in cell line genetic 
background, Eed heterozygous, Eed-null and wild-type ES cells were derived from 
genetically matched blastocysts (Azuara et al., 2006), and each fused to hB-
lymphocytes. As shown in Figure 5.2b, successful reprogramming, as judged by 
induction of several human genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, 
hTert and hRex1) was abolished in Eed-deficient ES cells (ESL32), but not in the 
heterozygous (ESL12) or wild-type ES cells (ESL21) (a complete kinetic analysis is 
provided in Appendix II, Figure A8). My results confirm that loss of Eed and H3K27 
methylation impair the ability of ES cells to dominantly reprogram human lymphocytes. 
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Figure 5.2. Eed is required for the ES cell-mediated reprogramming of human lymphocytes. (a) 
Whole cell lysates from wild-type (ESL21, +/+), heterozygous (ESL12, +/-) and Eed-deficient ES cells 
(ESL32, -/-) were analysed by Western blotting using antibodies to mono- (H2K27m1), di-(H2K27m2), or 
trimethylated H3K27 (H2K27m3). Equivalent protein loading is shown by Lamin B and total Histone 3 
detection. The deletion of the PRC2 member Eed in ES cells and the subsequent global reduction of 
H3K27 methylation levels are highlighted in red. (b) Wild-type (ESL21, black bars), heterozygous (ESL12, 
grey bars) and Eed-deficient ES cells (ESL32, white bars) were fused to human B-lymphocytes. 
Successful reprogramming was measured by the level of activation of human embryonic genes (hOct4, 
hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and hRex1) by qRT-PCR 3 days after cell fusion. Data 
were normalised to hGapdh expression. Error bars indicate the s.d. of 3 independent experiments. 
 
 To assess whether the loss of Eed is the cause of the ES cell reprogramming 
defect, Eed expression was restored in Eed-null ES cells (B1.3 cell line) using a 180 Kb 
BAC clone carrying Eed gene and neomycin resistance gene (see section 2.2 for cell 
line derivation details). ES cell colonies resistant to neomycin were screened for the 
presence of Eed protein and H3K27 trimethylation by Western blotting (Figure 5.3a). 
ES cells in which Eed isoforms (Montgomery et al., 2005; Montgomery et al., 2007) 
were re-expressed and H3K27 trimethylation was re-established (B1.3BAC) were then 
fused to hB-lymphocytes, and reprogramming assessed by qRT-PCR of human 
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embryonic genes. Reconstitution of Eed expression in Eed-deficient ES cells rescued 
their reprogramming defect (Figure 5.3b, compare solid and open bars on histograms). 
This data confirm that Eed has a specific role in maintaining the reprogramming activity 
of ES cells. Not all genes were equally affected by Eed deletion; for example hTle1 and 
hDnmt3b activation was variable and their expression was eventually detected (see 
Figures 5.2 and 5.3). 
 
Figure 5.3. Restoring Eed expression in Eed-deficient ES cells rescue their reprogramming defect. 
(a) Eed-deficient ES cells (B1.3) were rescued by insertion of a BAC clone that carried the Eed gene and 
neomycin resistance gene (B1.3BAC). Whole cell lysates from rescued cell lines (B1.3BAC) and controls 
(B1.3Neo) were analysed by Western blotting using antibodies to the Eed protein and anti-trimethylated 
H3K27 (H3K27m3). Equivalent protein loading is shown by Lamin B and total H3 detection. (b) B1.3BAC 
and B1.3Neo ES cells were fused to human B-lymphocytes and successful reprogramming was measured 
by the level of activation of human embryonic genes (hOct4, hNanog, hCripto, hDnmt3b, hTle1, hTert and 
hRex1) by qRT-PCR 3 days after cell fusion. hHprt was added as a control gene. Data were normalised to 
hGapdh expression. Error bars indicate the s.d. of 2 independent experiments. 
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5.3. PRC2 activity and H3K27 methylation are required for 
the reprogramming mediated by ES cells 
 
Methylation of H3K27 is catalysed by PRC2, a complex that depends on three 
core components: embryonic ectoderm development (Eed), suppressor of zeste 12 
(Suz12) and the HMT enhancer of zeste homologue 2 (Ezh2) (Cao et al., 2002; Cao 
and Zhang, 2004; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 2002). To 
address whether the lack of reprogramming seen in Eed-deficient ES cells is indeed 
due to the loss of H3K27 methylation, rather than any other putative function of the Eed 
protein, ES cells genetically deficient for Suz12 (Fujimura et al., 2006) or ES cells that 
are inducible null for Ezh2 [see section 2.1.2 for cell line details (Su et al., 2003)] were 
fused to human B cells. Similarly to what was observed in Eed-deficient ES cells, 
trimethylated and dimethylated H3K27 were not detected in Suz12-null ES cells and 
levels of monomethylated H3K27 were markedly reduced (Figure 5.4a, left panel). The 
Ezh2-1.3 ES cell line, that carries tamoxifen-inducible conditional knockout Ezh2 
alleles, was progressively depleted of Ezh2 protein following addition of tamoxifen 
(Figure 5.4a, right panel). Although the cells continued to self-renew in the absence of 
Ezh2 (Ezh2-1.3 ∆/∆), withdrawal of Ezh2 resulted in the loss of trimethylated H3K27, a 
reduction in dimethylated H3K27 and a slight reduction of monomethylated H3K27. 
Ezh2 protein levels were reduced following Suz12 deletion (Figure 5.4a), whereas 
Suz12 protein levels were unaffected by Ezh2 removal, consistent with previous 
observations (Montgomery et al., 2005; Pasini et al., 2004). Suz12 and Ezh2 null ES 
cells were fused to lymphocytes and reprogramming was assessed by quantitative RT-
PCR of the human ES-associated genes (Figure 5.4b and 5.4c; complete kinetic 
experiments are provided in Appendix II, Figure A9 an A10, respectively). Deletion of 
the PRC2 core components Suz12 and Ezh2 abolished the reprogramming activity of 
ES cells. The reprogramming defect seen with Ezh2-null ES cells was less pronounced 
than that seen for Eed-/- or Suz12-/- cells; hNanog and hCripto were detected at low 
levels following fusion with Ezh2-1.3 ES cells treated with tamoxifen for 96 hours, or 
with Ezh2-null ES cells. This observation could however, be explained by an 
incomplete removal of H3K27 methylation following Ezh2 withdrawal. Collectively, 
these data illustrate the importance of Eed, Suz12 and Ezh2 for reprogramming and 
implicate PRC2 and the methylation of H3K27 as crucial components of the ES cell 
reprogramming machinery. 
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Figure 5.4. Methylation of H3K27 in ES cells is required for successful reprogramming. (a) Whole 
cell lysates from wild-type (Suz12WT, +/+), Suz12-deficient ES cells (Suz12KO, -/-), Ezh2-1.3 flx /flx 
[untreated or treated with 800nM of tamoxifen for 48 (tmx 48) and 96 (tmx 96) hours] and Ezh2-deficient 
ES cells (∆/∆) were analysed by Western blotting using antibodies to mono-(H2K27m1), di-(H2K27m2), or 
trimethylated H3K27 (H2K27m3). The deletion of Suz12 and Ezh2 was confirmed using antibodies against 
the Suz12 and Ezh2 proteins. Equivalent protein loading is shown by Lamin B and total H3 detection. The 
deletion of the PRC2 members Suz12 and Ezh2 in ES cells and the subsequent global reduction of H3K27 
methylation levels are highlighted in red. (b) Wild-type (Suz12WT, black bars) and Suz12-deficient ES 
cells (Suz12KO, white bars) and (c) Ezh2-1.3 [untreated (flx / flx, black bars) or treated with 800 nM of 
tamoxifen for 48 (tmx 48, dark grey bars) and 96 (tmx 96, light grey bars) hours] and Ezh2-deficient Es 
cells (∆/∆, white bars) were fused to human B-lymphocytes. Successful reprogramming was measured by 
the level of activation of human embryonic genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert 
and hRex1) by qRT-PCR 3 days after cell fusion. Data were normalised to hGapdh expression. Error bars 
indicate the s.d. of 3 independent experiments. 
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5.4. PRC1 cooperates with PRC2 to maintain the 
reprogramming ability of ES cells 
 
Although the mechanism through which PRC2 inhibits productive transcription 
remains unclear, it is known that methylated H3K27 provides a binding site for PRC1 
(Cao et al., 2002; Hernandez-Munoz et al., 2005; Kuzmichev et al., 2002; Ringrose and 
Paro, 2004), a multiprotein complex that includes the Ring1A and Ring1B core 
proteins. Several studies suggested that Ring1A/B function as ubiquitin ligase for 
H2AK119 (Cao et al., 2005; de Napoles et al., 2004; Wang et al., 2004a) and that this 
modification may in turn mediate gene repression. To understand whether the 
reprogramming activity of stem cells is maintained by PRC1 we used the ES-ERT2 ES 
cell line that carries tamoxifen-inducible conditional knockout Ring1B alleles, and is 
also homozygous null for the functional homologue Ring1A (Endoh et al., 2008; Stock 
et al., 2007). Thus, following addition of tamoxifen, ES-ERT2 cells are progressively 
depleted of Ring1B protein and global H2A ubiquitylation (within 48 hours), whereas 
overall levels of PRC2 proteins and associated trimethylated H3K27 are largely 
unaffected (Endoh et al., 2008; Stock et al., 2007). ES-ERT2 ES cells untreated and 
treated with tamoxifen for 24, 48 and 96 hours were fused to hB-lymphocytes and 
reprogramming analysed by the expression of the human embryonic genes hOct4, 
hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and hRex1 0 to 3 days (Figure 5.5; 
qRT-PCR data in Appendix II, Figure A11). Although hOct4, hDnmt3b and hTle1 
transcription were initiated normally in Ring1B-null ES x hB cultures, hNanog and 
hCripto activation was substantially reduced (ES-ERT2 following treatment with 
tamoxifen for 96 hours) and hSox2, hTert and hRex1 expression was not detected. The 
reprogramming reduction seen in ES-ERT2 cells upon tamoxifen treatment is 
reminiscent of that of ES cells lacking the core components of PRC2, but less dramatic. 
Genome-wide studies have shown that PRC1 and PRC2 share many (Boyer et al., 
2006; Lee et al., 2006; Negre et al., 2006; Tolhuis et al., 2006) but not all genomic 
targets (Bracken et al., 2006). This observation suggests that the maintenance of 
reprogramming capacity of ES cells is mediated, at least partially, by cooperation 
between PRC2 and PRC1 activity. 
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Figure 5.5. Conditional removal of Ring1B results in the decreased reprogramming activity of ES 
cells. ES-ERT2 cells [untreated (flx / flx, black bars) or treated with 800 nM of tamoxifen for 24 (tmx 24, 
dark grey bars), 48 (tmx 48, light grey bars) and 96 (tmx 96, white bars) hours] were fused to human B-
lymphocytes. Successful reprogramming was measured by the level of activation of human embryonic 
genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and hRex1) by qRT-PCR 3 days after cell 
fusion. Data were normalised to hGapdh expression. Error bars indicate the s.d. of 2 independent 
experiments. 
 
5.5. The inability of PcG-deficient ES cells to reprogram is 
dominant over wild-type ES cells 
 
Polycomb proteins repress many transcriptional regulators which in turn 
positively and negatively regulate many genes (Azuara et al., 2006; Boyer et al., 2006; 
Bracken et al., 2006; Jorgensen et al., 2006). To investigate the mechanistic role of 
Polycomb repressors in reprogramming I asked whether PcG proteins directly or 
indirectly regulate factors previously implicated in reprogramming (Silva et al., 2006; 
Takahashi et al., 2007; Yu et al., 2007). Gene expression analysis of mOct4, mNanog, 
mSox2, mc-Myc, mKlf4 and mLin28 by quantitative RT-PCR (Figure 5.6a) did not show 
major differences in expression levels between ES cells lacking the PRC2 components 
Eed, Suz12 and Ezh2 (which lack reprogramming activity) and matching wild-type cell 
lines. Nevertheless, slight variations of Oct4 levels was shown to have a big impact in 
reprogramming (see section 4.5), therefore levels of Oct4 were elevated by the 
introduction of Flag-tagged mouse Oct4 in Eed-deficient ES cells (B1.3-Oct4, Figure 
5.6b) and fused these with human B-lymphocytes (Figure 5.6c). 
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Figure 5.6. PRC2-deficient ES cells do not lack factors implicated in reprogramming. (a) Gene 
expression analysis by qRT-PCR of mOct4, mNanog, mSox2, mc-Myc, mKlf4 and mLin28 in ES cells 
deficient for the PRC2 (white bars) members Eed (Eed -/-), Suz12 (Suz12 -/-), Ezh2 (Ezh2 tmx 96; Ezh2 
∆/∆) and matching wild-type controls (black bars). (b) Eed-deficient ES cells overexpressing Oct4 protein 
(B1.3-Oct4) were generated by insertion of Flag-tagged mouse Oct4 cDNA in B1.3 cells (Eed -/-). Western 
blotting with anti-Oct4 and anti-Flag antibodies confirmed the presence of Flag-tagged Oct4 protein by 
transduced cells (B1.3-1D3 and B1.3-2D1) at similar levels as endogenous Oct4 protein. Equivalent 
protein loading is shown with Lamin B detection. B1.3-Oct4 cells were fused to hB-lymphocytes and the 
expression of hES-specific genes (hOct4, hNanog, hCripto and hRex1) was assessed by qRT-PCR 
analysis 2 days after cell fusion. Positive (Eed-deficient ES cells rescued with a BAC clone containing the 
Eed gene; B1.3BAC.1 and B1.3BAC.2) and negative controls (neomycin resistant Eed-deficient ES cells 
where no exogenous Oct4 protein was detected; B1.3-1D2 and B1.3-2C5) were included for this analysis. 
Data were normalised to Gapdh expression. Error bars indicate the s.d. of 2-3 independent experiments. 
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Oct4 overexpression did not rescue the reprogramming defect of Eed-deficient ES cells 
as assessed by the expression analysis of the human embryonic genes hOct4, hCripto, 
hNanog and hRex1 by qRT-PCR 2 days after cell fusion. Thus, these experiments 
suggest that the role of PcG proteins in reprogramming is independent of the 
pluripotency network of factors in which Oct4 plays a central role. 
In contrast to pluripotency and reprogramming factors, several lineage 
determinants are de-repressed in ES cells lacking PRC2 activity and H3K27 
methylation (Azuara et al., 2006; Boyer et al., 2006; Jorgensen et al., 2006; Lee et al., 
2006). These include transcriptional regulators of extra-embryonic lineages such as 
Cdx2 and Hand1 (trophectoderm-specific) or Gata6 and Hnf4 (primitive endoderm-
specific) [Figure 5.7a and (Jorgensen et al., 2006)]. It is possible that mis-expression of 
these lineage-specific transcription factors “tip the balance” of reprogramming towards 
extra-embryonic lineages upon cell fusion with hB-lymphocytes. To directly test this 
possibility I fused Eed-deficient (ESL32), heterozygous (ESL12) and wild-type (ESL21) 
ES cells with human lymphocytes and analysed the induction of hCdx2, hHand1, 
hGata6 and hHnf4 (Figure 5.7b). TS cells (Tanaka et al., 1998) and extra-embryonic 
endoderm stem (XEN) (Tanaka et al., 1998) cells were respectively fused to hB-
lymphocytes as positive controls (Santos & Pereira, unpublished data). This analysis 
showed that lack of Eed did not induce reprogramming towards trophectoderm or 
primitive endoderm, confirming the general inability of Eed-deficient ES cells to 
reprogram lymphocytes.  
Failure of Eed-deficient ES cells to reprogram has at least 2 explanations: (a) 
ES cells lack some critical reprogramming factor or (b) mutant ES cells express factors 
that block or inhibit reprogramming. To distinguish between these possibilities, 
heterokaryons were generated between human B cells, wild-type mouse ES cells 
(E14tg2A) and Eed-deficient ES cells (B1.3) (Figure 5.8, hB x mES x mES Eed-/-). To 
facilitate the identification of fused cells containing at least 1 lymphocyte-derived, 1 
mES-derived and 1 mES Eed-/- derived nuclei, mouse E14tg2A ES cells were pre-
labelled with DiI and Eed-/- ES cells with DiD. The two labelled cell populations and 
puromycin resistant hB-lymphocytes (see section 2.1.2 for cell line details) were mixed 
in a 1:1:1 ratio and inter-species heterokaryons were generated in suspension by PEG-
mediated cell fusion. After 2 days of culture in the presence of puromycin, dual-stained 
cells were purified by FACS sorting. Reprogramming was then judged by induction of 
several human genes (hOct4, hNanog, hCripto, hDnmt3b, hTle1, hTert and hRex1) 
analysed by quantitative RT-PCR. 
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Figure 5.7. De-repression of Polycomb target genes does not induce reprogramming to extra-
embryonic lineages. (a) The expression of trophectoderm-specific (mCdx2 and mHand1) and primitive 
endoderm-specific (mGata6 and mHnf4) genes was assessed by qRT-PCR in ES cells deficient for Eed 
(ESL32; Eed -/-), and matching wild-type (ESL21; Eed +/+) and heterozygous (ESL12; Eed +/-) controls. 
mCdx2, mHand1, mGata6 and mHnf4 expression is shown as fold increase relative to the signal obtained 
in wild-type ES cells. (b) Wild-type (ESL21, black bars), heterozygous (ESL12, grey bars) and Eed-
deficient ES cells (ESL32, white bars) were fused to human B-lymphocytes. Reprogramming was 
measured by the activation of human trophectoderm-specific (hCdx2 and hHand1) and primitive 
endoderm-specific (hGata6 and hHnf4) human genes by qRT-PCR over 3 days after cell fusion. 
Trophectoderm stem cells (TS, blue bars) and extra-embryonic endoderm stem cells (XEN, red bars) were 
fused to hB-lymphocytes and included as positive controls for this analysis. Data were normalised to 
hGapdh expression. Error bars indicate the s.d. of 3 independent experiments. 
 
Notably, in heterokaryons where Eed-deficient ES cells were present (Figure 5.8; hB x 
mES x mES Eed-/-, highlighted in red) the expression of the majority of reprogrammed 
human transcripts was reduced approximately 8-fold. This result suggests that Eed-
deficient ES cells are functionally dominant over their wild-type counterparts. Thus, my 
data show that PcG proteins maintain ES reprogramming activity by restricting the 
expression of factors that have a negative impact on this conversion. 
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Figure 5.8. Eed-deficient ES cells dominate when fused to wild-type ES cells and human 
lymphocytes. (a) Shows the experimental strategy used to generate inter-species heterokaryons between 
wild-type ES cells, Eed-deficient ES cells and human B-lymphocytes [(B) hB x mES x mES Eed-/-; 
highlighted in red]. E14tg2A mouse embryonic stem cells (mES) and B1.3 Eed-deficient ES cells (mES 
Eed-/-, highlighted in red) were respectively labelled with the cell membrane dyes DiI and DiD and fused 
with puromycin resistant lymphocytes (hB Puror) in the presence of PEG. Double labelled heterokaryons 
(resistant to puromycin) were FACS sorted after 2 days of cell fusion. Successful reprogramming was 
measured by the level of activation of human embryonic genes (hOct4, hNanog, hCripto, hDnmt3b, hTle1, 
hTert and hRex1) by qRT-PCR 0 and 2 days after cell fusion. The control for this analysis included 
heterokaryons between wild-type ES cells (DiD labelled), wild-type ES cells (DiI labelled) and human B-
lymphocytes [(A) hB x mES x mES; black bars). hHprt was added as a control gene. Data were normalised 
to hGapdh expression. 
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5.6. Discussion and future perspectives 
 
 Pluripotent stem cells are able to self-renew, generate specialised progeny and 
reprogram differentiated cells upon hybridoma formation (Do et al., 2007; Tada et al., 
1997; Tada et al., 2001). Here, the reprogramming activity of pluripotent ES, EG and 
EC cells was assessed in embryonic heterokaryons. I show that pluripotent cells share 
the ability to reprogram human B-lymphocytes, inducing the rapid re-expression of 
endogenous human genes associated with pluripotency. Using genetically engineered 
mouse ES cells I demonstrate that the reprogramming activity of stem cells was 
critically dependent on PcG proteins. Deletion of the PRC2 members Eed, Suz12 and 
Ezh2 or the PRC1 core components Ring1A/B abolishes ES cell dominant 
reprogramming of lymphocytes. Remarkably, the reprogramming phenotype of cells 
with impaired PRC2 function, and therefore lacking H3K27 methylation, is dominant 
over wild-type ES cells. This result implies that the repressive chromatin mark 
catalysed by PRC2 play a crucial role in ES cell reprogramming capacity possibly by 
restricting the expression of factors that inhibit reprogramming. 
My results show that activation of endogenous human gene expression 
program associated with pluripotency by lymphocyte-derived nuclei begins rapidly after 
fusion with ES, EG or EC cells. These cells share the expression of many pluripotency-
associated factors, exogenous requirements to maintain self-renewal and the ability to 
differentiate into multiple lineages (Andrews et al., 2005; Chambers and Smith, 2004). 
Previous data showed that when mouse EC cells are fused with somatic cells, notably 
thymocytes from adult mice, the resulting hybrid cells exhibit the general features of EC 
cells (Do et al., 2007; Gmur et al., 1980; McBurney, 1977; Miller and Ruddle, 1976; 
Rousset et al., 1980). My data show that P19 and F9 EC cells were also able to 
reprogram hB-lymphocytes in heterokaryons similarly to ES cells. EC cells have a more 
restricted lineage potential than ES cells and the F9 cell line have a propensity to 
differentiate towards endoderm lineages (Hogan et al., 1981), whereas P19 cells 
preferentially differentiate towards neuronal lineages (Jones-Villeneuve et al., 1983). 
The replication timing of a subset of genes was also shown to differ between EC cell 
lines (Azuara et al., 2006); several neural genes replicated later in F9 cells while Rex1 
replicated later in P19, consistently with the transcriptional inactive status of Rex1 in 
P19 cells (Hosler et al., 1989). Do et al (Do et al., 2007) fused F9 or P19 cells with 
neurosphere cells and the resulting hybrids upregulated endodermal or neural markers, 
respectively. In line with the previous data, slight but consistent differences were also 
observed in inter-species heterokaryon analysis: hSox2 and hRex1 were initiated solely 
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when P19 or F9 cells were respectively used as fusion partners to hB-lymphocytes. 
Therefore, the reprogramming of precise genes upon heterokaryon formation can 
reflect the different potential of EC cell lines. EG cells were also able to reprogram hB-
lymphocytes in heterokaryons, albeit less efficiently than ES cells. These differences 
could depend on temporal stem cell origin as EG cells were derived from PGCs at 11.5 
dpc and ES derived from ICM of embryos at 3.5 dpc. Contrasting with this observation 
it was reported that hybrid clones were obtained at a similar rate (2.8 ×10-4) between 
EG and mouse thymocytes (Tada et al., 1997) and ES and mouse thymocytes (Tada et 
al., 2001). It is difficult to know from the experiments presented here whether this 
discrepancy is due to heterokaryon versus hybrid formation, species differences or 
even genetic background. This issue will be further addressed in the future. In addition 
future experiments will examine the potential of EG cells to reset imprinted genes. This 
may provide further insights into the mechanisms of epigenetic modification in the germ 
line (Reik et al., 2001). The shared reprogramming potential of different pluripotent 
cells in heterokaryons implicates dominant reprogramming as a general feature of 
undifferentiated embryonic cells. 
Results show that ES cells lacking PcG proteins lose the ability to induce 
nuclear reprogramming. PcG proteins were previously characterised in Drosophila 
melanogaster as a series of multiprotein complexes that are crucial for maintaining the 
inactive state of homeotic, and other important regulators in developing embryos 
(Lewis, 1978; Pirrotta, 2006; Ringrose and Paro, 2004). Subsequent biochemical 
analyses have identified distinct Polycomb repressive complexes and revealed the 
enzymatic activities of some of their components (Levine et al., 2004). In mammals, 
PRC2 has three central components, Suz12, Eed and Ezh2, a histone 
methyltransferase that catalyses the methylation of lysine 27 on histone H3 (Cao et al., 
2002; Cao and Zhang, 2004; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et 
al., 2002). The three components of PRC2 are all essential for mouse embryonic 
development (Erhardt et al., 2003; Faust et al., 1998; O'Carroll et al., 2001; Pasini et 
al., 2004), but ES cells lacking Eed (Morin-Kensicki et al., 2001), Suz12 (Bracken et al., 
2006; Fujimura et al., 2006) and Ezh2 can be derived, despite the lack of global levels 
of H3K27 methylation. This suggests that PRC2 activity is not essential for ES cell self-
renewal. Moreover, ES cells lacking Eed (and PRC2 activity) were recently shown to 
be functionally pluripotent (Chamberlain et al., 2008). Importantly, my data show that 
when PRC2 function is compromised (by deletion of Eed, Suz12 or Ezh2), mouse ES 
cells lose its ability to reprogram human B cells upon cell fusion, arguing the essential 
function of PRC2 and H3K27 methylation in the reprogramming process. Interestingly, 
loss of reprogramming correlates with phenotypic severity. The incomplete loss of 
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H3K27 methylation in Ezh2 null ES cells (when compared to Eed and Suz12 null ES 
cells) correlates with incomplete loss of reprogramming activity. Both Eed and Suz12 
mutations affect the stability of the Ezh2 protein (Montgomery et al., 2005; Pasini et al., 
2004) whereas Ezh2 mutation does not affect the protein levels of Suz12 (and probably 
not Eed). Therefore partial compensatory effects of the homologous protein Ezh1 
(Laible et al., 1997; Su et al., 2003) are likely to occur as the other core components of 
the complex are still present. 
Methylation of H3K27 itself is thought to provide a binding site for PRC1 (Cao et 
al., 2002; Hernandez-Munoz et al., 2005; Kuzmichev et al., 2002; Ringrose and Paro, 
2004), a multiprotein complex that includes the Ring1A and Ring1B core proteins. 
Several studies suggested that Ring1A/B function as ubiquitin ligase of H2AK119 (Cao 
et al., 2005; de Napoles et al., 2004; Wang et al., 2004a) and that this histone 
modification may facilitate gene repression. These observations suggest that PRC1 
and PRC2 collaborate in maintaining silent chromatin at developmentally sensitive sites 
within the genome. According to these findings my results indicate that the PRC1 core 
components Ring1A/B are also required for reprogramming confirming their co-
operative function. However, the reprogramming defect in Ring1A/B deficient ES cells 
was shown to be less pronounced than in PRC2-deficient ES cells. As Ring1A/B 
deletion is incompatible with self-renewal and ES cells in the absence of Ring1A/B 
cannot be stably obtained it is still possible that more time may be required to abolish 
residual reprogramming activity. In addition, Ring1A/B-knockout ES cells show 
derepression of a number of transcriptional regulators, which are also upregulated in 
cells that lack PRC2 activity (Endoh et al., 2008; Jorgensen et al., 2006; Stock et al., 
2007), but at some target genes (for example, Math1), derepression is selectively seen 
in PRC2 mutant ES cells (Jorgensen et al., 2006). Consistent with this idea, PRC1 
binding and H2AK119 ubiquitylation is retained at the inactive X-chromosome even in 
the absence of PRC2 (Schoeftner et al., 2006). 
To the best of my knowledge the involvement of PcG proteins as essential 
components of the ES cell nuclear reprogramming machinery is a novel finding. 
Previous studies in Drosophila melanogaster have reported the differential regulation of 
several PcG and TrxG proteins in regenerating leg disc cells (Klebes et al., 2005; Lee 
et al., 2005; McClure and Schubiger, 2008). Notably these studies have also shown 
that leg-to-wing induced transdetermination (Maves and Schubiger, 1995) frequency is 
enhanced in PcG and TrxG heterozygous mutant flies and that downregulation of 
Polycomb function was observed in transdetermined cells (Lee et al., 2005). These 
results support the role of PcG and TrxG proteins sustaining lineage-specific 
transcriptional programs (Ringrose and Paro, 2004), and regulating transdetermination 
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events (Klebes et al., 2005; Lee et al., 2005; McClure and Schubiger, 2008). My results 
in turn showed that disruption of Polycomb function in undifferentiated ES cells impair 
their ability to reprogram differentiated lymphocytes. Taken together these findings 
highlight the potential binary function of Polycomb in undifferentiated versus somatic 
cells. It is well established that some Polycomb proteins are over-represented in cancer 
and stem cells. The distinction however in which Polycomb confer “stemness” to cells, 
as opposed to the maintenance of differentiated cell fates remain poorly understood. 
One proposed possibility is that several variations of PcG complexes dictate their 
different functions (Valk-Lingbeek et al., 2004). 
My data suggest that PcG-deficient ES cells are dominant over wild-type ES 
cells but the underlying molecular mechanism that implicate Polycomb in 
reprogramming remain unclear and several possibilities deserve consideration. The 
study of Sustar and Schubiger (Sustar and Schubiger, 2005) reported that 
transdetermination in Drosophila correlates with an extension of the S-phase of cell 
cycle. It was proposed that this change in cell-cycle regulation is a prerequisite for the 
change in cell fate. Interestingly, PcG targets include genes involved in cell-cycle 
regulation (Bracken et al., 2006; Ringrose et al., 2003; Valk-Lingbeek et al., 2004). 
Moreover, BMi-containing Pc complexes and Brahma-containing trx complexes have 
been shown to interact with E2F (Trimarchi et al., 2001) and cyclin E (Brumby et al., 
2002), respectively, proteins which are essential for S-phase entry. These observations 
raise the possibility that Polycomb and the S-phase may coordinate a shift in cell 
commitment. It is not known whether DNA replication plays a role in cell fate 
conversion in embryonic heterokaryons (discussed in section 4.6). However, this 
represents a possible mechanism for the involvement of Polycomb proteins in 
reprogramming and will be further investigated in the future. 
Another explanation is that reprogramming is dependent or sensitive to 
expression of specific transcriptional regulators targets of PcG proteins. Recent 
genome-wide studies that have mapped the binding sites of PcG components in 
humans (Bracken et al., 2006; Lee et al., 2006), mice (Boyer et al., 2006) and 
Drosophila melanogaster (Negre et al., 2006; Schwartz et al., 2006; Tolhuis et al., 
2006) have shown that many PcG targets encode transcriptional regulators that are 
inactive in pluripotent cells but become derepressed upon differentiation. Many of these 
genes carry bivalent chromatin patterns (that is, both “active” and “inactive” histone 
modifications) in undifferentiated ES cells (Azuara et al., 2006; Bernstein et al., 2006). 
PcG proteins were demonstrated to be important for restricting the expression of these 
genes, since ES cells that lack PcG proteins showed an inappropriate upregulation of 
many tissue-specific targets (Azuara et al., 2006; Boyer et al., 2006; Jorgensen et al., 
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2006). The majority of these genes are transcriptional regulators involved in 
developmental processes and consequently activate and repress many genes, 
therefore lacking a factor that “activate” reprogramming is formally possible. My data 
show that several factors previously implicated in reprogramming are expressed in 
PcG-deficient ES cells and overexpression of Oct4 does not rescue the phenotype of 
Eed-deficient ES cells. Importantly, when fused to wild-type ES cells and hB-
lymphocytes, Eed-deficient cells were shown to be dominant. These results strongly 
suggest that PcG-deficient ES cells do not lack factors required for reprogramming, 
neither Polycomb proteins are themselves acting in trans in the human lymphocyte 
nucleus, but mis-expression of some Polycomb target genes may repress 
reprogramming. Importantly, understanding the roles of such targets and establishing 
whether these are direct will be essential to rationalise the defect of PcG mutants on 
reprogramming. Among PRC2 direct targets are Cdx2 and Hand1 (Boyer et al., 2006; 
Bracken et al., 2006; Lee et al., 2006), genes involved in trophectoderm specification. 
Niwa et al. (Niwa et al., 2005) reported that in pre-implantation embryos, Cdx2 is 
initially coexpressed with Oct4 forming a complex for the reciprocal repression of their 
target genes in ES cells. This suggests that reciprocal inhibition between lineage-
specific transcription factors might be involved in the first differentiation steps of 
mammalian development. Accordingly, Cdx2 and Hand1 were derepressed in Eed, 
Suz12 and at less extent in Ezh2 deficient ES cells (Appendix II, Figure A12), a result 
that can be correlated with the reprogramming defect of these cell lines. The possibility 
that lineage determinants such as Cdx2 and Hand1 expressed by PcG-deficient ES 
cells are directly repressing reprogramming is currently being addressed using RNAi 
approaches for Polycomb target genes. Whether reprogramming can be restored by 
the downregulation of such genes in PcG-deficient ES cells is a question that urge to 
be answered. Recent evidence in the reprogramming of mouse B-lymphocytes and 
fibroblasts to pluripotency using the iPS strategy provided valuable evidence that 
lineage regulators can potentially repress reprogramming. For instance, the successful 
reprogramming of mouse B-lymphocytes (Hanna et al., 2008) require the inactivation of 
the B cell-specific factor Pax5 or the forced expression of C/EBPα. Both manipulations 
interfere with the transcriptional network of hB-lymphocytes and has been shown to 
induce reprogramming into macrophages (Xie et al., 2004). Finally, Mikkelsen et al. 
(Mikkelsen et al., 2008) suggested that the re-activation or incomplete repression of 
lineage-specifying factors during the reprogramming process may block the 
endogenous pluripotency regulatory network. Transient silencing of one or more of 
these factors, combined with demethylation drugs, improved reprogramming efficiency. 
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In summary pluripotent stem cells are able to self-renew, generate differentiated 
progeny and reprogram differentiated cells upon cell fusion. Here I have shown that 
ES, EG and EC cells share the ability to reprogram differentiated cells in heterokaryons 
and that this unique feature can be uncoupled from self-renewal and pluripotency by 
the deletion of Polycomb repression in undifferentiated ES cells. 
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CHAPTER 6. GENERAL DISCUSSION 
 
 
During development, cells respond to signals that commit them to a 
developmental pathway. Transplantation and culture experiments have shown that 
cellular memory is stable and can be propagated through cell division. In this study, 
however, I have examined the requirements to override or reverse the differentiated 
state using experimental heterokaryons. 
 
 
6.1. Inter-species heterokaryons as an 
experimental system for reprogramming studies 
 
Although under normal circumstances the pattern of gene expression of 
differentiated cells is stable and heritable, specialisation can be reversed or changed if 
regulatory circuits are altered by introduction of exogenous factors or by fusion with 
different cell partners. In this context, my study demonstrates the usefulness of 
experimental heterokaryons not only for previous discoveries, for example in cancer 
biology (Harris et al., 1969), monoclonal antibody production (Kohler and Milstein, 
1975), gene activation (Baron and Maniatis, 1986; Blau et al., 1983) and cell cycle 
(Rao and Johnson, 1970), but also for understanding the plasticity of the differentiated 
and pluripotent state. In this study, I exploit heterokaryons formed between cell-types of 
different species to allow the distinction of the events that occur in the donor nucleus 
from those of the recipient. The use of inter-species heterokaryons provides a useful 
approach to uncover the mechanisms underlying reprogramming. It is possible to 
analyse the epigenetic changes at the reprogrammed nucleus over time, including 
nuclear organisation and DNA/chromatin modifications, in addition to examining the 
requirement for the type or concentration of trans-acting factors. This approach coupled 
with pharmacological inhibition, gene knock-out or knock-down allows factors that are 
required to directly induce reprogramming to be defined individually, as well as in 
combination. My study shows that inter-species heterokaryons offer a powerful 
approach to trace the contribution of individual factors for direct reprogramming. 
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6.2. Acquisition and extinction of gene expression 
programs are separable events during reprogramming 
 
In this study I show that dominant conversion of human lymphocytes to muscle 
is a multi-step process that includes changes in nuclear architecture and gene activity. 
Upon heterokaryon formation, nuclei of lymphocytes adopt an architecture that 
resembles that of muscle and initiates muscle-specific gene expression, in an order 
that recapitulates ordered gene expression in developing muscle. The establishment of 
this muscle-specific program was coordinated with the shutdown of several 
lymphocyte-associated genes. Inhibition of HDACs during reprogramming selectively 
blocks the silencing of lymphocyte-specific genes, but does not prevent the 
establishment of muscle-specific gene expression. My results reinforce the established 
role of HDACs in gene silencing, but also show that the establishment of muscle gene 
expression and the extinction of lymphocyte identity are distinct and separable 
components of lineage conversion (Figure 6.1). It is likely that a distinct set of factors 
are implicated in either the silencing or activation of gene expression programs during 
reprogramming. In addition to HDACs, transcriptional repressors, HMTs and DNA 
methyltransferases are also expected to be involved in silencing of lineage 
inappropriate genes (Figure 6.1, top panel). Conversely, the activation of the novel 
program of gene expression should be mediated by HATs and histone demethylase 
activity in concert with sequence-specific transcriptional activators (Figure 6.1, bottom 
panel). The individual role of each of those factors during lineage conversion of 
lymphocytes to muscle may be addressed in the future. In 2004, Xie and colleagues 
reported that enforced expression of C/EBPα and C/EBPβ in differentiated B-
lymphocytes led to their reprogramming into macrophages (Xie et al., 2004). C/EBPs 
induced these changes by inhibiting the B cell commitment transcription factor Pax5, 
leading to the downregulation of its target CD19, and synergising with endogenous 
PU.1, leading to the upregulation of its target Mac-1 and other myeloid markers. The 
two processes were also shown to be mechanistically separable, since in PU.1-
deficient pre-B cells, C/EBPs induced CD19 downregulation but not Mac-1 activation. 
The activation of macrophage gene expression is impaired by limiting the availability of 
a key transcriptional activator while extinction of lymphocyte identity is unaffected. 
Similarly, my results show that Oct4 withdrawal in embryonic heterokaryons results in 
the impaired activation of pluripotency-associated genes but not the silencing of 
lymphocyte-specific genes. These observations provide complementary proof that 
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activation and silencing are indeed mechanistically distinct components of nuclear 
reprogramming (Figure 6.1). 
The molecular mechanisms that prevent the expression of lineage inappropriate 
genes by differentiated cells (phenotypic exclusion) remain poorly understood (Fougere 
and Weiss, 1978). Here, I show that two different programs became co-expressed 
(usually mutually exclusive) upon HDAC inhibition, providing some molecular evidence 
for the processes that control phenotypic exclusion. Furthermore, my results 
underscore the importance of gene silencing for successful reprogramming and 
suggest that, in future, it may be possible to preserve certain characteristics of donor 
cells through lineage conversion, by restricting the availability of HDACs. 
 
  
 
Figure 6.1. Molecular mechanisms underlying acquisition and silencing of gene expression 
programs during reprogramming. Reprogramming of one cell-type to another involves the 
establishment of the novel program of gene expression (bottom panel) and the coordinated silencing of 
lineage inappropriate genes (top panel). Pharmacological inhibition (HDACi) of histone deacetylase 
(HDAC) activity during the reprogramming of B-lymphocytes to muscle selectively blocks the silencing of 
lymphocyte-specific genes, but does not prevent the establishment of muscle-specific gene expression. In 
addition to HDACs, other regulators might be implicated in the extinction of gene expression programs (top 
panel, question marks) which are probably different from those required for de novo gene activation 
(bottom panel, question marks). Ac – histone acetylation; Me – histone methylation; HMTs – histone 
methyltransferases; HATs – histone acetylatransferases. 
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6.3. Implications of reprogramming to pluripotency 
in heterokaryons 
 
One of the most pressing objectives of medical research today is the 
development of approaches to restore the function of damaged tissues. An important 
goal for this work is the isolation of stem cell populations to replace missing or non-
functioning cells. Because problems of immune rejection are likely to occur unless the 
recipient and donor stem cells are very closely matched, a desirable strategy is to 
convert differentiated cells from patients into immature tailored stem cell populations. 
Here, I provide evidence that transcriptional and epigenetic conversion of human B-
lymphocytes towards a multipotent state is initiated much more rapidly than previously 
thought, occurring in transient heterokaryons before nuclear fusion and cell division. 
Reprogramming of human lymphocytes by mouse ES cells elicits the expression of a 
human ES-specific gene profile, in which markers of human ES cells are expressed but 
markers that are specific to mouse ES cells are not. Once reprogramming is initiated by 
factors produced by the dominant mouse ES cell nucleus, is both self-sustaining and 
heritable. Collectively these results may have an impact for generating human ES-like 
cells. Proof that mouse ES cells can dominantly reset the multi-lineage potential in 
human somatic cells, together with evidence that this process begins prior to nuclear 
fusion and cell division, suggests that improved methods for removing the mouse 
nucleus from heterokaryons (Pralong et al., 2005) may be applicable for generating 
human stem cell lines without genetic alterations. 
 
6.4. Mechanistic aspects of reprogramming 
towards pluripotency 
 
In this study I show that mouse pluripotent cells share the ability to reprogram 
human B-lymphocytes in heterokaryons, inducing the rapid re-expression of 
endogenous human genes associated with pluripotency. Using genetically engineered 
mouse ES cells, I demonstrate that the reprogramming activity of ES cells was critically 
dependent on the transcription factor Oct4 and PcG proteins (Figure 6.2). However, 
successful reprogramming of human lymphocytes occurs independently of Sox2, a 
factor thought to be required for the generation of iPS cells from somatic cells. More 
recent studies reported the derivation of iPS cells from neural stem cells independently 
of Sox2 (Di Stefano et al., 2008; Eminli et al., 2008; Kim et al., 2008b). However it is 
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not clear whether this factor is not required for reprogramming since neural stem cells 
endogenously express Sox2. Masui et al. have suggested that the essential function of 
Sox2 is to stabilise ES cells by maintaining the adequate level of Oct4 expression 
(Masui et al., 2007). Therefore we propose that Sox2 is not an essential factor for the 
induction of pluripotency and can be potentially substituted in the future with other 
factors (Figure 6.2) (Pereira et al., 2008). The reported combination of factors is 
sufficient to initiate the reprogramming cascade but which of those are essential for the 
reprogramming process? It is possible that Oct4, which in normal development is 
already expressed in the oocyte, may be the most upstream gene in the molecular 
circuitry of pluripotency, and the only obligatory factor to initiate reprogramming. It 
appears that c-Myc significantly enhances and accelerates the process but is 
dispensable in both human and mouse iPS cells. How c-Myc function at the molecular 
level to enhance reprogramming remains unclear. Interestingly, a recent study 
suggests that, in addition to its transcription factor activity, c-Myc is also implicated in 
the induction of DNA replication (Dominguez-Sola et al., 2007). Since the majority of 
factors implicated in reprogramming (Sox2, c-Myc, Lin28 and Nanog) can be 
dispensable or replaced, they could serve to increase the efficiency of re-wiring the 
pluripotency network. However, addressing the role of each of these factors individually 
in heterokaryons would increase our understanding of which factors are essential 
versus which are sufficient for reprogramming. The iPS studies have illustrated the 
importance of combinations of factors for reprogramming, but also suggested that 
additional ones may be needed for efficient conversion to pluripotency. In this study, I 
show that ES cell-mediated reprogramming is dependent on PRC2 function. The 
catalysis of the methylation mark on histone H3 lysine 27 by PRC2 represses a range 
of developmentally-associated genes in ES cells, which when inappropriately 
expressed may inhibit reprogramming. This can change our view of the reprogramming 
of somatic cells to the pluripotent state. In addition to the activation of pluripotency-
associated gene transcripts in somatic cells, the efficient repression of genes involved 
in the determination of unrelated lineages might be required for successful 
reprogramming (Figure 6.2). This provides a rationale for using distinct protein cocktails 
to directly re-set lineage potential. Thus the PRC2 members, Eed, Suz12 and Ezh2, 
are strong candidates to be directly introduced into somatic cells along with Oct4 to 
increase the efficiency of the reprogramming process. 
The network of factors implicated in the reprogramming of a somatic cell to 
pluripotency remains obscure. Experimental heterokaryons coupled with conditionally 
targeted mouse ES cells offer a powerful approach to trace the contribution of 
individual factors. Furthermore, knocking down Oct4 expression in a wild-type ES cell 
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line with siRNAs, similarly to conditional knock-out ES cells, abolished reprogramming 
(Appendix II, Figure A13). This provides proof-of-principle that RNAi approaches can 
be used for screening reprogramming factors. RNAi provide a more feasible approach 
to unbiasly identify the network of factors essential for reprogramming to pluripotency. 
When the optimal combination is found, new methods for the introduction of proteins in 
cells without any underlying genetic modification must be developed. The use of fusion 
proteins with the HIV TAT-sequence can render cell-permeant reprogramming factors 
(Bosnali and Edenhofer, 2008; Glover et al., 2005) and represent an attractive 
alternative for the orchestration of pluripotency in somatic cells. 
 
 
Figure 6.2. A model for the role of Oct4, Sox2 and PRC2 in the reprogramming to pluripotency. 
Upon cell fusion, embryonic stem cells have the ability to reprogram somatic cells, inducing the rapid re-
expression of endogenous genes associated with pluripotency (lower panel). Genetically engineered 
mouse ES cells were used to address the requirements for conversion of somatic cells to pluripotency. 
Reprogramming is critically dependent on Oct4, since Oct4 deletion abolishes the reprogramming capacity 
of ES cells. This effect is thought to be mediated by the direct activation of Oct4 target genes, essential for 
the pluripotent-state. Sox2, in contrast to Oct4, is not required to convert human B-lymphocytes into a 
multi-potent state but instead is thought to maintain the adequate Oct4 levels in ES cells (right panel). 
Reprogramming activity of stem cells is reliant on Polycomb proteins. Deletion of the Polycomb repressive 
complex 2 (PRC2) components Eed, Suz12 and Ezh2 and the histone mark that this complex catalyses 
(H3K27 – histone H3 lysine 27) impairs reprogramming (left panel). Although the mechanism of action is 
not clear, it is possible that PRC2 restricts the expression of developmental-associated genes that inhibit 
ES cell reprogramming network (question mark). 
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6.5. Epigenetic stability and flexibility of cellular 
states in development 
 
A common notion in developmental biology is that cell differentiation proceeds 
through a series of successive binary decisions by which cells adopt alternative 
phenotypes. Linked to this concept, although by no means essential, is that 
differentiation is irreversible. However, evidence for in vivo and in vitro reprogramming 
continues to challenge these concepts of unidirectional, irreversible differentiation 
along distinct cell lineages. At the molecular level, the stability of the differentiated state 
must be ensured by a complex, dynamic network of factors. What are these 
mechanisms and how are they actively maintained and yet reversed with relative ease 
during reprogramming? Although autoregulation of regulators seems to play a key role 
in stability, recent advances in chromatin biology have considerably broadened our 
understanding of the mechanisms of cell commitment and specification. We now know 
that there can be different “levels” of regulation defined by different chromatin 
configurations that can be inherited through rounds of cell division. Recent studies, 
however, have revealed that the balance between the active and inactive chromatin 
states in the cell is surprisingly flexible, raising questions as to how chromatin changes 
in development should be interpreted. Thus, a full understanding of the role of 
chromatin in developmental plasticity will require knowledge of times, reaction rates, 
concentrations, half-lives, dissociation constants, and other variables that explain how 
the reversal of individual epigenetic modifications is achieved at the right place for the 
right length of time. Perhaps a substantial challenge from the recent observations of 
nuclear reprogramming will be to develop a more detailed understanding of the 
chemistry underlying the complex network of factors, to provide a more solid basis for 
the concept of epigenetic reprogramming. 
 
Taken together my findings highlight the importance of chromatin events during 
cell fate reprogramming. The proposed future experiments aim to increase our 
understanding of molecular processes underlying epigenetic reprogramming, and may 
provide promising perspectives for the development of direct reprogramming 
strategies. 
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APPENDIX I – PRIMER SEQUENCES 
 
Table A1. Primers used for the selective amplification of human transcripts by 
semi-quantitative RT-PCR. 
 
Species/Gene Tm n  Sequence 5’-3’ 
s GCAGCAACGGAGAAAAACTC 
hCD20 60ºC 25 
as CTGATCTTGGGGAGGTTCTG 
s CGAGGAGAGCTGGGACTATG 
hCD37 60ºC 25 
as AGACGTGGTCCAGGTTTCTG 
s TTGCGATTTCCGTGTAAAAG 
hCD45 60ºC 25 
as GTTCCCAAATCATCCTCCAG 
s GCTCGTCGTACTCCATCAGC 
hPax5 60ºC 25 
as CGTTGTACGAGGAATACTGAGG 
s AGCCACATCGCTCAGACAC 
hGapdh 60ºC 19 
as AGGGGTCTACATGGCAACTG 
s CAGCGAATGCAGCTCTCAC 
hMyogenin 60ºC 25 
as CAGAAGTAGTGGCATCTGTGG 
s TGGGGAAAATGTTACTCTGC 
hMrf4 60ºC 25 
as GAAGGCTACTCGAGGCTGAC 
s GCAGGAGTTGCTGAGAGAGC 
hMyf5 60ºC 25 
as TTAGGCCCTCCTGGAAGAAG 
Tm indicates the annealing temperature of the primers and n the number of cycles of amplification used in 
PCR reactions. s indicates the sense and as the anti-sense primer. 
 
Table A2. Primers for the selective amplification of human or mouse transcripts 
by quantitative RT-PCR. 
 
Human specific primers for qRT-PCR 
Species/Gene  Sequence 5’-3’ 
s TCTGCTCCTCCTGTTCGACA 
hGapdh 
as AAAAGCAGCCCTGGTGACC 
s TCCTTGGTCAGGCAGTATAATCC 
hHprt 
as GTCAAGGGCATATCCTACAACAAA 
s TCGAGAACCGAGTGAGAGGC 
hOct4 
as CACACTCGGACCACATCCTTC 
s CCAACATCCTGAACCTCAGCTAC 
hNanog 
as GCCTTCTGCGTCACACCATT 
s AGAAGTGTTCCCTGTGTAAATGCTG 
hCripto 
as CACGAGGTGCTCATCCATCA 
s GTCAAGCTACACACAGGACTTGACAG 
hDnmt3b 
as AGTTCGGACAGCTGGGCTTT 
s GCCAGCATCATCAAACCCC 
hTert 
as CTGTCAAGGTAGAGACGTGGCTC 
 182
s TGTCTCCCAGCTCGACTGTCT 
hTle1 
as AAGTACTGGCTTCCCCTCCC 
s CACACTGCCCCTCTCACACAT 
hSox2 
as CATTTCCCTCGTTTTTCTTTGAA 
s GCGTACGCAAATTAAAGTCCAGA 
hRex1 
as CAGCATCCTAAACAGCTCGCAGAAT 
s GTGGCTGCACAACAACCTTATTT 
hCD37 
as GCCTAACGGTATCGAGCGAG 
s GCTCAAGACGCTGGAAAGTATTATT 
hCD19 
as GATAAGCCAAAGTCACAGCTGAGA 
s CCCCATCTACCCAATACTGTTACAG 
hCD20 
as TGGGTCTGGAGCACGTTCTT 
s CCCCATGAACGTTACCATTTG 
hCD45 
as GATAGTCTCCATTGTGAAAATAGGCC 
s AGCTTCCAGTCACAGCATAGTGTC 
hPax5 
as ACCTTCGTCTCTCTTGCGCTT 
s GCAAGTGAGAGCTTCCTGAGCT 
hFgfr2 
as ACCTTCAATCGAGGCAGGAA 
s GCCGCCGTGATCAGTTG 
hFgfr2 
as GCGCCCTTTATCTGCAAGTACT 
s TCACATCAAGCTACAACTTCAAGCA 
hFgf2 
as AAGCCAGTAATCTTCCATCTTCCTT 
s TGGTCTTGAGTATCCTGAGCG 
hBmp4 
as GCTGAGGTTAAAGAGGAAACGA 
s CCAACATGACTTGCGACTACGT 
hLifr 
as CCTGGTCGAAACTCATCAGATTCTAT 
s AAGCAGCGAGCTTGATGAGC 
hJak3 
as GTCTATGGCCCCCAGGTGTA 
s CCTGGCAGGGCTCACACT 
hALPL 
as AAACAGGAGAGTCGCTTCAGAGA 
s TCAGCAGGGCATCGCAT 
hColagenIVα1 
as AAATGTCATTTCAGGCCTAGTGG 
s TGTGGCCCAGAGGCTTCTC 
hNestin 
as CAGGGCTGGTGAGCTTGG 
s ACCAGCTACATCGCCTACCTGA 
hHnf4 
as CAGGAGGAAAACCTTCGTGCT 
s CCGAGTCCAGGATCCAGGTA 
hMixl1 
as CTCTGACGCCGAGACTTGG 
s ACGCCGAGCTCAGCAAGAT 
hSox7 
as TCCACGTACGGCCTCTTCTG 
s ACCACCTTATGGCGCAGAAAC 
hGata6 
as TTTTTCATAGCAAGTGGTCTGGG 
s CAGGACGAAAGACAAATATCGAGTG 
hCdx2 
as CCAGATTTTAACCTGCCTCTCAGA 
hHand1 s ACCAGCTACATCGCCTACCTGA 
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as CAGGAGGAAAACCTTCGTGCT 
s GGAGATCGAGAGGACAGCGT 
hEbf 
as GTCAATGAGGCGCACGTAGA 
s AACTTAAATGCCCCCCTCCCC 
hMyoD 
as TTCAGTTCTCCGCCTCTCCTAC 
s GGTCCGTGACATCAACGAGG 
hE2A 
as CTTTGGGATTCAGGTTCCGCT 
Mouse primers for qRT-PCR 
Species/Gene  Sequence 5’-3’ 
s TGCACCACCAACTGCTTAGC 
mGapdh 
as GGCATGGACTGTGGTCATGAG 
s CGTGGAGACTTTGCAGCCTG 
mOct4 
as GCTTGGCAAACTGTTCTAGCTCCT 
s GAACTATTCTTGCTTACAAGGGTCTGC 
mNanog 
as GCATCTTCTGCTTCCTGGCAA 
s CACCAACCCAGGGTATCAGTT 
mCripto 
as AGAGTTCTGTCCAGTGTCGTC 
s ACTGCCTGGAGTTCAGTAGGA 
mDnmt3b 
as CCCTGTCTGATGGAGTTCGAC 
s GAGTGGAAACTTTTGTCCGAGA 
mSox2 
as GAAGCGTGTACTTATCCTTCTTCAT 
s TCTGAGTGGGCAGTCTCACTT 
mTle1 
as GAAGAAGGGTCCTCGTTAGACA 
s TCAAGAGCAGTAGTCGCCAG 
mTert 
as TCTCGGGACAGGATAGCATCT 
s CTCCTAGCCGCCTAGATTTCCA 
mRex1 
as CGTGTCCCAGCTCTTAGTCCATT 
s GCAGAGCATCAACTGGCTG 
mFgfr1 
as GGTCACGCAAGCGTAGAGG 
s GAGGAATACTTGGATCTCACCCAGC 
mFgfr2 
as CTGGTGCTGTCCTGTTTGGG 
s GGCTCTACTGCAAGAACGGC 
mFgf2 
as TGGAGTTGTAGTTTGACGTGTGG 
s GAGGGATCTTTACCGGCTCC 
mBmp4 
as GTTGAAGAGGAAACGAAAAGCAG 
s GCAGAGCATCAACTGGCTG 
mLifr 
as GGTCACGCAAGCGTAGAGG 
s CTTCCGCCTGATCTGCGAC 
mJak3 
as TGGCAAAGTCTAACGTGATGG 
s TCAACCTCGCCACAACCTTCCC 
mCdx2 
as TGGCTCAGCCTGGGATTGCT 
s ACGTGCTGGCCAAGGATGCA 
mHand1 
as TGGTTTAGCTCCAGCGCCCA 
mCD19 s GGAGAGCACCCGGTCAGA 
 184
as CCACACTGCTGACCTTGCAA 
s AAGTACTTCCTCTTCGTTTTCAACCT 
mCD37 
as ACCTGAGACAGCCAGGACCTT 
s TGTACCACCAGGGACTGACAAG 
mCD45 
as TCTGGCTCACAGTGGAGTACATATG 
s TCCTTTCCAACTCGCTAACCC 
mKlf4 
as CGGATCGGATAGCTGAAGCTG 
s TTCATCTGCGATCCTGACGAC 
mc-Myc 
as AGGGGTCAATGCACTCGGA 
s TCACTGGCCCTGGTGGTGTGTT 
mLin28 
as TGGACACGAGGCCACCATATGG 
s GACTCCTACTTCCTCTTCTTCTAATTCAGA 
mGata6 
as ACCTGAATACTTGAGGTCACTGTTCTC 
s AATGGACAGATGTGTGAGTGGCC 
mHnf4 
as CCAGCAGCTTGCTAGATGGC 
s GCCTCTCGGCCATTTCTCAG 
mMsx1 
as CGGTTGGTCTTGTGCTTGCG 
s AATTACCCACGCAGCGGC 
mPax3 
as GCACAGGATCTTAGAGACGCAACC 
s GGAGAAGCTTCGTTGCACGC 
mMath1 
as GGGACATCGCACTGCAATGG 
s TGTGCAGAGCCTGCCCCTTAA 
mNKX2.2 
as GCCCTGGGTCTCCTTGTCAT 
s CGGCAGGAGCAAGGTGAGAT Oct4βgeo transgene (within neor 
gene) as CAAGATGGATTGCACGCAGG 
s AAGTTGACCAGTGCCGTTCC Sox2Zeo transgene (within Zeor 
gene) as TGAACAGGGTCACGTCGTCC 
s indicates the sense and as the anti-sense primer. 
 
Table A3. Primers for the selective amplification of human genomic regions by 
quantitative PCR. 
 
Replication Timing, ChIP and MDIP analysis 
Species/Gene  Sequence 5’-3’ 
s GGTGAGTCTGTGTGGTCAGCAGTCTCT 
hβ-Amylase promoter 
as CCACGGTGCTCTGGTAGATAACGTAAG 
s TTTGTCCCCGGACCTGCTGCC 
hα-globin promoter  
as CCCCACGGTCGGCTGACAC 
s TTGGGAGTTGAAAGTTGGGTGT 
hOct4 promoter  
as AGGCTGGTCTTGAATTCCTGTC 
s CAGGTCAATGCAGGTGGAAAC 
hDppa5 promoter 
as CCAGCAGGTTGCCAACTCTT 
s ACTTCAAGTCTGGAGCCCCC 
hCripto promoter 
as GCCTGAGGAGCTAGGTGTGTGT 
hDnmt3b promoter s TGTGTGTCTCCGTTCGGGTT 
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as ATCAGAAGCCCTAAGCGGGA 
s TCACGTCCGGCATTCGTGGT 
hTert promoter 
as TCGAATCGGCCTAGGCTGTG 
s ACGGCCTCCCAATTTACTGG 
hNanog promoter 
as GGTTCAACAGGAATGGGATAAAAC 
s AAAGCCATCGTGAGCCTCAT 
hGdf3 promoter 
as GACAGAGTGAAAAGGAGACATGCA 
s TCCCGCTGGATCTTTAAGTAGAA 
hFoxd3 promoter 
as CGGTAGTCGAAAGTCCCGTTT 
s GGCAGGCAAAATGTGAATGAG 
hGbx2 promoter 
as GAAGCCGGCGTACTTATCTCC 
s CGTGAGAGAGTGTTGGCACCT 
hSox2 promoter  
as TTGTTCTCCCGCTCATCCAC 
s AAATAGCTTTCTTCAAGCCGCC 
hDppa4 promoter 
as CGGAGACATTGGGAGATTGAG 
s CTGTTTTCCCCACCATCTCGT 
hTle1 promoter 
as TCCTTCACCTTCGTGTGCTTCT 
s CTCATGTGATCCCCCCGTCT 
hRex1 promoter  
as TACGCGTGGGTGTAATCACATT 
s GAACAATGCGAGTGAGCAACTTCAGG 
hIkaros promoter 
as GGCCGAGCGTCCCGCCCAGGCTG 
s ACATTCACACGAGCATCCAGG 
hIgf2/hH19 ICR 
as GCTCTTTAGGTTTGGCGCAAT 
s AATTCGTTGGAAACGGGAT 
hα-Satellite 
as TTCAAAGAGGTCTACATGTCCC 
s AAACGTGACTGAGAAACTTGATCGC 
hMyoD promoter 
as TTTCCTTTGCCTGTCCAAACTCTG 
s GGTGCAGATCATCCCCTTGA 
D. melanogaster Gbe locus 
as TTACCCGACGGCGAAAG 
s indicates the sense and as the anti-sense primer. 
 
Table A4. Primers for the selective amplification of human bisulfite converted 
genomic regions by PCR. 
 
Bisulfite genomic sequencing analysis 
Species/Gene region  Sequence 5’-3’ 
s TAGTTGGGATGTGTAGAGTTTGAGA 
hOct4 region 1 
as TAAACCAAAACAATCCTTCTACTCC 
s AAGTTTTTGTGGGGGATTTGTAT 
hOct4 region 2 
as CCACCCACTAACCTTAACCTCTA 
s GTTAGAGGTTAAGGTTAGTGGGTG 
hOct4 region 3 
as AAACCTTAAAAACTTAACCAAATCC 
s TGTTGAAGGTTGGGGAGATGGGA 
hIgf2/hH19 ICR 
as CCCAAACCATAACACTAAAACCCTC 
s indicates the sense and as the anti-sense primer. 
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APPENDIX II – COMPLETE DATA SETS 
 
 
 
 
 
Figure A1. Replication timing analysis of pluripotency-associated genes in human B-lymphocytes. 
The replication timing of each gene (hOct4, hDppa5, hCripto, hDnmt3b, hTert, hNanog, hGdf3, hFoxd3, 
hGbx2, hSox2, hDppa4, hTle1 and hRex1) was defined accordingly to its peak abundance in G1-S1 phase 
(early, green), S2 phase (middle-early, dark green), S2-S3 phase (middle, yellow), S3 phase (middle-late, 
orange) or S4-G2 (late, red), using a quantitative PCR-based assay (Azuara et al., 2006). Genes are 
ordered according to their replication timing. hα-Globin and hβ-Amylase were included as controls for an 
early and a late replicating gene, respectively. Drosophila melanogaster Gbe is an internal control for 
uniform recovery of BrdU-labelled DNA. Error bars indicate the s.d. of 2 independent experiments. 
 
 
 
 
 
Figure A2. Kinetic of human lymphocyte reprogramming by mES cells after Oct4 ablation. ZHBTc4 
ES cells expressing Oct4 (black bars), or in which Oct4 expression has been partially or completely 
ablated by the addition of doxycycline for 6 and 12 hours (grey and white bars, respectively) were fused to 
hB-lymphocytes. The activation of human ES-specific genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, 
hTle1, hTert and hRex1) and silencing of lymphocyte-specific genes (hCD19, hCD45 and hCD37) were 
quantified by qRT-PCR over the period of 3 days after cell fusion. hHprt was added as a control gene. 
Data were normalised to hGapdh expression. Error bars indicate the s.d. of 2-3 independent experiments. 
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Figure A3. Kinetic of human lymphocyte reprogramming by mES cells after Sox2 ablation. 2TS22C 
(black bars), Sox2 depleted cells (grey and white bars; doxycycline 12 and 24 hours, respectively) and 
2O1 cells (red bars; Sox2-deficient mES cells in which mOct4 expression is constitutively up-regulated) 
were used as fusion partners with hB cells and reprogramming was assessed by quantification of human-
ES transcripts (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and hRex1) using qRT-PCR over 3 
days after cell fusion. hHprt was added as a control gene. Data were normalised to hGapdh expression. 
Error bars indicate the s.d. of 2-3 independent experiments. 
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Figure A4. Reprogramming is self-sustaining and can be maintained in the absence of ES-derived 
Oct4. Dox treatment of ZHBTc4 ES cells results in morphological changes characteristic of trophectoderm 
differentiation (upper panel) which were not observed in hybrid clone 4 and 12 under the same conditions 
after 2 (d2) or 5 (d5) days of Dox treatment. GFP protein (Oct4 promoter-driven) remains detectable in 
hybrid cells throughout the experiment. 
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Figure A5. Inhibition of de novo protein synthesis in heterokaryons did not alter the overall human 
pattern of gene expression. OS25 ES cells were fused to hB cells and reprogramming was assessed by 
quantification of human-ES transcripts (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and 
hRex1) using qRT-PCR 2 days after cell fusion. After PEG treatment heterokaryons were treated 
continuously with 0.1 µg/ml of ciclohexime D (white bars) or with carrier control (black bars) for two days. 
Data were normalised to hGapdh expression. Error bars indicate the s.d. of 2 independent experiments. 
 
 
 
 
 
 
 
Figure A6. Kinetic of human lymphocyte reprogramming by embryonic carcinoma cells. P19 (light 
purple bars) and F9 (dark purple bars) embryonic carcinoma cell lines were fused to hB-lymphocytes. The 
activation of human ES-specific genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and 
hRex1) was quantified by qRT-PCR over the period of 3 days after cell fusion. hHprt was added as a 
control gene. Data were normalised to hGapdh expression. Error bars indicate the s.d. of 2-3 independent 
experiments. 
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Figure A7. Kinetic of human lymphocyte reprogramming by embryonic germ cells. 23G (light blue 
bars) and 19G (dark blue bars) embryonic germ cell lines were fused to hB-lymphocytes. The activation of 
human ES-specific genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and hRex1) was 
quantified by qRT-PCR over the period of 3 days after cell fusion. hHprt was added as a control gene. 
Data were normalised to hGapdh expression. Error bars indicate the s.d. of 2-3 independent experiments. 
 
 
 
 
 
Figure A8. Kinetic of human lymphocyte reprogramming by mES cells after Eed ablation. Wild-type 
(black bars), heterozygous (grey bars) and Eed-deficient (white bars) embryonic stem cells were fused to 
hB-lymphocytes. The activation of human ES-specific genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, 
hTle1, hTert and hRex1) was quantified by qRT-PCR over the period of 3 days after cell fusion. hHprt was 
added as a control gene. Data were normalised to hGapdh expression. Error bars indicate the s.d. of 3 
independent experiments. 
 
 
 
 191
 
 
Figure A9. Kinetic of human lymphocyte reprogramming by mES cells after Suz12 ablation. Wild-
type (black bars) and Suz12-deficient (white bars) embryonic stem cells were fused to hB-lymphocytes. 
The activation of human ES-specific genes (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and 
hRex1) was quantified by qRT-PCR over the period of 3 days after cell fusion. hHprt was added as a 
control gene. Data were normalised to hGapdh expression. Error bars indicate the s.d. of 3 independent 
experiments. 
 
 
 
 
Figure A10. Kinetic of human lymphocyte reprogramming by mES cells after conditional Ezh2 
removal. Ezh2-1.3 ES cells expressing Ezh2 (black bars), or in which Ezh2 expression has been partially 
or completely ablated by the addition of 800 nM tamoxifen for 48 and 96 hours (dark and light grey bars, 
respectively) and Ezh2-deficient ES cells (white bars) were fused to hB-lymphocytes. Reprogramming was 
assessed by quantification of human-ES transcripts (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, 
hTert and hRex1) using qRT-PCR over 3 days after cell fusion. hHprt was added as a control gene. Data 
were normalised to hGapdh expression. Error bars indicate the s.d. of 3 independent experiments. 
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Figure A11. Kinetic of human lymphocyte reprogramming by mES cells after conditional Ring1B 
removal. ES-ERT2 ES cells expressing Ring1B (black bars), or in which Ring1B expression has been 
partially or completely ablated by the addition of 800 nM tamoxifen for 24, 48 and 96 hours (dark grey, light 
grey and white bars, respectively) were fused to hB-lymphocytes. Reprogramming was assessed by 
quantification of human-ES transcripts (hOct4, hNanog, hCripto, hDnmt3b, hSox2, hTle1, hTert and 
hRex1) using qRT-PCR over 3 days after cell fusion. hHprt was added as a control gene. Data were 
normalised to hGapdh expression. Error bars indicate the s.d. of 2 independent experiments. 
 
 
 
 
 
 
Figure A12. mHand1 and mCdx2 are derepressed in PRC2-deficient ES cells. (a) Gene expression 
analysis by qRT-PCR of mHand1 and mCdx2 in ES cells deficient for the PRC2 (black bars) members Eed 
(Eed -/-), Suz12 (Suz12 -/-), Ezh2 (Ezh2 tamoxifen 96 hours; Ezh2 ∆/∆) and matching wild-type controls 
(white bars). Data were normalised to mGapdh expression. Error bars indicate the s.d. of 2 independent 
experiments. 
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Figure A13. siRNA-mediated knock-down of mOct4 abolishes reprogramming. (a) E14tg2A ES cells 
were transfected with either mOct4-siRNA or target-less-siRNA (a negative control siRNA designed to 
have no expected targets in human and mouse cells) vectors. 48 hours later, transfected cells (GFP+) 
were FACS sorted and analysed by quantitative RT-PCR analysis. mOct4-siRNA targeted cells showed a 
>90% reduction in Oct4 transcript levels as compared to cells transfected with target-less-siRNA (control). 
(b) E14tg2A ES cells expressing mOct4-siRNA or control-siRNA were fused to hB-lymphocytes, and 
successful reprogramming was assessed by quantifying the abundance of human ES-associated 
transcripts (hNanog and hCripto) two days after fusion by qRT-PCR. Successful reprogramming judge by 
the activation of human pluripotency-associated transcripts was abolished by pre-treatment of mES cells 
with Oct4-siRNAs. Data were normalised to Gapdh expression. Error bars indicate the s.d. of 2 
independent experiments. 
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